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1. Hemodilutie droogt bij oon de hoge prevolentie van onemie bij potienten met 
hortfolen. (Dit praefschrift) 
2. Hortfolen leidt tot beenmergdisfundie. (Dit proefschrift) 
3. De centrole rol van een verstoorde hemodynomiek in de pothogenese van onemie 
bij potienten met hortfolen, suggereert dot hortfundieverbetering anemia kon 
tegengoon. (Dit proefschrift) 
4. Erythropoietine verbetert de hortfunctie in rotten met hortfolen. Deze effecten van 
erythropoietine kunnen niet worden toegeschreven oon de verhoging van het 
hemotocriet. (Dit proefschrift) 
5. Hortfunctieverbetering door erythropoietine in rotten met hortfolen wordt 
voornomelijk bewerkstelligd door stimulotie van de erythropoietine receptor in het 
hart. (Dit proefschrift) 
6. Stimulotie van de Vosculor Endothelial Growth Factor (VEGF)-productie door 
ischemische cardiomyocyten is cruciool voor erythropoiefine geinduceerde 
hortfunctieverbetering. (Dit proefschrift) 
7. lnfroductie van fose O onderzoek kon een belangrijke reductie van tijd en kosten 
bewerkstelligen bij de ontwikkeling van nieuwe geneesmiddelen. 
8. Wanneer je jezelf schoort ender "believers", word! wefenschop een religie. 
9. De promovendus is geboof bij een Afrikoonse beleving van fijd. 
10. Het broeikaseffect lijkt voorol een probleem bij mooi weer. 
11 . Als de reglemenfen van de Formula 1 worden foegepost op de Tour de Fronce, 
zouden de wielrenners olleen nag op driewielers zonder versnellingen mogen 
rijden. 
12. All work and no ploy makes Jock a dull boy. (James Howell) r n: I 
"''1t O -.�' 
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and aim of the thesis 
Chapter l 
Introduction 
Chronic heart failure (CHF) represents a complex of symptoms related to impaired 
cardiac function which affects 5 million people in the US and 7 million people in 
Europe. 1 CHF is the final common endpoint of cardiac disease and a leading cause 
of death in the Western world. Although significant morbidity and mortality benefits 
have been made over recent years, still over half of CHF patients die within five years. 1 
In addition to increased mortality, frequent hospital admissions, extensive diagnostic 
testing and the use of multiple pharmacological agents account for an immense 
healthcare expenditure, estimated at $25 billion in the US annually.' 
The mainstay of treatment of CHF is pharmacological and focused on the 
suppression of neurohormonal activation in order to attenuate the progression of 
cardiac dysfunction.1 Besides cardiac dysfunction, CHF is often accompanied by 
dysfunctions of other organs, including the endothelium, lungs, kidneys, liver, skeletal 
muscle and the brain, as well. The extent of dysfunction of other organ functions might 
have more impact on prognosis than the ventricular dysfunction itself. For example, 
the extent of kidney dysfunction more accurately predicts outcome in CHF patients 
than left ventricular ejection fraction (LVEF). 3 Research on the etiology and possible 
reversal of these collateral organ dysfunctions in CHF might therefore significantly 
improve clinical outcome. 
The importance of anemia in heart failure 
Anemia is frequently found in CHF-patients and its presence has been associated 
wilh significantly impaired morbidity and mortality.4· � Therefore, anemia might be 
regarded as an additional collateral organ dysfunction of the CHF-syndrome. Anemia 
causes chronic volume overload to the left ventricle, which results in increased oxygen 
consumption, left ventricular dilatation and left ventricular hypertrophy, thereby 
further reducing cardiac function in CHF. These detrimental effects of anemia in heart 
failure patients have already been described in Fishbergs' textbook of heart failure 
in 193 7.° Despite the longstanding knowledge of the consequences, anemia in CHF 
it is currently still under recognized and under treated in clinical practice. A recent 
survey of more than 6000 ambulatory CHF patients showed that although anemia 
was present in 17% of patients, clinical evaluation of anemia was only performed in 
3%.7 The severe under evaluation is probably attributable to the fact that the etiology 
of anemia is often unexplained and thus treatment options are limited. Resolving the 
preponderant etiology is therefore warranted. 
Role of erythropoietin in the pathophysiology of anemia 
Erythropoietin (EPO) is the principal hormone responsible for the regulation of red 
blood cell production. EPO is secreted in the kidney in response to hypoxia and in 
turn targets the bone marrow to increase the production of red blood cells. The high 
incidence of renal dysfunction in CHF patients suggests that impaired EPO-production 
by the kidney could be the underlying cause. Moreover, it has been suggested that 
the sensitivity of the bone marrow to EPO is also impaired. Both dysregulation of 
EPO synthesis or an altered response to EPO might cause anemia in CHF. EPO is of 
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particular interest because recombinant human EPO has been used to treat anemia for 
several decades and preliminary studies have demonstrated efficacy in CHF patients. ij 11 
Nevertheless, a central pathophysiological role for endogenous EPO in anemia in CHF 
remains to be established. 
Effect of EPO on the myocardial microvasculature 
In heart failure, microvascular adaptation to cardiomyocytes hypertrophy is required 
to compensate for the increased metabolic demand of hypertrophied cardiomyocytes. 
Insufficient microvascular adaptation to cardiomyocyte hypertrophy has been 
identified as a key pathophysiological feature in heart failure. 11• 13 Indeed, the transition 
from compensatory hypertrophy to heart failure is associated with down regulation 
of angiogenic factors and consequent inhibition of microvascular growth. 14 Moreover, 
inhibition of angiogenesis accelerates the progression of heart failure while stimulation 
of angiogenesis restores myocardial dysfunction. 14 16 Therapies that restore the cardiac 
microvasculature might therefore significantly improve cardiac function and potentially 
morbidity and mortality as well. Although EPO has previously been considered an 
exclusive hematopoietic hormone, functional EPO-receptors have been detected in 
several other organs, including the heart. 17 EPO has been shown to salvage myocardial 
tissue during experimental myocardial infarction. 18 Moreover, EPO consistently restores 
microvascular insufficiency and improves cardiac function in experimental models 
of CHF. 19• 20 EPO might therefore have an important therapeutic potential in CHF, 
beyond the regulation of erythropoiesis. However, the mechanisms of EPO-induced 
neovascularization in CHF are not well described. It is unknown whether these ancillary 
cardiac effects are mediated tlrrough stimulation of endothelial progenitor cells in 
the bone marrow, tlrrough direct effects on cardiac cells or alternatively represent an 
epiphenomenon of increasing hematocrit levels. 
11 
Chapter 1 
Aim of the thesis 
The aim of the present thesis is twofold: 
In the first part of the thesis we evaluate the role of endogenous EPO in 
the pathophysiology of anemia in CHF. 
In chapter 2, we review the biological function ofEPO in the control ofred blood cell 
production and introduce the extra-hematopoietic EPO-receptor system. In chapter 
3, we evaluate whether anemia is related to impaired production of EPO as a result 
of impaired kidney perfusion. In chapter 4, we evaluate whether hematopoietic 
progenitor cells of CHF patients exhibit impaired sensitivity to EPO and whether 
this contributes to anemia. In chapter 5, we summarize our findings and postulate a 
model which explains how anemia is related to impaired cardiac performance. 
2 In the second part of the thesis we evaluate the mechanisms through 
which exogenous EPO restores cardiac microvascularization anf function 
in chronic heart failure. 
In chapter 6, we evaluate the role of bone marrow derived endothelial progenitor 
cells. In chapter 7, we investigate whether the cardiac effects of EPO are in part 
attributable to the presence of ischemia. In chapter 8, we evaluate whether the cardiac 
effects of EPO are attributable to elevated hematocrit levels. In chapter 9, we focus on 
the effect of EPO on angiogenic factors in the heart. 
12 
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Chapter 2 
Abstra c t  
Erythropoietin (EPO) is a glycoprotein hormone implicated in the regulation of red 
blood cell production. Anemia is common in chronic heart failure (CHF) patients 
and associated with an inappropriately low EPO-production, suggesting a role for 
its recombinant human form (rhEPO) in treatment. Although safety concerns have 
been raised regarding treatment with rhEPO in patients with chronic kidney disease, 
treatment with rhEPO in patients with CHF has so far been safe and well tolerated. The 
effect of rhEPO on outcome in anemic CHF patients is under investigation in a phase 
III clinical trial. In addition to its erythropoietic effects, EPO has been detected in 
the cardiovascular system, fueling intense research into possible non-hematopoietic 
effects. EPO has been shown to exert protective effects on the heart during acute 
myocardial ischemia and improve cardiac function in experimental CHF. Acute 
protection is mediated through reduction of apoptotic cell death. Improvement of 
cardiac function in CHF is related to myocardial neovascularization. EPO thus exhibits 
a vast array of beneficial effects in cardiovascular disease. In addition to the correction 
of anemia in CHF, rhEPO might therefore also benefit patients with cardiovascular 
disease. 
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I n t r o d u c ti o n  
Erythropoietin (EPO) is a hematopoietic hormone, and its recombinant human form 
(rhEPO) has provided a breakthrough in the treatment of anemia caused by EPO 
deficiency in chronic kidney disease. Over the past decade the indication for rhEPO 
has markedly broadened and now also includes anemia in patients with cancer who 
are receiving chemotherapy, patients with HIV who are treated with zidovudine, 
and treatment of myelodysplastic syndromes. rhEPO treatment is also granted before 
major surgery as a prophylaxis to reduce blood transfusions or for patients who are 
unwilling to receive blood. Moreover, treatment of anemia with rhEPO in patients 
with chronic heart failure (CHF) seems safe and well tolerated, leading to a phase 
III clinical trial currently enrolling patients. Recently however, a functional EPO­
receptor (EPOR) was detected outside the hematopoietic system, fuelling intense 
research into possible non-hematopoietic effects. From this , EPO has emerged as a 
myocardial survival and vascular growth factor with a promising protective potential 
in the setting of acute and chronic myocardial ischemia. This review focuses on the 
cardiovascular EPO-EPOR system and the potential role of treatment with rhEPO in 
cardiovascular patients with or without anemia. 
E ry t h r o p o i e t i c  effects  of  E P O  
EPO is a glycoprotein hormone mainly implicated in the regulation of red blood 
cell production. EPO is produced in the fetal liver and the adult kidney under the 
transcriptional control of hypoxia inducible factor- l a  (HIF - l a) . '  Although EPO is 
critical for the regulation of erythropoiesis, the production of EPO is not stimulated 
by diminished red blood cell numbers but instead through the downstream effect 
on tissue oxygen supply. Under normoxic conditions the continuous production 
of HIF- 1  a is antagonized by immediate degradation in the proteasome, making it 
functionally inactive. Hypoxia directly inhibits proteasomal degradation, resulting 
in exponentially increased expression of HIF - 1  a and transcription of a variety of 
hypoxia responsive genes including EPO. The renal medulla is especially sensitive 
to alterations in partial oxygen tension, which, together with the ability to rapidly 
increase EPO levels and exponentially augment red blood cell production, allow for 
tight regulation hemoglobin (Hb) levels and consequent tissue oxygen supply. 
EPO targets a transmembrane member of the cytokine type l receptor super­
family, ubiquitously expressed on erytlrroid progenitor cells. Binding of EPO results 
in dimerization of EPOR, which in turn activates the receptor associated janus 
tyrosine kinase-2 (JAK2). JAK2 further propagates tl1e signal by engaging secondary 
signal transduction molecules, including transducers and activators of transcription 
(STAT) , mitogen-activated protein kinases (MAPK) , and phosphatidylinosol 3 -kinase 
(PI3K)-protein kinase B pathways. The principal effect of EPO is the reduction of 
physiologic apoptosis associated with cell turnover in erytlrroid progenitor cells but 
1 9  
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in conjunction with other growth factors EPO additionally stimulates proliferation 
and differentiation of these cells. 2 
Erythropoiesis in  C H F  
Anemia (as defined by the World Health Organization as Hb levels < 1 3  g/dl in men 
and < I 2 g/ dL in women) is commonly observed in patients with CHF. 3.4 Anemia 
causes chronic volume overload to the left ventricle which results in increased oxygen 
consumption, left ventricular (LV) dilatation, and LV hyperthrophy, thereby negatively 
affecting cardiac function in CHF. Indeed, the presence of anemia in CHF has been 
consistently associated with impaired survival. 
The exact etiology of anemia in CHF has not been fully resolved and is likely to 
be multifactorial within the population as well as within each patient.3 ·4 In contrast 
to patients with chronic kidney disease, circulating EPO levels are elevated in patients 
with CHF, increase with the progression of disease, and independently predict 
impaired survival.5 However, when EPO levels are corrected for the prevailing Hb 
by calculating the observed/predicted (O/P) EPO ratio, the vast majority of patients 
with CHF display signs for insufficient EPO production. Opasich et al. 6 demonstrated 
that over 90% of anemic CHF patients display significantly depleted O/P EPO ratios 
compared with healthy controls, which was recently confirmed by our group.6 The 
impaired EPO production is caused by a combination of decreased renal function and 
a direct inhibition of EPO production in the kidney by pro-inflammatory cytokines 
and angiotensin converting enzyme inhibitors.4 On the other hand, the relatively 
elevated EPO levels in CHF are indicative of reduced responsiveness of erythropoietic 
cells to EPO. Experimental evidence for reduced erythropoiesis in CHF was reported 
by Iversen et al." In mice with heart failure after myocardial infarction (MI), the 
erythropoietic progenitor pool was reduced by 40%, apoptosis was increased and 
proliferation of these cells markedly impaired. This was associated with increased 
tumor necrosis factor (TNF)-a /Fas expression and increased cytolytic activity of 
bone marrow natural killer cells, suggesting an important role for inflammation in 
erythropoiesis inhibition. Interleukin- I ,  TNF-a and interferon a, 13, and y directly 
inhibit the formation of mature erythropoietic cells from erythropoietic progenitors 
in the bone marrow.� CHF is frequently associated witl1 elevated levels of pro­
inflammatory cytokines, and markers for inflammation are independently related to 
elevated EPO levels.7· 1 0  Moreover, we have recently demonstrated that anemia in CHF is 
partially explained by elevated levels of AcSDKP, a negative regulator ofhematopoietic 
stem cells. 1 1  The inhibitory effects of inflammatory cytokines and AcSDKP might 
increase the EPO levels required to maintain adequate red blood cell production. 
In addition to inhibition by circulating factors, erythropoietic progenitor cells of 
patients with CHF might exhibit impaired function. Hence, CHF is not primarily 
associated with defective EPO production but rather an inability to adjust production 
to an increased demand. 
20 
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Additional mechanisms may contribute to the development of anemia in CHF. 
We recently demonstrated that in addition to blunted EPO production and impaired 
renal perfusion, anemia in CHF is associated with enhanced fluid retention. 7 F luid 
retention can result in expansion of plasma volume and consequent hemodilution 
which may cause pseudo-anemia. Furthermore, CHF is infrequently associated with 
biochemical indices of impaired iron supply, but iron stores in the bone marrow are 
significantly depleted. 1 2 Although this might indicate systemic iron deficiency, it is 
more likely caused by diversion of iron to the reticuloendothelial system as part of the 
anemia of chronic disease. 13 F inally, the vast majority of patients in CHF use platelet 
aggregation inhibitors or anticoagulants , which might cause chronic microscopic 
blood loss. The extent to which this plays a role in CHF is not well described. 
The dis cover y  of a car diovas cular E P O­
E P O R  system 
The first evidence for a biologic role for EPO outside tl1e hematopoietic system came 
from tissue expression studies in 1 992 which demonstrated EPO messenger RNA in 
the brain. i. In addition to the adult kidney and the fetal liver, expression of EPO and 
EPOR has now been detected in the brain, heart, reproductive organs, and endothelial 
and vascular smooth muscle cells. 1 5 In contrast to tl1e ubiquitous high expression on 
erythroid cells , expression of EPOR in non-hematopoietic tissues is relatively low. 1 ; 
Expression of both EPO and EPOR, however, rapidly increase following hypoxia 
and a number of other metabolic stressors including pro-inflammatory cytokines, 
hypoglycaemia, and increased reactive oxygen species. In addition , EPOR expression 
is stimulated by rhEPO, most notably in conjunction with hypoxia. 1 7 Hence, while 
healthy non-hematopoietic tissues are relatively insensitive to EPO, an ischemic insult 
will results in autocrine/paracrine production of EPO and increased sensitivity of 
target cells. 
Research into the endogenous significance of this extra-hematopoietic EPO­
EPOR system has been hampered by the pivotal importance of its hematopoietic 
counterpart. EPO and EPOR knockout mice die at 1 4  weeks gestation due to severe 
anemia and, in addition , exhibit ventricular hypoplasia and a markedly impaired 
vascular development. 18 These findings have been interpreted as proof that ( cardio) 
vascular EPOR is crucial for the development of the cardiovascular system, but recent 
evidence has abrogated this hypothesis. 1 9  Suzuki et al. developed a murine model in 
which EPOR expression is restricted to the erytl1ropoietic lineage, by targeted knock­
in of the EPOR gene ligated to the GATA- I promoter, a transcription factor exclusive 
to erythroid lineage cells. This results in mice that exclusively express the EPOR in 
erythroid lineage cells while the other organs are devoid of an EPOR. Surprisingly, 
despite the absence of an EPOR in the cardiovascular system, these mice develop 
normally and are fertile, indicating that the cardiovascular EPO-EPOR system is 
dispensable for normal development. 1 9 Nevertheless, four outstanding publications by 
2 1  
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the same group revealed that these mice exhibit markedly increased susceptibility to 
acute and chronic cardiovascular disease, including more extensive Mis after ischemia 
reperfusion injury, 20 an impaired angiogenic response to femoral artery occlusion, 19 
augmented pressure overload-induced LV dysfunction,  21 and accelerated hypoxia 
induced pulmonary hypertension. 23 The same group demonstrated a correlation 
between high serum EPO and smaller myocardial infarct size in patients, interpreted 
as proof of a possible endogenous protective mechanism. 24 The latter findings should ,  
however, be interpreted with caution, as  higher EPO levels were associated with 
lower Hb levels, and the appropriate multivariable corrections were not made. More 
compelling evidence was recently published by Ferrario et al. who demonstrated an 
Hb-independent increase in EPO production after MI, persisting until 7 days after 
MI. 25 It is unknown whether the increased circulating EPO levels result from cardiac 
EPO production , although increased EPO-production after MI has been demonstrated 
in the murine heart. Together these results indicate the existence of an endogenous 
EPO-EPOR system as part of an endogenous defense mechanism against a broad 
spectrum of acute and chronic cardiovascular disease. 
EPO treatment for acute myoca rdia l ischemia 
The anti-apoptotic effects of EPO are crucial for the regulation of red blood cell 
production but might become equally important for the treatment of acute myocardial 
ischemia. Following an acute MI , extensive myocardial apoptosis ensues which in part 
determines the extent of the permanent myocardial damage. EPO exerts potent anti­
apoptotic effects in a number of cellular systems including cultured endothelial cells 
and neonatal rat cardiomyocytes. 1 5 Moreover, EPO prevents apoptosis from a number 
of sources , but hypoxia is most extensively studied. The signal transduction pathways 
associated with the anti-apoptotic actions of EPO in extra-hematopoietic cells display 
remarkable similarities to erythroid cells including PI3K-AKT, STAT, and MAPK. 
Research has however in part been restricted to these pathways. H It is widely accepted 
that cytoprotection by EPO is caused by its anti-apoptotic effects. Nevertheless , EPO 
has been linked to an attenuated inflammatory response of cardiomyocytes , associated 
with upregulation of endothelial nitric oxide synthase ( eNOS). 26 Interestingly, the 
anti-apoptotic effects of EPO are abrogated by specific eNOS blockers or in cells 
derived from eNOS knockout mice, suggesting that eNOS upregulation is crucial for 
the anti-apoptotic effects of EPO as well.2' The activation of the eNOS pathway might 
suggest that in addition to the anti-apoptotic effects , systemic EPO treatment might 
improve endothelial function and consequently reduce peripheral resistance. 
Numerous studies have translated the cytoprotective in vitro effects into ex and 
in vivo models of acute myocardial ischemia reperfusion injury and permanent 
coronary artery ligation. n In the first in vivo study, Calvillo et al. administered a 
high dose of EPO (5000 U/kg) for 7 consecutive days after myocardial ischemia 
reperfusion injury in rats , which resulted in a SO% reduced loss of cardiomyocytes 
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and significantly preserved cardiac function, but to a 30% increased hematocrit as 
well. 28 Although this study was unable to fully separate cardioprotective effects from 
the hematopoietic effects, other studies have proven the hematocrit independent 
nature of cardioprotection. 29 EPO exerts protective effects in models of ischemia/ 
reperfusion injury and permanent coronary artery ligation in mice, rat, rabbits and 
dogs, with doses ranging from 8000 U/kg to J OO U/kg. 29 Moreover, protection is 
induced when EPO is administered before ischemia, during ischemia, and at the 
onset of reperfusion, providing a broad window opportunity.3° Finally, tl1e effects 
of a single dose of EPO on infarct size and cardiac function are still present 9 weeks 
later. 3 1  Together these experimental data suggest a promising role for rhEPO as a 
cardioprotective agent in the setting of an acute MI. 
E P O  treat ment in C H F  
Irrespective of epicardial coronary anatomy, perfusion of the myocardium is impaired 
in heart failure due to disproportionate cardiac hyperthrophy relative to (micro) 
vascular growth, resulting in low-grade ischemia.12·33 In addition to the negative 
inotropic effects of impaired perfusion, ischemia will result in a switch from fast 
energy consuming a-myocin heavy chain (MHC) isoforms to slow �-MHC isoforms, 
which further impairs contractility. 
Therapies aimed at improving cardiac microvascularization might improve cardiac 
function in CHF. EPO has been shown to stimulate neovascularization by promoting 
proliferation and survival of endothelial cells in vitro and stimulating angiogenesis 
in vivo.34 36 In addition, EPO induces the proliferation, differentiation, and adhesion 
of a subset of bone marrow derived progenitor cells with an endothelial phenotype 
( endothelial progenitor cells [EPC]) in vitro and results in marked mobilization of 
EPC in vivo.37 39 EPC specifically home to sites of neovascularization and contribute 
to tl1e formation of new vessels.40 In order to evaluate the effects of EPO on cardiac 
function and neovascularization, we induced heart failure in rats by coronary artery 
ligation and treated them with a high dose (40 mg/kg/3 weeks) of the long acting 
EPO analogue darbepoetin alfa, starting 3 weeks after MI. 3 1  Altl10ugh this delayed 
treatment did not result in a reduction of infarct size measured after 9 weeks of 
treatment, cardiac function was significantly improved. The improved cardiac function 
was associated with increased capillary density and increased capillary:myocyte ratio, 
indicating neovascularization. 
The beneficial effects of EPO on cardiac function and microvascularization 
in post-MI LV dysfunction have recently been confirmed by three independent 
studies.4 1-41 Furthermore, in a distinct model of chronic myocardial dysfunction, 
EPO prevented doxorubicin induced deterioration of cardiac function which was 
also associated with neovascularization of the myocardium.44 45 The EPO-induced 
neovascularization is consistently associated with increased circulating EPC. 
Interestingly, in a model of doxorubicin induced myocardial dysfunction, infusion 
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of isolated EPC resulted in improved cardiac function and neovascularization in a 
magnitude equal to EPO.H We recently investigated the contribution of EPC to EPO 
induced neovascularization by replacing bone marrow of rats with genetically labeled 
cells, which allows differentiation between EPC mediated neovascularization and in 
situ proliferation of endothelial cells.46 This study revealed that approximately 30% 
of the new vessels were comprised of bone marrow-derived cells indicating that 
EPC contribute to EPO-induced neovascularization. The remaining vessels however 
comprised of in situ proliferated myocardial endothelial cells, associated with a 
fivefold increased expression of vascular endothelial growth factor (VEGF) . EPO­
induced neovascularization in post-MI heart failure therefore seems mediated through 
a combination of EPC recruitment from the bone marrow and increased myocardial 
expression ofVEGF. 
The dosing regimens used in previous studies all resulted in a significant 
increase in hematocrit levels. When applied to the clinical situation, this could lead to 
hypertension, seizures, vascular tl1rombosis, and death, possibly related to abruptly 
increased hematocrit levels. H Therefore, we recently compared the effects of a high 
EPO dose with a low-dose that had no effect on hematocrit. Similar to high-dose EPO, 
low-dose treatment resulted in slightly less pronounced but statistically significantly 
improved cardiac function and improved myocardial microvascularization 
(unpublished data) . Another option to avoid the potentially negative effects of 
chronic EPO therapy on hematocrit values could be the use of recently discovered 
non-erythropoietic derivates of EPO, retaining the tissue protective property, without 
the undesired effect on erythropoiesis.48 The possibility to separate the erythropoietic 
and tissue-protective effects is explained through structural differences between 
receptors in bone marrow and in "peripheral" tissues.-19 Two independent studies 
have demonstrated that these non-erythropoietic EPOs retain their cardioprotective 
potential in models of acute Mr.so. s i It is uncertain whether these new EPOs will 
improve cadiac function in CHF. 
C lini cal perspec tives 
The observation that anemia in CHF is associated with defective EPO production has 
prompted the evaluation of rhEPO for its treatment. Several safety and efficacy studies 
have evaluated correction of anemia in CHF with rhEPO with or without concomitant 
administration of intravenous iron. The first study was performed by Silverberg et al . 
who randomized 3 2 patients with mild anemia to receive either rhEpo and intravenous 
iron or no additional treatment, resulting in significant improvement in New York 
Heart Association functional class and cardiac function.s 1 These findings have been 
corroborated by several randomized, double-blind, placebo-controlled studies. In 
addition to the amelioration of anemia, EPO treatment improved LV ejection fraction, 
renal function, exercise capacity and quality-of-life scores and reduced natriuretic 
peptides and hospital admissions for CHF. 3 A pooled analysis of the two largest studies, 
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which combined the data of more than 320 patients, revealed a trend to reduced 
risk of the combined endpoint of CHF-related hospitalization and all-cause mortality 
in the rhEPO-treated groups. n Based on these findings, a large multicenter, double­
blind, randomized, placebo-controlled trial was designed, which has recently started 
enrolling patients (RED-HF).  On the other hand, the recently published CHOIR study 
in patients with chronic kidney disease, demonstrated that normalization ofHb values 
to reference ranges (Hb > 1 3 .5 g/dL) with rhEPO resulted in significantly more 
cardiovascular events compared to target levels to 1 1 . 3  g/dL, confirming previous 
findings from Besarab et al.47·54 These results have intensified the debate on the safety 
of rhEPO. As a result , the Food and Drug Adminstration has recently recommended 
"the lowest possible dose to slowly raise the hemoglobin concentration to the lowest 
level that will avoid the need for a blood transfusion." Of note, the possible beneficial 
effects of rhEPO in chronic kidney disease patients seem to be distinctly different 
from patients with CHF. So far, no deleterious effects of rhEPO have been observed in 
patients with CHF, but current trials will be carefully monitored. 
Besides clinical CHF trials , two phase II trials are running in patients with an 
acute MI. In this setting, only one bolus of EPO is used, and therefore the risks of an 
unwanted hematocrit-elevation are very limited. We recently performed a randomized 
safety and feasibility study with a single 3 00 µg bolus of the long acting EPO analogue 
darbepoetin alfa, administered during primary percutaneous coronary intervention 
for a first acute Ml. EPO treatment was both safe and well tolerated, caused only 
a small but nonsignificant increase in hematocrit levels and significantly increased 
circulating EPCs. 55 These findings led to the design of a randomized multi center 
study that evaluates whether EPO can attenuate post-MI loss of cardiac function , 
currently enrolling patients at our center (NCT0044948 8).  The similar REVEAL study 
is currently performed in the US (NCT00378352) .  The results of these studies are 
clearly awaited. 
C o n c l u s i o n s  
Although recently scrutinized for other indications, no deleterious effects of rhEPO 
have been observed in anemic patients with CHF. The efficacy of rhEPO for the 
correction anemia in CHF is currently under investigation. Recent evidence has however 
transformed EPO from a designated erythropoietic growth factor to a cytokine that is 
now recognised for its pleiotropic tissue protective properties. The endogenous EPO­
EPOR system is crucial for protection against acute and chronic myocardial ischemia 
and systemic administration of rhEPO has promising beneficial effects in acute and 
chronic cardiac disease. Whereas the setting of an acute MI might benefit most from 
the EPO-induced protection against apoptotic cell death, the chronically failing 
heart seems to improve through EPO-induced neovascularization (Fig. I ) .  Therefore, 
in addition to the correction of anemia in CHF, rhEPO might benefit patients with 
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CHOIR-Correction of Hemoglobin and Outcomes In Renal insufficiency; RED-HF­
Reduction of Events with Darbepoetin alfa in Heart Failure; REVEAL-Reduction 
of infarct Expansion and Ventricular remodeling with Erythropoietin After Large 
myocardial infarction. 
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Chapter 3 
A bs trac t  
Aims 
Anemia is  prevalent in the chronic heart failure (CHF) population, but its cause is 
often Wlknown. The present study aims to investigate the relation between anemia, 
renal perfusion, erythropoietin production, and fluid retention in CHF patients. 
Methods a n d  res u lts 
We studied 97 patients with CHF, of which 1 5  had anemia (Hb, 1 3 .0 g/dl in men 
and Hb, 1 2 .0  g/dl in women) , without hematinic deficiencies. Glomerular filtration 
rate (GFR) and extracellular volume (ECV) were measured as the clearance and the 
distribution volume of constantly infused 1 25!-iothalamate, respectively. Effective 
renal plasma flow (ERPF) was determined as tl1e clearance of 1 3 11-hippuran. Anemic 
CHF patients displayed significantly reduced GFR (P=0 .002) , ERPF (P=0.005) 
and EPO production (P = 0.00 1 ) ,  and an elevated ECV (P=0.0 1 5) .  Multivariable 
analysis demonstrated that lower GFR (P=0.003) , lower ERPF (P=0.004) , lower EPO 
production (P=0.006) , and a higher ECV (P=0.00 1 )  were significant independent 
predictors of lower hemoglobin levels. 
Conclusions 
Anemia in CHF is  not only independently associated with impaired renal perfusion 
and blunted EPO production, but to fluid retention as well. 
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I n t r o d u c t i o n  
Anemia is present in a substantial part of the chronic heart failure (CHF) population, 
ranging from 1 5-55%, depending on the definition of anemia and severity of 
disease. 1 
Anemia is independently associated with increased morbidity and impaired 
prognosis, although the cause of anemia is frequently unknown. H CHF is associated 
with elevated levels of erythropoietin (EPO) , suggesting impaired erythropoietic 
activity in the bone marrow. 1 ·6•7 Recently, we demonstrated that anemia in CHF could 
partly be explained by increased serum levels of AcSDKP, a negative regulator of 
hematopoietic stem cell proliferation.8 In addition, we hypothesize that CHF will 
compromise renal perfusion resulting in impaired EPO production, thereby causing 
anemia. F inally, it has been suggested that anemia in CHF may be partly explained by 
fluid retention and consequent haemodilution.9 However, the relative contribution 
of renal perfusion, EPO production, and fluid retention to the presence of anemia in 
CHF has so far not been well described. We therefore evaluated the relation between 
anemia, effective renal plasma flow (ERPF), EPO production, and extracellular volume 
(ECV) in CHF patients. 
M e t h o d s  
Patient population 
Clinically stable CHF patients on outpatient follow-up at our department were asked 
to participate, as described in detail previously. 10 Approximately 1 2 1  patients were 
asked to participate. In total, 1 1  0 patient were included into the original analysis and 
finished the study. Owing to missing hemoglobin levels, 1 3  patients were excluded 
form analysis, leaving 9 7  subjects for analysis. Briefly, inclusion criteria were age. 
1 8  years and left ventricular ejection fraction (LVEF) ,  45%. All patients used renin­
angiotensin system blockers, and medication had remained stable for at least 1 month. 
Exclusion criteria included stroke, myocardial infarction, or cardiac revascularization 
procedures within the last 3 months or scheduled for these procedures, unstable 
angina, primary renal disease, prior organ transplant, or chronic use of renal function 
compromising medication. 
Cardio-renal haemodynamic parameters 
LVEF was determined by nuclear ventriculography or echocardiography using 
Simpsons rule. Mean arterial pressure (MAP) was calculated from systolic and 
diastolic blood pressure measurements obtained immediately before 1 151-iotholamate 
and 1 3 1I-hippuran clearance measurements from I O  consecutive measurements in 
supine position using an automated system. N-terminal proBNP (NT-proBNP) was 
determined by electrocherniluminescence immunoassay on the Roche Elecsys (Roche 
diagnostics, Netherlands) . Glomerular filtration rate (GFR) and ERPF were measured 
3 5  
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by constant infusion of the radiolabelled tracers ml-iothalamate and 1 3 1 1-hippuran. 1 1  
Briefly, after drawing a blank blood sample, a priming solution containing 0.4 mL/ 
kg body weight of the infusion solution (0.04 MBq of 1 251-iothalamate and 0.03 MBq 
of 1 3 1 l-hippuran) plus an extra amount of 0.6 MBq of 1 251-iothalamate was given at 
8 a.m., followed by infusion at 1 2  mL/h, adapted to 9 mL/h in subjects with renal 
function impairment as estimated from previously obtained serum creatinine values. 
This ensures steady-state plasma levels of 1 3 11-hippuran and 1 251-iothalamate after a 
run-in period of 2 h, as verified by hourly blood samples. Subsequently, clearances of 
1 1 1!-iothalamate and 1 3 1!-hippuran and the distribution volume of 1 25!-iothalamate were 





. \' respectively, and (U.V) /P
(
'- 1 1 ) was corrected for voiding errors uppurm ,vl ,a .1ma1c 
by the ratio of the urinary to plasma clearance of 1 3 1 !-hippuran. U.V represents the 
urinary excretion of the tracer and I.V the infusion rate of the tracer; P represents the 
values in plasma calculated from the samples bracketing each clearance period. The 
body surface area (BSA) was calculated as 0.007 1 84.weight0 •25 .length0.125. and GFR 
and ERPF were expressed per 1 . 73  m2 of BSA. Renal blood flow (RBF) was calculated 
as ERPF / I -haematocrit. The filtration fraction (FF) was calculated as the ratio of GFR 
and ERPF and expressed as percentage. ECV was estimated from the distribution 
volume of 1 2 1I-iotholamate 1 2• 1 1  and calculated as [(I.V + B.V)- U.V]/ pi01h'''"''"" during 
steady state. B.V represents the bolus infusion of the tracer. GFR and ERPF were 
expressed per 1 . 73 m1 of BSA, and ECV was expressed as L/kg body weight. 
H e m oglobin levels, h a e m atin ic parameters, a n d  EPO levels 
Hemoglobin, iron, ferritin, transferrin, and vitamin B 1 1  and B 1 2  levels were 
determined at the local laboratory facilities. EPO levels were determined by IMMULlTE 
EPO assay (DPC, Los Angeles, CA, USA). To define the relation between EPO levels 
and a given Hb, we included 1 5 reference subjects referred to our department with 
complaints of chest pain or palpitations. The reference subjects had a mean age of 5 0  
± 4.5 years and had normal LVEF (LVEF > 60%) , normal renal function, no signs of 
inflammation, or symptoms of CHF. 1 • An exponential regression equation of serum 
EPO vs. Hb (mmol/1) was calculated, resulting in the following equation log EPO = 
3. 0 1 5  -( 0 . 1 3  0 * Hb) . Predicted log EPO and observed/ predicted log EPO ratio (log 
serum EPO/predicted log EPO) were calculated with this equation. Mean O/P ratio in 
reference subjects was 0.90±0.029 (95% CI 0.64- 1 . 1 2) .  Total iron binding capacity 
(TIBC) was calculated by multiplying serum transferrin x 20. Transferrin saturation 
(FeSat) was calculated as (serum iron/TIBC) * 1 00%. Iron deficiency was defined as 
ferritin levels , 30  mg/L or FeSat, 1 5%. According to local laboratory reference ranges, 
deficiency in vitamin B 1 1  and B 1 2  was defined as levels, 1 42 pmol/L and 50 pg/ml, 
respectively. 
High-sensitivity CRP was determined by nepholometry. The threshold for 
detection was 0. 1 56 mg/L; when CRP levels below the detection limit, were assigned 
the value 0. 1 5  6 mg/1 for statistical purposes. 
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Statistics 
Data are given as mean ± standard deviation when normally distributed, as median 
and interquartile range when skewed distributed, and as frequencies and percentages 
for categorical variables. Differences between groups were compared with Student's 
t-test, Mann-Whitney U test, x2 of F isher's exact test where appropriate. A P-value, 
0.05 was considered statistically significant, and all reported probability values are 
two-sided. Correlation between Hb, EPO or O/P ratio, and various other variables 
was performed using Pearson's correlation coefficients. Non-normally distributed 
continuous variables were log-transformed. The variables age, sex, pharmacological 
treatments , NewYork Heart Association (NYHA) functional class , LVEF, ERPF, GFR,  F F, 
ECV, NT-proBNP, CRP, and MAP were assessed for univariate linear association with 
Hb or log EPO. Variables that showed a significant (P < 0. 1 5) univariate association 
were included stepwise in a multivariable linear regression model on the basis of 
on the strength of the univariate association. All the variables described earlier were 
added to the final model simultaneously to assure that addition of these variables did 
not significantly increase the predictive accuracy of the model. The final model was 
assessed for first line interaction. 
Resul t s  
Patien t  characteristics 
Seventy six percent of subjects were male and age ranged from 2 7 to 8 1  years. 
NYHA functional classes I, II, III, and IV comprised 14 ,  44, 3 1 ,  and 1 0% of patients , 
respectively. 
Difference in characteristics between anemic a n d  non-anemic 
CHF patien ts 
In the total population, 1 9  patients (20%) were anemic according to the WHO 
criteria (Hb , 1 3 .0 g/dL in men and Hb , 1 2.0  g/dL in women) . Iron deficiency was 
present in 4 out of 1 9  anemic (2 1 % ) and 3 out of 7 8 non-anemic ( 4%) CHF patients. 
Other hematinic deficiencies were not observed. The iron-deficient patients were 
excluded from further analysis, leaving 7 5 non-anemic subjects and I 5 subjects with 
unexplained anemia. Differences in characteristics between anemic and non-anemic 
subjects are summarized in Table I .  Anemic subjects were significantly older and in 
a higher NYHA class. Although LVEF was comparable, compared with non-anemic 
patients, anemic patients showed more severe haemodynamic impairment, reflected by 
reduced MAP (86.8 ± 1 3  vs. 7 6.8 ± 1 4  mmHg; P=0.007) ,  ERPF (286 ± 83 vs. 2 1 9  ± 
74 rnL/min/ 1 .73 m2 ; P=0.005) and RBF (502 ± 1 50 vs. 348 ± 1 2 1  mL/min/ 1 .73 
m2; P<0.00 1 ) ,  and elevatedNT-proBNP levels [ I O  (260-1 355) vs. 1 004 (720-1 904) 
pg/rnL; P=0.029]. Anemic CHF patients were more often using diuretics (65 vs. 8 7%; 
P=0.045) and despite this displayed significantly elevated ECV (0.25  ± 0.5 vs. 0.29 ± 




Age (years) 56.3 ± 12  65.6 ± 9 0.004 * 
Sex (n, % male) 58 (85 ) 10 (71 ) 0.5 10  
NYHA class 2.3 ± 0.8 2.8 ± 0.8 0.036* 
BMI {kg/M2) 27.8 ± 4  26.1 ± 3 0.140 
lschemic etiology (n, %) 38 {50) 7 (47) 
Heart rate 65 ± 2  64 ± 3  0.834 
MAP {mmHg) 86.8 ± 1 .5 76.8 ± 3 .6 0.007* 
lVEF (%) 28 ± 10  26 ± 6  0.525 
NT pro-BNP {pg/ml) 5 10  (260-1 355) 1 004 (720-1904) 0.029* 
Creatinine (mg/dl) 1 .2 I 1 -2)  1 .2 I 1 . 1 - 1 .7) 0.150 
Urea (mg/dl) 19 ( 1 6-22) 35 (23-40) <0.001 * 
Plasma sodium (mEq/l) 1 37 ± 3  1 36 ± 3  0.589 
GFR (ml / min / 1 .73 m2) 79 ± 25 56 ± 28 0.002• 
ERPF (ml / min / 1 .73 m2) 286 ± 83 219 ±  74 0.005* 
RBF (ml / min / 1 .73 m2) 502 ± 150 348 ± 121 <0.001 * 
FF (%) 28 (26-30) 26 (20-29) 0.370 
FENa {%) 0.88 ± 0.33 0.97± 0.52 0.370 
ECV /body weight (L/kg) 0.25 ± 0.5 0.29 ± 0.4 0.015*  
Mild RF  {GFR <60) 16 (21 %) 9 (60%) 0.004* 
Severe RF (GFR<30) 4 (5%) 3 (20%) 0.088 
Hb (mg/dl) 15 ± 0.7 1 2.7 ± 0.4 <0.001 * 
Serum EPO (U/l) 15.7 ( 1 1 -21 ) 1 8.5 ( 1 2-31 )  0.357 
0 / P ratio 1 .15 ± 0.2 0.93 ± 0.1 8  0.001 • 
CRP {mg/l) 2.15 (0.95-4.06) 2.38 {0.77-5.66) 0.733 
ACE inhibitors, n {%) 66 {88) 12 {80) 
ARB, n {%) 9 ( 12 )  3 (20) 0.414 
Beta blokkers, n {%) 62 (83) 1 3  (87) l 
Diuretic, n {%) 49 (65) 13 (87) 0.045* 
Aldosterone ant. (%) 51  (BB) 7 (47) 0.144 
*p<0.05 All continuous variable are presented as mean ± SD, if normally distributed and as median value 
with 25'h - 75"' percentile when skewed distributed. NYHA; New York Heart Association functional class, 
BMI; Body Mass Index, MAP; mean arterial pressure, lVEF; left ventricular ejection fraction, NT pro_BNP; 
N terminal pro_broin natriuretic peptide, GFR; glomerular filtration rate, ERPF; effective renal plasma flow, 
RBF; renal blood flow, FF; filtration fraction, ECV; extracellular volume, FENa; fractional Na excretion, 
Hb; hemoglobin, RF; renal failure, EPO, erythropoietin levels, 0 / P ration, ratio between observed ond 
predicted logEPO, CRP; C-reactive protein, ARB; angiotensin receptor blokker, aldosteron ant; aldosteron 
antagonists. 
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as anemic patients did not display oedema, nocturia, or dyspnoea more frequently 
( data not shown). Plasma sodium levels and fractional sodium excretion were similar, 
implicating that the elevated ECV was not caused by excess sodium intake. Although 
creatinine levels were comparable between groups, urea levels were elevated [ 1 9  ( 1 6-
22) vs. 3 5  (23-40) mg/dL; P=0.007] and GFR (79 ± 25 vs. 56+28 mL/min/ 1 . 73 
m2; P=0.002) was significantly reduced in anemic patients. Moreover, anemic patients 
had a higher incidence of moderate renal failure (GFR<60 mL/min/ 1 . 73 m2) and 
a trend towards more severe renal failure (GFR, 30 mL/min/ 1 . 73 m2) (2 1 vs. 60%, 
P<0.005 and 5 vs. 20%, P=0.088,  respectively) . 
By definition, Hb level was significantly lower in anemic subjects. However, EPO 
levels were comparable between anemic and non-anemic CHF patients. Additionally 
observed/predicted (O/P) ratio was significantly reduced in anemic subjects ( 1 .  1 5  ± 
0.2 vs. 0.93 ± 0 .2 ,  P=0.00 1 ) ,  indicating blunted EPO production. O/P ratio was 
significantly higher in non-anemic CHF patients compared with reference subjects 
(P=0.026), whereas O/P ratio in anemic CHF patients and controls were comparable. 
Thus, EPO production is elevated in both anemic and non-anemic CHF patients. But 
based on their Hb, it should have been higher in anemic CHF patients. It therefore 
seems that the compensatory rise in response to anemia is impaired. 
Hb levels a n d  EPO production in th e CHF population 
CHF patients displayed a relatively moderate negative correlation between EPO 
and Hb levels (R=-0.28 1 ,  P=0.007).  A moderate significant correlation was also 
observed between EPO levels and both CRP (R=0. 28 I ,  P=0.007) and NYHA class 
(R=0.2 1 0 , P=0.05) ,  and a trend with NT-proBNP (R=0. 1 93 ,  P=0.07) .  No significant 
correlation was observed between EPO levels and other markers for cardiorenal 
hemodynamic status, or renal function parameters. O/P ratio correlated with Hb 
(R=0.397, P=0.00 1 ) ,  GFR (R=0.237, P=0.024) , and FF (R=0.285 ,  P=0.007) .  
Predictors of  Hb a n d  serum EPO 
Univariate and multivariable linear associations between Hb and EPO levels are 
displayed in Tables 2 and 3, respectively. Sex, lower EPO (Figure I A) ,  lower GFR 
(Figure I B) , lower ERPF (Figure I C) ,  and higher ECV (Figure I D) were independently 
associated with lower Hb levels, accounting for 3 1 -44% of the variance in Hb levels. 
The variables CRP, NYHA class, NT-proBNP, and Hb showed significant univariate 
association with plasma EPO. However, higher CRP and lower Hb levels were the 
only independent predictors of higher serum EPO levels. Inclusion of the full list of 
possible predictive variables did not result in a significant increase in the adjusted R 1 , 




Table 2. Univariate, and multivariable predidors of Hb levels. 
Variable B SE B SE 13 Part. car. p 
Sex - 1 .41 0.30* - 1 . 189 0.258 -0.394 -0.449 <0.001 
Age -0.022 0.012* 
GFR 0,02 0.005* 0.037 0.009 0.744 0.414 <0.001 
ERPF -0.004 0.002* -0.008 0.003 -0.534 -0.310 0.004 
NYHA -0.04 0.1 7* 
EPO -1 .55 0.57* - 1 .422 0.430 -0.266 -0.399 0.001 
ECV -6.36 2.95* -7.120 2.215 -0.259 -0.330 0.004 
MAP -0.03 0.01 * 
BNP -0.399 0. 144* 
Adjusted R-squore 0.436 
* p<0.15, GFR; glomerulor filtration role, ERPF; effective renal plasma flaw, NYHA; New York Heart 
Association functional class, EPO; serum erythropoie�n levels, ECV; extra cellular volume corrected for 
bodyweight, MAP; mean orleriol pressure, BNP; N terminal pro_bmin notriurelic peptide, 13; standardised 
beta, part. cor.; partial correlation coefficient 
Univariate Multivariable 
Variable B SE B SE p 
Sex 0.03 0.233 
Age 0.027 0.6 
Hb -0.052 0.019* -0.044 0.019 -0.233 0.025 
NYHA -0.06 0.03 1 *  
CRP 0.345 0.126* 0.125 0.054 0.234 0.024 
Adjusted R-square: 0.1 1 1  
* p<0.15. Hb; hemoglobin levels, NYHA; New York Heart Association functional class, CRP; C-reactive 
protein 
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Disc ussion 
The present study demonstrated that anemia in CHF patients was not only 
independently related to impaired renal perfusion and blunted EPO production, but 
to an increased ECV as well. However, in contrast to our expectations, serum EPO 
levels were not directly related to renal perfusion. 
The association between anemia in CHF and impaired EPO production has been 
suggested previously. 1 .7 Nevertheless, the presence of defective endogenous EPO 
production was not formally evaluated until recently. In a comprehensive retrospective 
analysis on the cause of anemia in CHF patients, Opasich et al. 1 5 found that 50% of 
anemic CHF patients showed evidence of impaired EPO production. Our data further 
substantiate these findings. 
The relation between renal perfusion and EPO levels has been evaluated previously 
in two populations comprising 1 3  and 1 4  CHF patients. 1 6· 1 7  In these studies, EPO 
production inversely correlated with RBF, ERPF and renal oxygen delivery, suggesting 
that impaired renal oxygenation caused the elevated EPO levels. However, in our 
far larger cohort ,  these findings could not be reproduced. Although there was no 




EPO production and GFR was observed, which might implicate that blunted EPO 
production results from impaired renal function and structural renal damage. 
Furthermore, circulating inflammatory cytokines and ACE-inhibitors can directly 
inhibit EPO production in the kidney and might contribute to the blunted EPO 
production. 18• 19  Additionally, impaired GFR could attenuate the excretion of circulating 
erythropoiesis-inhibiting factors ( e.g. AcSDKP), leading to enhanced plasma levels, as 
has been demonstrated in a hemodialysis population. 20 
The non-anemic CHF patients displayed higher EPO levels and O/P ratios 
than reference subjects, as has been described previously. Elevated EPO levels were 
independently related to higher CRP levels, suggesting that elevated EPO production is 
directly related to an enhanced inflammatory state. Several pro-inflammatory cytokines 
have inhibitory effects on erythropoiesis and are established as the cause of anemia 
associated with chronic inflammatory disease.2 1 CHF is associated with enhanced 
expression of a variety of pro-inflammatory cytokines, possibly contributing to the 
development of anemia. 6 In addition, we have recently demonstrated that anemia in 
CHF could be partially explained by elevated levels of AcSDKP, a negative regulator 
of hematopoietic stem cells. 8 These circulating factors inhibit erythropoiesis and can 
eventually result in elevated EPO requirements. Indeed, although EPO production was 
blunted, the circulating EPO levels in anemic CHF patients were not reduced but 
slightly elevated compared with non-anemic patients. The slightly elevated EPO levels 
were however insufficient for the prevailing Hb, reflected by significantly impaired 
O/P ratio. Hence, anemia in CHF does not result from the inability to produce EPO, 
but an inability to further increase baseline EPO production. 
As expected, anemic patients displayed elevated ECV, which was independently 
related to lower Hb levels. Impaired renal hemodynamics in CHF cause activation of 
RAS and vasopressin systems, resulting in salt and fluid retention and consequently 
increased ECV: Fluid retention in CHF can cause haemodilution, resulting in pseudo­
anemia, which carries an even worse prognosis than true anemia.9 In the present 
study, anemic subjects more frequently received diuretics but nonetheless displayed 
elevated ECV: Importantly, although fluid retention was related to anemia, signs and 
symptoms of fluid retention were absent. Thus, hemodilution seems to precede the 
clinical presentation of fluid retention. Therefore, starting or increasing the dose of 
diuretics should be considered before starting with EPO treatment. Since the etiology 
of anemia in CHF seems multifactorial, the preponderant cause should be identified 
on an individual basis, for instance, by determining the O/P ratio or ECV in addition 
to regular diagnostic procedures. 
Although the reduced renal perfusion, blunted EPO production, and elevated ECV 
could be the cause of anemia in CHF, they could also be a consequence. Lower Hb 
levels can result in peripheral tissue hypoxia, causing vasodilatation and consequently 
reducing blood pressure. 12 This will result in activation of the RAS and further 
compromise of RBF by renal vasoconstriction and fluid retention. The compromised 
kidney seems unable to meet the increased demand, and anemia ensues. The vicious 
cycle of CHF causing anemia and anemia causing further deterioration of CHF has 
been described as the cardiorenal anemia syndrome. 23 
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Thus, anemia in CHF is directly related to an impaired haemodynamic state, 
compromising renal perfusion, attenuating EPO production, and increasing 
fluid retention. Therefore, improvement of cardiac function and cardiorenal 
hemodynamics would be the most rational approach for the treatment of anemia 
in CHF. Additionally, administration of recombinant human EPO might break the 
vicious cycle by replenishing the insufficient EPO levels. 24 It is however uncertain 
whether supplementation of EPO in anemic CHF patients will decrease morbidity 
and mortality, as anemia might merely be a marker for impaired cardiac function. 
This will emerge from scheduled randomized clinical trails. The elevated ECV in our 
population suggests that concomitant meticulous correction of fluid overload might 
be feasible. Whether this will improve Hb and outcome in this population is however 
uncertain. 
L imitation s  
Our study has limitations. Apart from the obvious crosssectional design , the CHF 
population contained relatively few anemic CHF patients and anemic subjects had 
relatively mild anemia. Therefore, our data might not be representative for more 
severe forms of anemia and should be regarded as hypothesis generating. 
Conclusi ons 
Anemia in CHF is not only independently associated with impaired renal and blunted 
EPO production, but to fluid retention as well. 
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Chapter 4 
Abstr a c t  
B a c kg r o u n d  
Anemia of unknown etiology is frequently found in chronic heart failure ( CHF) patients 
and predicts a poor prognosis. We hypothesized that bone marrow dysfunction might 
be the underlying cause, and therefore evaluated erythropoiesis in CHF patients. 
M e th ods 
Bone marrow mononuclear cells (MNC) were harvested from the sternum during 
elective cardiac surgery from 1 2  patients with CHF (age 68 ± 2 ;  53% male, Left 
Ventricular Ejection Fraction (LVEF) 3 2  ± 1 . 8  %) and 1 2  age matched patients with 
normal left ventricular function (LVEF .!: 55%).  We quantified early hematopoietic 
progenitor cells (CD34 +) and committed erythroid lineage cells (CD7 l hngh•) , 
apoptosis (Annexin-v+ / DAPI+) and erythropoietin-receptor (EPO-R) density by 
flow cytometry. The potential of isolated CD34 + HPCs to form erythroid colonies was 
assessed in methylcellulose medium containing incrementing doses of EPO. After 1 4  
days, the number of Burst Forming Units Erythroid (BFU-E) were counted. 
R e s u lts 
Fifty percent of CHF patients had anemia of undetermined origin. The erythroid 
lineage was significantly depleted in CHF patients, reflected by 2-fold lower number 
of CD34+ and a 30% reduction in CD7 l bright cells (P<0.05 for both) . Throughout 
the EPO dose-response range, CD34 + cells of CHF patients produced a 3-fold lower 
number of BFU-E colonies compared to controls (P<0.02). Bone marrow apoptosis 
was 3-fold increased in CHF patients compared to controls (P<0.0 1 ) ,  while EPO-R 
density was comparable. Moreover, BFU-E formation did not differ between anemic 
and non-anemic CHF patients (P=0.8) .  BFU-E numbers were inversely correlated 
with plasma NTproBNP levels (R= -0.5, P =0.03), even after adjusting for potential 
confounders. 
Conclusions  
CHF causes profound dysfunction of the hematopoietic compartment, reflected by 
impaired erythropoiesis. Although bone marrow dysfunction might render patients 
more susceptible to anemia, it does not exclusively explain its occurrence . 
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I n t r o d u c t i o n  
Chronic heart failure (CHF) is the final common endpoint of the majority of cardiac 
conditions and represents the leading cause of death in the Western world. Anemia of 
undetermined origin is frequently found in patients with CHF, and predicts an even 
poorer prognosis. 1 •2 Resolving the preponderant etiology of anemia in these patients 
is therefore warranted. 3 
An intriguing finding in CHF patients is that erythropoietin (EPO) levels are 
relatively elevated and the strong and linear association between hemoglobin (Hb) 
and EPO levels is distorted.< 6 These findings suggest that hematopoietic cells of CHF 
patients are relatively insensitive to EPO and may require more EPO to maintain 
adequate erythropoiesis. The relative resistance to EPO might in part be explained 
by the anti-proliferative effects of inflammatory cytokines or ACE-modulating drugs 
in the circulation.7 1 0  In addition, CHF patients might exhibit specific cellular EPO­
resistance, for instance by down regulation of the EPO-receptor (EPO-R) or its 
downstream signal transduction pathways in erythroid cells. 1 1 Interestingly, bone 
marrow cells of CHF patients have been shown to display significantly reduced 
myeloid and endothelial progenitor cell colony formation, suggesting that bone 
marrow function might be generally affected. 1 2  
We hypothesised that CHF is associated with general bone marrow dysfunction 
which might in part explain the high incidence of anemia in these patients. An 
important determinant of adequate hematopoiesis is the clonogenic expansion of 
hematopoietic progenitor cells (HPCs) into mature hematopoietic cells. We therefore 
compared the in vitro clonogenic potential of isolated CD34+ HPCs from CHF patients 
with age matched controls and evaluated their relation to the severity of CHF and the 
presence of anemia. 
M e t h o d s  
Patients 
We enrolled symptomatic heart failure patients scheduled for elective cardiac surgery 
with left ventricular ejection fraction (LVEF) < 0.40 and age > 1 8  years and their 
age-matched controls with normal cardiac function (LVEF > 0. 5 5 ) .  Exclusion criteria 
included previous chemotherapy, previous or primary hematological disease, solid 
tumors within the last 7 years, chronic inflammatory disease, substance abuse, current 
severe renal failure or organ transplant recipients. The protocol was approved by the 
local ethical committee and all patients provided written informed consent. 
Biochemical analysis of peripheral blo od 
Hemoglobin (Hb) , hematocrit, leucocyte numbers, renal function, N-terminal 
pro-brain natriuretic peptide (NTproBNP) , lactate dehydrogenase (LDH) , ferritin, 




local laboratory facilities. Erythropoietin (EPO) levels were determined as described 
previously.
1 Transferrin saturation was calculated as previously described. 6 Iron 
deficiency was defined as ferritin levels < 20 µg/L or FeSat < 1 0%. According to the 
local laboratory reference ranges, deficiency in vitamin B 1 1  or B 1 2  was defined as 
levels < 1 42 pmol/L and 50 pg/ml, respectively. 
Bone m arrow samples 
Whole bone marrow was recovered from the sternum during surgery and transferred 
into sterile tubes containing RPMI 1 640 medium (Cambrex, NJ, USA) with 
preservative free heparin. MNCs were isolated from whole bone marrow through 
density centrifugation with Lymphoprep (Fresenius, Norway) according to suppliers' 
guidelines. 
Flow c ytometry 
Bone marrow MNCs were incubated with PerCP-labelled anti-human CD34, or APC­
labelled anti-human CD7 l (BD BioSciences, Erembodegem, Belgium) to evaluate 
consecutive stages in erythroid differentiation. EPO-receptor (EPOR) density was 
determined with a Phycoerythrine (PE) labelled anti human EPOR antibody (R&D 
Systems, USA) . EPO-R density was estimated from the mean fluorescent intensity. 
Variation coefficient throughout the study period for PE measurements was less 
than 5 % as determined with the Califlow kit (Sferotec, Germany) . Early apoptosis 
in MNCs was evaluated with the with the Annexin V kit (BENDER med systems, 
Austria) , which entails a FITC labelled anti human Annexin-V (Ann-V) antibody. 
Diamidino-2-phelylindole (DAPI , 0.5 µg/ml) was used to evaluate the integrity of 
the cell membrane and identify later stages of apoptosis. Cells were considered early 
apoptotic if Ann-5+ / DAPI and late apoptotic if Ann-5 ' / DAPI+. Samples were 
measured on the LSR-11 flow cytometer (Becton and Dickinson, USA) and analysed 
usingWinlist software (version 6.0,  Versity Software, USA) . 
Isolation of hematopoietic progenitor cells 
Hematopoietic progenitor cells were isolated on the basis of CD34 expression from 
bone marrow MNCs using the MiniMACS immunomagnetic magnetic separation 
system (Militenyi Biotec , Germany) according to the manufacturers guidelines. 
In vitro erythopoiesis 
Isolated CD34+ cells ( 1 04) were aliquoted in quadruplicate in Methocult H4230 
medium (Stem Cell Technologies, United Kingdom) containing 0.02, 0. 1 .  0.2 ,  1 ,  
2 or 1 0  iU/mL of recombinant human erythropoietin (EPREX, Janssen-Cilag, the 
Netherlands) and cultured at 3 7° C and 5% CO
1 
in a humidified atmosphere. After 1 4  
days, the number of burst forming units erythroid (BFU-E) colonies were counted. 
To control for procedural variation, a reference sample comprising of pooled CD34+ 
cells from 5 healthy controls was cultured in parallel with a single concentration of 
2 IU/ml ofEPO in each experiment. BFU-E colony numbers were normalized to the 
reference values and expressed as number of colonies per 1 04 CD34 + cells. In a subset 
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of cultures from 4 representative subjects per group, cells were resuspended from 
methylcellulose and counted to obtain the average number of cells per colony. 
Statis tical  an alysis 
Data are given as mean ± standard errors of the mean (SEM) for continuous 
variables or as percentages for categorical variables. Differences between groups 
were compared with students T-test, Mann Whitney-U test, Chi-square test or 
Fishers exact test, where appropriate. Differences in BFU-E dose-response curves 
between groups were assessed by ANCOVA for repeated measurements after log­
transformation. Correlations between BFU-E formation , bone marrow apoptosis 
and various other variables were performed using Pearsons correlation coefficients. 
Non-normally distributed variables were log-transformed. To control for potential 
confounders, standard linear regression analysis was used to control for age, sex, 
ACE-inhibitor therapy and Hb levels. P-values below 0.05 were considered to denote 
a statistically significant difference. Calculations were performed using SPSS-software 
(version 1 5) .  
Results  
CHF patients displayed slightly but non-significantly lower hemoglobin levels 
compared to controls ( 1 3  ± 0.5 versus (vs) 1 4  ± 0.3 ,  p=0.2) and six out of 1 2  CHF 
patients were anemic according to the World Health Organisation criteria (Hb < 1 3 
g/dL in men and Hb < 1 2  g/dl in women) . One non-anemic subject had mild iron 
deficiency, no other hematinic deficiencies were observed in the study population. 
CHF patients had a higher incidence of previous myocardial infarction ( 6 7% vs 
9%, P<0.0 1 ) ,  were more frequently on loop diuretics (67% vs 1 7%, p=0.04) and 
had higher NTproBNP levels (29 1 4  ± 1 070 vs 424 ± 256 ,  p<0.00 1 )  compared 
to controls. The indication for surgery, the use of ACE-inhibitors and estimated GFR 
were similar among groups. Other general characteristics of the study population are 
presented in table 1 .  
Eryth roid lineage a n d  apoptosis 
Both the percentage of CD34+ hematopoietic progenitor cells and CD7 l brigh, 
committed erythroid cells were significantly decreased in CHF patients compared to 
controls (0.77 ± 0. 1 1  % vs 1 .3 ± 0.25 % co34+ cells , and 2 1  ± 3 .5  % vs 3 1  ± 2.7 % 
CD7J bright cells P<0.05 , respectively, table 2).  Moreover, both early and late apoptosis 
was significantly increased in bone marrow MNCs of CHF patients (6.3 ± 1 . 6  % 
versus 2.2 ± 0.7 % ,  P<0.05 and 3.8 ± 0.7 % vs 1 . 3 ± 0.2 %, P<0.02 respectively, 
table 2).  Numbers of erythroid cells and apoptotic cells were comparable between 
anemic and non-anemic CHF patients , altl1ough a trend towards further reduction in 
CD71 hright cells was observed in the anemic CHF group (27 ± 3.9 % vs 1 5  ± 4.3 % 
CD71 bright cells in non-anemic vs anemic CHF patients , P=0.08 ,  table 2). 
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Table 1. Demagraphics of the study population. 
Patients and Controi. Anemic and Non-Anemic patients 
Variable Cantrals Total CHF p Non-anemic Anemic p 
(n=12) (n•12) CHF (n•6) CHF (n•6} 
Hemoglobln {mg / dl) 1 3.5 ± 0.3 12.8 ±0.5 0.2 1 3.3 ± 0 5 12.2 ± 0.7 
Age 68 ± 2  68 ± 2  68 ± 4  69 ± 2  0.8 
Male gender {n, %) 9 (56) 7 (44) 0 .7  3 (43) 4 (57) 0.5 
LVEF 58 ± 1 .6 32 ± 1.8 <0.001 * 32 ± 2.1 31 ± 3.2 0.9 
NTpraBNP (pg/ml) 424 ± 257 2913 ± 1070 <0.001 * 2491 ± 1667 3336 ±1481 0.2 
lschemic CHF {n, %) 8 (89%) 3 (38) 5 (63) 1 
eGFR, ml/min 86 ± 5  80 ± 7  0.5 82 ± 9  79 ± 1 0  0.8 
CABG (n, %) 1 1  t 92) 9 (75) 0.3 3 (50) 6 ( 1 00) 0.09 
Previous Ml (n, %) 1 ( 1 1 )  8 (89) 0.1 4 (67) 4 (67) 0.7 
Diabetes (n, %) 8 (53) 7 (46) 0.4 4 (67) 3 (50 0.5 
EPO levels (IU/ml) 1 3  ± 2  1 2  ± 2  0.4 1 4 ± 2  10 ± 3  0.3 
Tsai (%) 31 ± 4  25 ± 3  0.2 29 ± 2.8 21 ± 4  0.2 
Ferntin, µg/L 1 79 ± 52 220 ± 32 0.5 243 ± 36 200 ± 55 0.5 
Vitamin B 12, pmol/L 306 ± 43 373 ± 55 0.3 454 ± 93 292 ± 48 0.2 
Folate, nmal/L 30 ± 4  17 ± 2  0.03 19 ± 2  15 ± 3  0.2 
Medication, % use 
ACE inhibitors 9 (75) 11 (92) 0.7 6 ( 1 00) 5 (80) 0.5 
8-blocker 1 1  (92) 1 1 (92) 0.5 5 (80) 6 (80) 0.5 
Aldosterone antagonists 0 4 (33) 0.04* 1 (20) 3 (50) 0.3 
Loop diuretics 2 ( 1 7) 8 (89) 0.03* 3 (50) 5 (80) 0.3 
All variables are presented as mean ± standard error. CHF, Chronic Heart Faiure; NTpraBNP, N-terminal pra 
Brian Natriuretic Peptide; LVEF, left ventricular ejection fraction; eGFR, estimated glomerular filtration rate; 
Ml, myocardial infarction; E PO, erythropoietin; Tsai, % translerrin saturation; ACE-I, angiotensin converting 
enzyme inhibitor or angiotensin receptor blocker. 
Eryth ropo ietin receptor density 
Average EPOR density in EPOR expressing cells was slightly but not significantly 
higher in CHF patients compared to controls (relative fluorescence intensity 40 ± 3 
vs 3 3  ± I ,  P=0 .07, table 2) . The EPOR density was comparable between anemic and 
non-anemic CHF patients (40 ± 6 vs 4 1  ± 3 ,  P=0. 1 ,  table 2) .  
B FU-E fo rmation 
Throughout the EPO dose response range, the average number of BFU-E colonies 
after 1 4  days of culture was 2-3 -fold lower in CHF patients compared to controls 
(2 1 7  ± 30 vs 5 2 7  ± 98 colonies per 1 04 co34+ cells with 2 U/mL EPO, P=0.0 1 5  
general linear model, Figure I ) . The EPO-response of CD34 + cells, evidenced by the 
relative increase in BFU-E formation to incrementing doses of EPO did not differ 
between CHF patients and controls (P=0.9 ,  figure 2A) . 
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Table 2. Flow cytometry results. 
2 1 0  
,.. .... � Mefflk _... Non-Anlllllc ,......_ 
Variabl• Controls Total CHF p Non-anemic Anemic p 
(n•12) (n•,12) CHF (n•6) CHF (n,.6) 
Hematopoiefic progenitor 1 .3 (0.8-1.5) 0.7 (0.6-0.9) 0.038 *  0.7 (0.7-1 3) 0.6 (O 5-0.9) 0 3  
cells(% CD34") 
Commited erythroid cells 30 (25-40) 21 ( 1 3-29) 0.047* 26 (20-35) 14 (7-24) 0.08 
(% CD71 -bogl,I) 
Early apoptofic cells 
1 .5 (0.8-3.4) 5.3 (2.9-8. 1 )  0.01 * 5.3 (4.4-7.8) 4.7 (2-14) 0.9 
(% Ann-5 • / DAPI ) 
late apoptofic cells 
(0.8-1.7) 3.7 ( 1 .9-5.9) 0.003 * 4.5 (2.3-5.9) 2.7 ( 1 .9-5.5) 0.7 (% Ann-5 • / DAPI ") 
EPO-receptor density 
(mean fluorescent intensity) 33 (31-36) 41 (33-47) 0.074 43 (34-45) 34 (30-54) 0.1 
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A. In vitro BFU-E formation in anemic and nan-anemic CHF patients. B. Typical BFU-E colony of a CHF 
patient and a control subject. C. Graphic representation of number of erythroid cells per colony. BFU-E, burst 
forming unit-erythroid; CHF, chronic heart !oilure, *; p<0.05 versus control. 
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A. Relation beween clonogenic potential and the severity of heart failure. B. Relation beween clonogenic 
potential in vitro ond bone marrow apoptosis. NTproBNP, N-terminal pro Brion Natriuretic Peptide. 
BFU-E formation was identical in anemic and non-anemic CHF patients (202 ± 1 5  
vs 232 ± 3 5  colonies per 1 04 CD34+ cells and 2 U/mL EPO, P=0. 8 ,  figure 2A) .The 
BFU-E colonies of CHF patients appeared smaller and comprised of a lower number 
of cells (F igure 2B+C) . 
Predictors of impaired BFU-E formation 
A strong inverse correlation was observed between the number of  BFU-E-colonies 
in vitro and the percentage of apoptotic cells in the bone marrow (R=-0.5,  P=0.03 , 
figure 3B) or plasma NT-proBNP levels (R=-0 .5 ,  P=0.0 I ,  figure 3A) . When correcting 
for the potential confounding effects of age, gender, ACE-inhibition and pre-operative 
hemoglobin levels, NT-proBNP remained an independent predictor of BFU-E 
formation (B: -0 .29 ± 0.09, 13 : -0 .645 partial correlation coefficient -0 .6 ,  p<0 .0  I ) .  
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D isc ussion 
In the present study we demonstrate a profound bone marrow dysfunction in CHF 
patients. In a well established in vitro erythropoiesis assay, the clonogenic potential of 
CD34 + HPCs isolated from the bone marrow of CHF patients was at least three-fold 
lower compared to matched controls. Impaired erythropoiesis in vitro was accompanied 
by a relative depletion of the erythroid lineage and markedly increased apoptosis. 
Elevated levels of plasma NT-proBNP independently predicted a reduced clonogenic 
potential, indicating that the extent of erythropoiesis-impairment is related to the 
severity of heart failure. However, in contrast to our expectations, we did not observe 
specific EPOR down regulation in erythroid cells suggesting that the sensitivity to 
EPO is not impaired. Another surprising finding was that the response of erythroid 
progenitors was comparable in anemic and non-anemic CHF patients. Our findings 
therefore support the presence of a more generalized dysfunction in CHF, which 
may increase the susceptibility to anemia. Co-factors including circulating inhibitory 
factors and increased plasma volume may further explain this process. 1'·1 
Several studies have provided circumstantial lines of evidence that suggest the 
presence ofhematopoietic dysfunction in CHF, but withouth the distinction between 
an intrinsic defect of bone marrow cells versus inhibitory effects of exogenous 
factors. In the current experiment, we therefore evaluated the cellular function of 
isolated progenitor cells, which allowed us to exclude potential confounding effects 
of circulating inhibitory factors or leukocyte mediated suppression ofhematopoiesis. 
Therefore, we were able to establish an intrinsic impairment of erythropoiesis. Reduced 
erythroid colony formation of isolated CD34 + progenitor cells has so far only been 
documented in patients with rheumatoid arthritis and idiopathic neutropenia. 1 1 • 1 3 Of 
note, both these conditions are also associated with an increased incidence of anemia. 
Several mechanisms might attribute to hematopoietic dysfunction in CHF. In 
addition to the reduced number of BFU-Es, the colonies were also smaller with 
lower number of cells. F urthermore, bone marrow cells of CHF patients displayed 
markedly increased apoptosis, which inversely correlated with the BFU-E formation. 
Since EPO regulates physiological apoptosis in erythroid precursors, the observed 
increased apoptotic cell death during erythropoietic differentiation might explain 
the reduced clonogenic potential and smaller colony size caused by deficient EPOR 
signaling. However, in contrast to our expectations, CHF patients did not display 
down regulation of the EPOR, suggesting unaffected sensitivity to EPO. Moreover, 
dysfunction of the myeloid and endothelial lineage has been described, suggesting that 
that the defect is a more generalised phenomenon and might originate in early stem 
or progenitor cell. 1 2 • 1� A specific deficit in EPOR signalling therefore seems unlikely. 
Enhanced inflammation might also have induced apoptosis and reduced proliferation, 
which has been demonstrated in mice with heart failure after myocardial infarction. 1 0  
However, by evaluating isolated HPCs we circumvented potential direct effects of 
inflammatory cytokines or cell mediated cytotoxicity. 
Recently, we have demonstrated that circulating leukocytes ofCHF patients exhibit 
accelerated aging, reflected by markedly shorter telomere length. 15 Cells that reach 
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critically short telomeres either become apoptotic or enter replicative senescence. 
Telomere length associates with myeloid colony formation of bone marrow MN Cs 1 6  
and erythropoiesis , 1 7  so that the increased apoptosis and the impaired clonogenic 
potential might thus be explained by replicative exhaustion of HPCs. However, the 
exact mechanism of HPC-dysfunction remains elusive from our study and warrants 
further investigation. 
Clonogenic potential was similar in anemic and non-anemic CHF-patients, 
indicating that unexplained anemia in CHF does not merely reflect the severity of 
bone marrow dysfunction. However, the number of erythroid precursor cells was 
two-fold lower (P=0.08) in the bone marrow of anemic patients, indicating that 
despite an equally impaired clonogenic potential, erythropoiesis is further inhibited in 
anemic patients. Additional erythropoiesis inhibition might be caused by circulating 
inhibiting factors, which supports our findings that serum of anemic CHF patients 
inhibits erythropoiesis.5 The differences between anemic and non-anemic patients 
should be interpreted with caution because we studied only 6 anemic and 6 non­
anemic patients. 
To compensate for the bone marrow dysfunction, hematopoietic growth 
factor levels will increase, which explains, at least in part, the elevated EPO levels 
in CHF patients. Bone marrow dysfunction will also attenuate the flexibility to 
adapt erythropoiesis to an increasing demand, augmenting the susceptibility to 
other causes of anemia. Hence, all conditions that require increased erythropoiesis 
or that attenuate EPO production might readily result in anemia. In addition to 
impaired erythropoieis, unexplained anemia in CHF has been associated with an 
inappropriately low EPO-production by the kidney 6· 1 8 , enhanced inflammation 1 0, 
circulating hematopoieis inhibitory factors 7 and expansion of the plasma volume, 
which leads to hemodilution.6· 1 9  The finding that bone marrow dysfunction alone 
can not explain anemia is in accordance with the broad range of factors that have 
been associated with anemia in CHF and might partially explain its multifactorial 
etiology.20 In addition to anemia, bone marrow dysfunction might reduce stem cell 
mediated cardiovascular repair or the efficiency of the immune response, potentially 
increasing morbidity and mortality even further. 
Conclusion 
Chronic heart failure causes distinct bone marrow dysfunction which translates 
into impaired erythropoiesis. Although bone marrow dysfunction warrants patients 
more susceptible to anemia, it does not exclusively explain its occurrence. Additional 
research is required to define the type, extent and clinical relevance of bone marrow 
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Chapter 5 
A bstra ct 
Purpose of the review 
Anemia is common in patients with chronic heart failure (CHF) ,  and is related to 
increased morbidity and motality. The etiology of anemia in heart failure is complex 
and still not fully resolved. Recombinant human erythropoietin (EPO) might benefit 
patients with CHF both by correction of anemia and by other extra-hematopoietic 
effects. This review will describe current advances in the understanding of the 
pathophysiology of anemia and the potential therapeutic effects of EPO in CHF. 
Recent findings 
Recent attempts to resolve the preponderant etiology of anemia in CHF have further 
defined its multifactorial nature. The combination of impaired renal perfusion and 
function resulting in blunted erythropoietin (EPO) production as well as impaired 
erythropoiesis in the bone marrow account for a vulnerable erythropoietic system. 
Moreover, fluid retention has been shown to cause hemodilutional anemia even in 
the absence of congestive symptoms. The safety and feasibility of EPO to correcL 
anemia in CHF has been established and a recently started phase-3 clinical trial will 
hopefully provide definitive insight. In addition to the correction of anemia, EPO 
might improve cardiac function through direct effects on a myocardial EPO receptor 
and the recruitment of endothelial progenitor cells from the bone marrow. Moreover, 
EPO exerts important cytoprotective effects during experimental myocardial infarction 
which is currently evaluated in phase 2 trials. Although EPO shows great promise, we 
should not neglect other treatable causes of anemia. 
Summary 
Although the etiology of anemia in CHF is clearly multifactorial, correction of anemia 
with rhEPO seems promising. In addition to correction of anemia, rhEPO might exert 
important protective and regenerative properties on the myocardium. 
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I ntro duction 
Chronic heart failure (CHF) is a final common endpoint of the majority of cardiac 
conditions, affecting 5 million people in the US and 7 million people in Europe. 1 
CHF represents the leading cause of death in the Western world and accounts for 
an immense health care expenditure, estimated at $ 25 billion dollars in the US 
annually. The hallmark of the CHF syndrome is left ventricular dysfunction, although 
the downstream effects of circulatory failure dominate the symptomatic phenotype. 
CHF is often accompanied by dysfunctions of other organs. In stead of considering 
these as co morbidities, systemic organ dysfunction is increasingly recognized as an 
intricate part of the CHF syndrome. For example, the extent of kidney dysfunction 
more accurately predicts survival in CHF patients than left ventricular ejection 
fraction, suggesting that the peripheral effects of CHF modulate outcome. 1 Research 
on the etiology and possible reversal of the peripheral effects of CHF might therefore 
significantly improve clinical outcome. However, since most of the peripheral CHF 
syndrome result directly from circulatory failure, reversal seems hard to attain.Anemia 
in CHF might be an exception since it can be pharmacologically regulated, and has 
therefore spiked enthusiasm in the heart failure community. 3 .+ The present review 
discusses recent advances in the understanding of the etiology of anemia in CHF 
and the first results of treatment of CHF patients with erythropoietin stimulating 
proteins. 
The importance of anemia 
Anemia, defined by the World health organisation as Hb levels < 1 3 g/ dL in men 
and < 1 2  g/ dL in women, is observed in 4 % to 6 1  % of chronic heart failure (CHF) 
patients.+ The prevalence of anemia increases with disease progression, although 
actual numbers are inconsistent due to the wide range of hemoglobin (HB) cut offs 
used to define it. Anemia causes chronic volume overload to the left ventricle which 
results in increased oxygen consumption, left ventricular dilatation and left ventricular 
hyperthrophy, thereby negatively affecting cardiac function in CHF. Indeed, Post-hoc 
analysis of multiple randomised controlled trials in CHF patients have consistently and 
independently associated the presence of anemia with an impaired survival.+ Recent 
evidence also indicates that the prognostic significance of anemia can be extended to 
isolated cohorts of CHF patients with a preserved ejection fraction and non-ischemic 
etiologies. 5·6 Komajda et al. recently revealed that tl1e new onset of anemia at any time 
during the 5 year follow up of the COMET trial was independently associated with an 
impaired survival. 7 These data clearly indicate that the development of anemia should 
be considered a grave sign in any CHF patient. Moreover, the consistent association 
between anemia and impaired survival in CHF suggests a potent therapeutic potential 
for correction. 
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E t i o l o g y  of a n e m i a  
B lunte d  erythropoietin (EPO) production 
Recent studies have importantly improved our understanding of the etiology of 
anemia in CHF, but it is still far from resolved. The etiology is likely to be multifactorial 
within the population as well as within each subject. 1·4 Chronic kidney disease often 
accompanies anemia in CHF but in contrast to these patients, circulating EPO levels 
are elevated in CHF, increase with the progression of disease, and independently 
predict impaired survival. 8 However, when EPO levels are corrected for the prevailing 
Hb by calculating tl1e Observed / Predicted (0/P) EPO ratio, the vast majority of 
anemic CHF patients display signs of insufficient EPO production. Indeed, Opasich 
et al. demonstrated that over 90% of anemic CHF patients have significantly depleted 
0/P EPO ratios compared to healthy controls.9 Moreover, despite slightly elevated 
circulating EPO levels ,  anemic CHF patients also have markedly lower 0/P ratios 
tl1an their non-anemic counterparts. 1 0  Importantly, these findings are not restricted 
to patients wim coinciding chronic kidney disease, indicating that tl1e blunting of 
EPO production precedes renal failure. Thus, anemia in CHF is not merely caused by 
insufficient EPO-production but rather an inability to sufficiently adapt production 
to an increasing demand. Blunted EPO production is caused by decreased renal 
perfusion resulting in impaired renal function which both independently predict 
anemia in CHF. 1 0 (Figure I )  Furthermore, circulating inflammatory cytokines and 
ACE-inhibitors can directly inhibit EPO production in the kidney and might also 
contribute to the blunted EPO production. 
Depression of bone m a rrow fu n ction 
The relatively elevated EPO levels in non-anemic CHF patients are indicative for 
a reduced responsiveness of erythropoietic cells to EPO. Indeed, bone marrow of 
mice with heart failure after myocardial infarction exhibits markedly impaired 
erythropoiesis and decreased numbers of erythropoietic progenitor cells. 1 1  IL­
i ,  TNF -a and interferon a ,  � and y directly inhibit the formation of mature 
erythropoietic cells from erythropoietic progenitors in tl1e bone marrow. 12 CHF 
is frequently associated wim elevated levels of these cytokines, and markers for 
inflammation are independently related to elevated EPO levels. r n. , J  Moreover, we have 
recently demonstrated that anemia in CHF is partially explained by elevated levels of 
AcSDKP, a negative regulator of hematopoietic stem cells. 8 The inhibitory effects of 
inflammatory cytokines and AcSDKP will increase the EPO levels required to maintain 
adequate red blood cell production. Moreover, leukocytes from CHF patients show 
signs of accelerated aging and the functional capacity of several leucocytic subsets is 
impaired. H. , i  Since circulating leucocytes share ancestry in the hematopoietic stem 
cell , the latter might be functionally exhaust. Thus, independent of the presence of 
anemia, bone marrow function in CHF is depressed through exogenous inhibitory 
factors and an functional exhaustion of the hematopoietic stem cell pool. 
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Figure 1. Relation between hemoglobin levels and erythropoietin, renal perfusion. 
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Conge stion 
Fluid retention due to impaired renal perfusion in CHF can result in expansion of 
plasma volume and consequent hemodilution which may cause pseudo-anemia. 
Until recently pseudo-anemia was considered to be restricted to patients with acutely 
decompensated or end stage heart failure. 16 Recently we determined the extra cellular 
volume of 97 stable CHF patients on outpatient follow up at our department with 
a novel radionuclotide measurement. Anemic subjects displayed significantly higher 
extracellular volume and fluid retention was an independent predictor of anemia. No 
differences in signs and symptoms for congestion were observed between anemic 
and non-anemic subjects, indicating that subclinical fluid retention can already 
result in anemia. 1 0  Therefore, in addition to blunted EPO production and attenuated 
erythropoietic capacity of the bone marrow, subclinical fluid retention seems an 
important cause of anemia in CHF. (Figure 1 )  
Iro n  deficie n cy 
CHF is infrequently associated with standard biochemical indices of haematinic 




Figure 2. Possible causes contributing to the development of anemia in CHF. 
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in the bone marrow aspirates of 2 7 out of 3 7 anemic patients with end stage heart 
failure. 17 Although these results are indicative for the presence of reduced iron supplies 
in the bone marrow, and therefore reduced iron supply for erythropoiesis, a non­
anemic control group was unfortunately not included. Diversion of iron into the 
reticuloendothelial system is intrinsic to chronic disease states and iron deficiency is 
almost equally common in non-anemic CHF patients. 1 0, t l Therefore, the presence of 
reduced iron supplies in the bone marrow does not necessarily explain the occurrence 
of anemia. Prospective controlled studies are required to fully elucidate the role of 
iron deficiency in CHF. 
In summary, recent studies that aimed to identify the preponderant etiology of 
anemia in CHF have further defined its multifactorial nature. Many factors associated 
with anemia in CHF are also prevalent in non-anemic subjects. Bone marrow of 
CHF patients requires higher EPO levels to maintain adequate erythropoiesis due in 
part to functional exhaustion of stem cells as well as inhibition by inflammatory 
cytokines and ACE-inhibitors. Concomitantly, iron supplies are diverted from the 
bone marrow, further restricting erythropoiesis. Together these factors account for 
a vulnerable erythropoietic system. With disease progression, further deterioration 
of renal perfusion will cause kidney dysfunction and blunt EPO production, 
impairing the ability to respond to an increasing demand. Moreover, the impaired 
renal hemodynamics stimulate fluid retention and plasma expansion causing 
hemodillutional anemia. (Figure 2) 
66 
Etiology of anemia in chronic heart fai lure 
Rec o m binant human erythropoiet in 
The observation that anemia in CHF is associated with relatively insufficient EPO 
production and increased EPO-requirements in the bone marrow has prompted the 
evaluation of rhEPO for it's treatment. After an initial uncontrolled study the Israeli group 
of Silverberg et al. randomised 32 patients with mild anemia to receive either rhEpo 
and IV iron or no additional treatment, resulting in significant improvement in New 
York Heart Association (NYHA) functional class left ventricular ejection fraction, renal 
function and heart failure hospitalizations. 18 These findings have been corroborated by 
other open label studies, causing great enthusiasm in the cardiovascular community. 19•20 
Based on these findings, 3 double blind placebo controlled phase 2 clinical studies 
were designed to evaluate the effect of 26 weeks treatment with the rhEPO analogue 
darbepoetin alfa (AMGEN, CA, USA) on exercise capacity, NYHA functional class, left 
ventricular ejection fraction and quality oflife.21·22 Although EPO treatment with a fixed 
dose or a weight based approach successfully restored Hb levels to normal levels, the 
effects ofEPO on NYHA class, aerobic capacity, LVEF, and heart failure hospitalisations 
could not be confirmed. Since the AMGEN trials were properly designed, the results 
of these smaller open label studies might have arisen from chance or their open label 
design. The exercise tolerance and quality of life however showed favourable trends 
towards improvement, partially attaining statistical significance. Moreover, a pooled 
analysis of the two largest studies, which combined the data of more than 480 patients, 
revealed a trend (p=0.074) to reduced risk of the combined endpoint of CHF-related 
hospitalization and all-cause mortality in the rhEPO treated groups.23 Nevertheless, 
these studies were not powered for analysis of survival and the conclusions drawn are 
tantalizing but premature. A large multicenter, double-blind, randomized, placebo­
controlled trial has recently started enrolling patients (RED-HF) will hopefully provide 
a definitive answer. 
Safety issues  
In the fall of 2006 the CHOIR and CREATE studies were published , demonstrating 
that normalization ofHb values to reference ranges (Hb > 1 3 .5  g/dL) with rhEPO 
in chronic kidney disease patients resulted in significantly more cardiovascular events 
compared to target levels of I I .  3 g/ dL. 24·25 Moreover, several trials in oncology 
patients have been prematurely discontinued because of increased mortality in the 
EPO treated groups. 26 As a result , the FDA has recently issued a black box warning 
for erytliropoiesis stimulating agents recommending "the lowest possible dose to 
slowly raise the hemoglobin concentration to the lowest level that will avoid the need 
for a blood transfusion." The multicenter, double-blind randomised controled Trial 
to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) which evaluates the 
effect of darbepoetin alfa on cardiovascular events in CKD patients , has recently been 
evaluated by the data safety monitoring committee which saw: "no cogent reasons 
to recommend alteration or termination of the trial" .  (personal communication) In 
contrast to the studies described above, the TREAT study is blinded and adequately 




Of note, the etiology of anemia in CHF seems distinct from patients with chronic 
kidney disease and oncology. Hence, extrapolation of the results from these trials is 
thorny. Moreover, no deleterious effects of rhEPO have been observed in CHF patients 
so far, but current trials will be carefully monitored. 
Extra-hematopoietic effects of EPO 
The principal effect orEPOin the bone marrow is the reduction of thephysiologicalapoptosis 
associated with cell turnover in erythroid progenitor cells. However, in conjunction with 
other growth factors EPO also stimulates proliferation and differentiation of these cells.17 
Recently, these properties of EPO have been extended to the heart. Following an acute 
myocardial infarction, extensive myocardial apoptosis ensues which in part determines 
tl1e extent of the permanent myocardial damage. EPO exerts potent anti-apoptotic effects 
on the myocardium and numerous studies have translated the cytoprotective in vitro 
effects into ex and in-vivo models of acute myocardial infarction in rodents, rabbits and 
dogs. 18 We recently performed a randomised safety and feasibility study with a single 
bolus of EPO, administered during primary PCI for a first acute MI. EPO was both safe 
and well tolerated, caused only a small but non-significant increase in hematocrit levels 
and significantly increased circulating endothelial progenitor cells. 29 These findings 
led to the design of a randomised multicenter study tl1at evaluates whether EPO can 
attenuate post-MI loss of cardiac function, currently enrolling patients (NCT00449488). 
The similar REVEAL trial is currently performed in tl1e US (NCT00378352). In 
addition, EPO has consistently been shown to improve cardiac function in experimental 
models of chronic myocardial dysfunction.30 35 The improvement of cardiac function is 
consistently associated witl1 restoration of microvascular dysfunction, mediated through 
a combination of endothelial progenitor cell and vascular endotl1elial growth factor 
mediated neovascularization. 16 The beneficial effects of EPO in experimental CHF can 
also be induced witl1 doses that do not affect hematocrit levels. 17 These significant extra 
hematopoietic effects suggest tint EPO might also benefit non-anemic patients with 
cardiac disease. Furthermore, depending on the time after an ischemic insult, EPO exerts 
cytoprotective effects and in a later stage facilitates regeneration of the myocardium 
indicating a broad therapeutic window. (figure 3) 
Other t reat ment opt i ons 
Since the etiology of anemia in CHF seems to result form a combination of predisposing 
factors, correction of any of these components might also resolve anemia. Bolger et al. 
recently evaluated the effect of intra venous administration of iron sulphate alone on 
hemoglobin levels in 1 7 anemic CHF patients. 38 They observed a significant increase 
in hemoglobin levels suggesting iliat intra venous iron might be used to treat all 
anemic CHF patients. The increase in hemoglobin levels in ilie total population was 
however driven by patients that were actually iron deficient. Despite the lack of a proper 
control group, the study clearly indicates iliat any of the classical causes of anemia 
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Figure 3. Therapeutic potential of erythropoietin after myocardial infarction. 
Acute infarction 
Acute protection 








should first be treated before starting with more sophisticated tools. Because CHF is not 
associated with iron deficiency but rather a decreased iron supply for erythropoiesis , 
unrestricted supplementation of iron might result in toxic accumulation of iron in the 
reticuloendothelial system.39 Fortunately, the IRON-HF study will evaluate the use of 
intravenous iron CHF in a controlled fashion.�° F inally the fact that anemia in CHF 
is in part mediated through hemodilution, in spite of congestive symptoms, suggest 
that intensification of the diuretic regimen might be sufficient to raise hemoglobin 
levels. Hemodilutional anemia should indeed be considered in all anemic CHF patients , 
but uncontrolled administration of high dose diuretics might further impair kidney 
function in euvolemic patients. Since congestive signs and symptoms poorly predict 
actual volume status, radionucleotide based measurements should be used to identify 
patients with hemodillutional anemia. 
C o n c l usions 
Anemia has been recognized as a component of the peripheral CHF syndrome, which 
importantly modulates mortality. Recent studies that aimed to identify the etiology of 
anemia in CHF have further defined its multifactorial nature. Altl10ugh correction of 
anemia with rhEPO has recently been scrutinized for other indications, in CHF it so far 
seems safe and well tolerated. In addition to correction of anemia ,  rhEPO might exert 
important protective and regenerative properties on tl1e myocardium. 
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Chapter 6 
A bstra c t  
Aims 
Erythropoietin (EPO) improves cardiac function and induces neovascularization in 
chronic heart failure (CHF) , although the exact mechanism has not been elucidated. 
We studied the effects ofEPO on homing and incorporation of endothelial progenitor 
cells (EPC) into the myocardial microvasculature and myocardial expression of 
angiogenic factors. 
M e thods and results 
CHF was induced in rats by coronary artery ligation resulting in myocardial infarction 
(MI) after bone marrow had been replaced by human placental alkaline phosphatase 
(hPAP) transgenic cells. We studied the effects of darbepoetin alfa treatment (EPO, 
40 µg/kg, every 3 weeks, starting 3 weeks after MI) on longitudinal changes in left 
ventricular (LV) function, circulating EPC, myocardial histology, and expression 
of vascular endothelial growth factor (VEGF) determined 9 weeks after MI. EPO 
prevented LY-dilatation and improved cardiac function (all P<0.05) , which was 
associated with 4 2 % increased capillary growth (P<0. 0 I ) .  EPO-induced mobilization 
ofEPC from the bone marrow (P<0.0 I ) ,  which resulted in a 3-fold increased homing 
of EPC into the cardiac microvasculature. The percentage of the endothelium that 
consisted of bone marrow derived cells was significantly increased (3.9 ± 0 .5  vs. 
1 1 .4 ± 1 %, P<0 .00 I )  comprising 30% of the newly formed capillaries. In addition, 
EPO treatment resulted in a 4.5 -fold increased myocardial expression of VEGF, which 
correlated strongly with neovascularization (r=0 .67 ;  P<0.00 I ) .  VEGF was equally 
expressed by endothelial cells of myocardial and bone marrow origin. 
Conclusions 
EPO-induced neovascularization in post-MI heart failure is  mediated through a 
combination of EPC recruitment from the bone marrow and increased myocardial 
expression ofVEGF. 
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Intro du ction 
Chronic heart failure (CHF) represents a complex o f  symptoms related to impaired 
cardiac function affecting 5 million people in the US. Despite optimal treatment with 
current strategies , morbidity and mortality remain high. 1 CHF is associated with 
myocyte hypertrophy and impaired microvascularization of the myocardium, leading 
to a mismatch between oxygen demand and supply.2·3 Current therapies aimed at 
improving the microvasculature are under investigation, of which erythropoietin 
(EPO) is one of the most promising therapies.+-6 
EPO is an erythropoietic growth factor, promoting survival, proliferation, 
and differentiation of erythroid progenitor cells.7 We and others have recently 
demonstrated that EPO-treatment improved cardiac function in experimental models 
of CHF.8- 1 2 The improvement of cardiac function is consistently associated with an 
increase in capillary formation, although the mechanism of neovascularization is 
unknown. 
It has repeatedly been shown that EPO promotes proliferation and survival of 
endothelial cells in vitro and stimulates angiogenesis in vivo. 13-is In addition, EPO 
induces the proliferation, differentiation ,  and adhesion of a subset of bone-marrow­
derived progenitor cells with an endothelial phenotype [ endothelial progenitor 
cells (EPC)] in vitro and results in marked mobilization of EPC in vivo.8• 1 6- 1 8  EPC 
specifically home to sites of neovascularization and incorporate into newly formed 
vessels. 19 It is, however, unknown whether the mobilized EPC contribute to EPO­
induced neovascularization. 
We hypothesized that EPO-induced neovascularization is mediated through EPC 
recruited from the bone marrow in addition to in situ proliferation of myocardial 
endothelial cells. In order to study the effects of EPO on differentiation of EPC into 
the myocardial vasculature, bone marrow of rats was replaced with labelled bone 
marrow cells. 
Metho d s  
A n i m a ls 
We used male F ischer F344 rats (n = 65) weighing 200-230 g (Charles Rivers, 
France) as recipients and R26-hPAP rats [n = 1 0, F 344 background, ubiquitously 
expressing human placental alkaline phosphatase (hPAP)] as donors. 20 Animals were 
fed and housed, according to institutional rules , and the experimental protocol was 
approved by the Animal Ethical Committee of the University of Groningen. 
Bone  marrow labell ing 
In order to evaluate the effects of  EPO on homing and incorporation of  EPC into the 
endothelium, we replaced the bone marrow by genetically labelled bone marrow 
cells as described in detail previously:2 ' Briefly, 24 h after 9 Gray total body irradiation 
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of recipient rats, whole bone marrow cells (25 x I 06 nucleated cells) of donor 
rats were transfused to recipients. Rats were housed in filtertop cages and drinking 
water was supplemented with neomycin (0.3 5% wt/vol) , 2 weeks post and prior to 
irradiation. After 6 weeks, hPAP expression on leucocytes was evaluated by FACS, and 
rats with chimerism >80% were randomly allocated to MI or sham surgery. Successful 
haematopoietic recovery was further confirmed by full blood counts and chimerism 
was re-evaluated at sacrifice. This model allowed us to evaluate differentiation of bone 
marrow-derived cells into an endothelial phenotype. 
Experimental protocol 
Rats were randomly subjected to induction of myocardial infarction (MI) or sham surgery 
as described previously in detail. 1 1 Briefly, animals were intubated and mechanically 
ventilated with 2 . 5% isoflurane in room air enriched with 1 .0 L/min oxygen.After left­
side thoracotomy, MI was induced by ligating the proximal portion of the left coronary 
artery. In sham operated rats , the same surgery was performed without ligating the 
suture. Three weeks after coronary artery ligation, rats with MI were subjected to 
treatment with the long-acting EPO analogue darbepoetin alfa ( 40 µg/kg, Aranesp, 
Amgen Inc. , Thousands Oaks, CA, USA) or saline, administered intraperitoneally 
once every 3 weeks. Treatment allocation was balanced for left ventricular (LV) end­
diastolic diameter and LV fractional shortening determined by echocardiography. 
The dose of darbepoetin was based on our previous experiments, demonstrating 
increased neovascularization in this model. 1 1  At baseline, at week 3 (before therapy) 
and weeks 6 and 8 ,  cardiac function was determined by echocardiography. After 9 
weeks, haemodynamic function was assessed invasively, thereafter hearts were rapidly 
excised and weighed. Myocardial tissue was transected transversally and processed for 
immunohistochemistry or snap frozen for western blot analysis. 
Echocardiographic measurements 
Cardiac function was prospectively assessed by echocardiography (Vivid 7 ,  GE 
Healthcare, Chalfont St Giles , UK; equipped with a I 0-MHz phase array linear 
transducer) . The echocardiographic measurements were performed under general 
anesthesia with 2 .5% isoflurane, by two researchers blinded for the treatment 
allocation. Both 2-dimensional (2D) images in parasternal long-axis and short-axis 
view and 2-D guided M-mode tracing were obtained. Long-axis views were obtained, 
ensuring that the mitral and aortic valves and the apex were visualized. Short-axis 
views were recorded at the level of mid-papillary muscles. LV end-systolic diameter 
(LVESD) and LV enddiastolic diameter (LVEDD) were measured from the M-mode 
and calculated as an average from short and long-axis view. LV fractional shortening 
(FS %) was calculated as FS = (LVEDD - LVESD) /LVEDD x I 00%. LV ejection fraction 
(EF % ) was alculated using the Teichholz method of estimated LV volumes.12 
Hemodynamic m easurements 
At sacrifice, rats were anesthetized and a microtip pressure transducer (Millar Instr. 
Inc. , Houston, TX, USA) was inserted into the LV cavity via the right carotid artery. 
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After a 3-min period of stabilization, heart rate (HR), LV systolic pressure (LVSP), 
LV end-diastolic pressure (LVEDP) , and developed LV pressure ( dLVP = LVSP - LVEDP) 
were measured. As indices of contractility and relaxation , the maximal rates of increase 
and decrease in LVP (dP/dtmax and dP/dtmin) were determined. The catheter was 
retracted into the aortic arch and arterial systolic/ diastolic blood pressures (SBP, DBP) 
were recorded. 
I nfarct size, myocyte hype rtrophy, and capillary den sity 
Infarct size, myocyte hypertrophy, and capillary density were determined as described 
in detail previously. 1 1 Briefly, infarct size was determined by planimeter in transverse 
slices on picrosirius red/fast green-stained sections and expressed as the percentage 
of scar length to total LV circumference. Concentric myocyte hypertrophy, in the 
viable LV wall remote from the infarct, was measured in deparaffinized sections 
stained with Gomori's silver staining, as the cross-sectional area of transversally cut 
myocytes showing a nucleus, and averaged per tissue area. Endothelial cells were 
stained with biotin-labelled GSL-Lectin ( 1: 1 00 ;  Sigma-Aldrich, St Louis , MO, USA) , a 
size criterion of I O  µm was used to exclude small arterioles and venules , and image 
analysis was used to measure capillary density in the viable LY-wall, calculated as 
the number of capillaries per tissue area in the all transverse slice. As a measure of 
neovascularization, capillary-to-myocyte ratio was calculated dividing capillary with 
myocyte density. 
Circulating endothelial progen itor cells 
Whole blood was collected in heparine tubes ( 1 7  IU/mL). Mononuclear cells were 
isolated using Histopaque- 1 083  (Sigma Chemical, St Louis , MO, USA) according 
to the instructions supplied by the manufacturer. Isolated mononuclear cells ( I x 
I 06) were seeded on fibronectin-precoated 24-well plates (BD BioCoat , Bedford, 
MA, USA) in EndoCult medium (StemCell Technologies, London, UK) supplemented 
with Penicillin ( J OO U/mL) and Streptomycin ( 1 00 µg/mL). After 6 days , 
adherent cells were washed with medium, incubated with 1 , 1 '-dioctadecyl-3 ,3 , 3 ' , 
3 ' -tetramethylindocarbocyanine-labelled acetylated LDL ( 1 0  µg/mL Dil AcLDL; 
MolecularProbes, Invitrogen , Carlsbad, CA, USA) for 1 2  h, fixed with 1 % 
paraformaldehyde for 1 0 min, and counterstained with fluorescein isothyiocyanate­
labelled Griffonia (bandeiraea) simplicifolia lectin I, isolectin B4 (lectin, 1 0  µg/mL; 
Vector Laboratories, Burlingame, CA, USA) and DAPI for nuclear staining. Images 
were captured by an LSM 4 I O  confocal microscope (Carl Zeiss, Jena, Germany) . Cells 
double positive for DiIAcLDL and lectin staining were considered EPC and counted in 
high-power fields by co-localization analysis (Image-Pro Plus for Windows, version 
4.5.0.29) . For every rat, cells were seeded in duplicate and an average number ofEPC 
was calculated per well from five high-power fields. 
Fluorescent m icroscopy 
Cryosections were stained with primary antibodies [rabbit antihPAP, serotec ,  
London, U.K. ,  mouse anti-rat His5 2  (rat endothelial cell antigen) a kind gift from 
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Dr J.L. Hillebrands, and mouseanti-vascular endothelial growth factor (VEGF) ,  C- 1 ,  
Santa Cruz J followed by F ITC labelled goat anti rabbit-IgG- and TRITC, Alexa 5 5 5 or 
Cy5-labelled goat anti-mouse-IgG-isotype specific secondary antibodies. For nuclear 
staining, sections were mounted in vectash.ield mounting medium containing DAPI. 
Analysis was restricted to the viable LV wall. Cells that stained positive for hPAP were 
considered bone-marrow-derived and cells double positive for hPAP and His-52 were 
considered bone marrow-derived endothelial cells. Cells were enumerated per high 
power field by two researchers (B.D.W. , H.O.) blinded for the treatment allocation in 
five randomly chosen high power fields of the non-infarcted LV wall. The percentage 
of the endothelium composed of bone-marrow-derived cells was calculated by co­
localization analysis. The surface area that stained double positive for hPAP and his52 
is expressed as percentage of the total his-5 2  positive area. 
Eryth ropoietin, e rythropoietin-recep tor, and vascular 
e n doth e lial g rowth factor expres s i o n  
In  order to evaluate the effects of EPO on expression of  angiogenetic factors and the 
EPO receptor, samples of the viable LV free wall (non-infarcted area) were snap frozen 
in liquid nitrogen and stored at -80°C. The expression ofEPO, EPO-receptor, and VEGF 
was determined in tissue homogenates of seven randomly selected rats per treatment 
group by standard western blotting techniques under denaturing conditions, as 
described previously. 23 Membranes were reprobed for GAPDH to confirm equal 
protein loading and transfer. Signals were detected by the ECL-detection method and 
quantified by densitometry. Results are expressed as arbitrary units and represent the 
ratio between EPO, EPO-receptor, or VEGF and GAPDH per lane. Primary antibodies 
were purchased from Santa Cruz biotechnology [EPO H I  26 ,  I : 250 ;  EPO-receptor 
M-20 ,  I : 500; VEGF C I , I : 250  (recognizes all splice variants ofVEGF)J or Fitzgerald 
Industries (GAPDH 6c5 ,  I :  I 0000) and horeseradish peroxidase conjugated anti­
mouse or anti-rabbit IgG were used as secondary antibodies. 
Plas m a  e ryth rop oietin and vascular  e n do th e lial g rowth factor 
leve ls 
Plasma levels ofEPO andVEGF levels were determined by a commercial Enzyme Linked 
Immunosorbent Assay according to the guidelines provided by the manufacturer 
(Quantikine, R&D systems, Londen, UK). 
Statistical a n a lysis 
Data are presented as mean ± SEM when normally distributed and median + interquartile 
range when skewed distributed. Differences among groups were tested using one-way 
analysis of variance, followed by LSD post-hoc analysis if normally distributed, and 
by Kruskal-Wallis test followed by Mann Whitney U test with Bonferroni correction 
when skewed. Correlations were assessed with Spearman's correlation test. All reported 
probability values are twotailed , and a P-value ,0.05 was considered statistically 
significant. All statistical analyses were performed with SPSS version 1 2.0. 
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Table 1 .  General characteristics and myocardial function. 
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1 1 2±8 
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274±1 1  
1 08±41 





-73 1 1 ±5951 
28 1±5 
4.0±0]1 









-8749 ±287" 1 
290±6 
3.6±0.211 
Data are presented as mean ± SEM; n indicates number of animals; bpm, beats per minute; LYSP, left 
ventricular systolic pressure; LYEDP, left ventricular end-diastolic pressure; dLYP, developed left ventricular 
pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; dP/Dt max and dP/dT min, maximal 
rates of increase and decrease in LYP; BW, bodyweight. # Infarct size, as % of LY-circumference of the mid 
papillary slice. * p<0.05; tp<0.01 vs. Sham; +p<0.05, §p<0.01 vs. Ml. 
Results 
Eryth ropo ietin preve n ts p rogression o f  left-ven tricular­
dysfu n ction a n d  i m p roves capillary densi ty, associated with 
m a rked m o b ilization of e n dothelial  progen itor cells 
Three rats were excluded from analysis due to failed bone marrow transplantation. 
Twenty-four hour mortality after MI was 3 1  % ( 1 6  rats) and three rats (two in MI­
EPO and one in MI) were excluded because the infarct size was <25% of the LV 
circumference. The final population comprised 1 2 rats per MI group and 9 rats in the 
sham group. General characteristics are presented in Table I .Although hematocrit values 
were comparable between groups at the start of treatment, EPO treatment resulted in 
maximal 3 1  % increase in hematocrit increasing from 50 ± 0.3 to 64 ± I %  I week 
after treatment. Although the hematocrit decreased during the following 2 weeks until 
the next EPO treatment, it remained significantly elevated in MI-EPO compared with 
sham and MI throughout tl1e experiment ( all P < 0. 0 I ) .  Serial echocardiographic 
parameters are presented in Figure 1 . Induction of MI resulted in marked enlargement 




Figure 1 . Effect of EPO on myocardial remodeling after myocardial infarction. 
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0 wk 3 wk 6 wk 8 wk 
Changes in echocardio-graphic indices of LV function end LV end diostolic diameter during 8-weeks follow­
up after coronary artery ligation. 
* p<0.05 vs. Ml, * * p<0.01 vs. Ml. LVEDD ind icates left ventricular end-diastolic diameter 
In the following weeks, the deterioration of LV performance and LV dilatation 
(LVEDD) progressed in the untreated MI group, but remained stable in the EPO 
treated group (all P<0.05). LY-systolic pressure, LV developed pressure, myocardial 
contractility (dP/dtmax) and relaxation (dP/dtmin) and LVEDP were all significantly 
impaired in both MI groups compared with sham, and significantly improved after 
EPO treatment (Table I ) .  Histological infarct size was comparable between all MI 
groups. Cardiomyocytes' crosssectional area increased in both MI groups compared 
with sham (P<0.0 1 ) ,  but was not significantly different between MI and MI-EPO. 
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Figure 2. Effect of EPO treatment on neovascularization. 
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A. Measurements of capillary density in number of capillaries per mm2. B. Bar graph representing the 
capillary-to-myocyte ratio in different groups. * p<0.05 vs. Ml ,  * * p<0.01 vs. Ml 
Capillary density was significantly reduced in the saline treated MI group (P<0.0 I ) . 
EPO treatment increased capillary density by 33% (Figure 2, P<0.0 1 )  restoring it to 
sham levels. The capillary-to-myocyte ratio increased by 42% in the EPO treated group 
compared with sham and MI (Figure 2, P<0.0 I ) , indicating the formation of new 
vessels, rather than resulting from reduced cardiomyocyte hypertrophy. Treatment 
with EPO resulted in a four-fold increase in tl1e number of circulating EPC compared 
witl1 the MI group (P<0.0 1 ;  Figure 3).  
Eryth ropoietin augments h o m in g  a n d  in corporation 
of e n dothelial  pro g e n itor ce lls into th e myocardial 
microvasculatu re 
In tl1e non-infarcted LV free wall of the MI rats, a slight nonsignificant increase in the 
number of bone-marrow-derived cells (hPAP+) and bone-marrow-derived endothelial 
cells (hPAP+ , his 52+) was observed compared witl1 sham (Figure 4). This was 
markedly stimulated by EPO treatment, resulting in a 29% increased influx of bone 
marrow- derived cells and a 2. 1 -fold increase in bone-marrow-derived endothelial cells 
(P<0.05)The percentage oftl1e endotl1elium that comprised bone-marrow-derived cells 
did not differ significantly between MI and sham groups. However, this was markedly 
augmented by EPO treatment, increasing from 3.9 ± 0.5 to 1 1 .4 ± I %  (Figure 4; 
P<0.00 1 vs. sham and MI). EPO treatment resulted in a 33% increase in capillary 
density and tl1e percentage of the endothelium tl1at comprised bone-marrow-derived 
cells increased from 4 to 1 1  %. Therefore, -30% of tl1e newly formed endothelium 
comprised bone marrow-derived cells. The enhanced incorporation resulted from 
specific homing of EPC, reflected by a significantly higher ratio between bone marrow­
derived endothelial cells and total bone marrow-derived cells (P<0.00 I ,  Figure 4) . 
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Figure 3. Effects of EPO treatment on number of circulating Endothelial Progenitor Cell. 












SHAM M M! EPO 
A. Graphic representation of number of EPC. B. Endothelial progenitor cell under high magnification (white 
arrow), positively stained for Dil AcLDL (red cytoplasm) ond lectin (green cytoplasm), including DAPI nuclear 
staining (blue). * p<0.01 vs. Ml. 
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A. Myocardial section stained with hPAP bone morrow derived (green). His 52 (endothelium, red) and DAPI 
(nucleus, blue) detected at 63% magnification. The three panels display the endothelium, bone morrow 
derived cells and the fluorescent overlay respectively, demonstrating bone morrow derived endothelial cells 
(BMDEC) which appear yellow. B. Bar graph representing the total number of bone morrow derived cells in 
the myocardium. C. Bar graph representing the numbers of BM DEC per high power field. 
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SHAM Ml M EPO 
D, Bar graph representing the ratio between BMDEC and total bone marrow derived cells, E, Bar graph 
representing the percentage of endothelium comprised of bone marrow derived cells, F, Representative 
fluorescent overlay of the treatment groups at 40x magnification, BMDEC appear yellow, BMDC, bone 
marrow derived cells; BMDEC, bone marrow derived endothelial cells; hPAP, human placental alkaline 
phosphatase, * p<0,05 vs, Ml, * * p<0,01 vs, ML 
Moreover, a strong correlation was observed between circulating EPC and myocardial 
bone-marrow-derived endothelial cells (R = 0.64, P < 0,00 1 )  indicating that the 
increased EPC incorporation was directly related to increased EPC mobilization, 
Erythropoietin in duces vascular endothelial growth fa ctor 
expression and upregulates its own receptor 
Three weeks after the last EPO administration, plasma EPO levels were comparable 
between MI groups [20 (2-76) vs. 1 8  ( 1 -29) pg/ml in MI and MI-EPO groups, 
respectively], and slightly but non-significantly higher than sham [7 ( 1-30) pg/ml], 
Myocardial expression of EPO was however two-fold higher in both MI groups (P < 
0,05, Figure 5).  EPO-receptor expression was slightly decreased in MI compared witl1 
sham group, EPO treatment resulted in a 3-fold upregulation ofEPO-receptor expression 
(P < 0,01 vs, sham and MI, Figure 5). Altliough plasma VEGF levels were comparable 




Figure 5. Expression of EPO, EPO-receptor and VEGF in the left ventricular free wall. 
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A. Bar graph and representative bonds showing the difference in the expression of EPO in the left ventriculor 
free woll. B. Ber graph and representative bonds showing the difference in the expression of EPO-receptor in 
the left ventriculor free wall. C. Bar graph ond representotive bonds showing the difference in the expression 
of VEGF in the left ventricular free wall. D. Scatter plot delineating the relation between capillary to myocyte 
ratio and VEGF expression in the left ventricular free wall of oil groups (shorn, Ml and MI-EPO). EPOR, EPO­
receptor; VEGF; vascular endothelial growth factor. • p<0.05 vs. Ml, t p<0.01 vs. Ml 
respectively J, a moderate increase in the expression of VEGF was observed in the 
MI-group (Figure 5 ,  P = 0.07 trend) , but expression of VEGF was increased 4.5-
fold after EPO treatment (P < 0.0 1 vs. sham P < 0.02 vs. MI) . The expression of 
VEGF was strongly correlated with new capillary growth (Figure 5, R = 0. 6 7, P = 
0.00 I ) .  Triple staining with hPAP, His-52,  and VEGF antibodies revealed that VEGF 
immunoreactivity was equally expressed in the endothelial cells of bone marrow and 
myocardial origin (Figure 6) . 
Disc ussion 
The present study demonstrates for the first time that bone-marrow-derived progenitor 
cells are involved as a cardiac repair mechanism of systemic EPO treatment. EPO 
induced neovascularization is associated with increased mobilization, myocardial 
homing, and vascular incorporation of EPC, which comprise 30% of the newly 
formed endothelium. The augmented EPC-mediated neovascularization resulted in a 
marked improvement of the myocardial microvascularization, which was associated 
with attenuated MI-induced progression of LV-dilatation and decline in LV function. 
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Figure 6. Expression of VEGF by bone morrow derived and non-bone marrow derived 
endothelial cells. 
A. Representative fluorescent overlay showing bane marrow derived endothelium (endothelium (his 52, blue) 
bone marrow derived cells (hPAP, green). B. Representative fluorescent overlay showing VEGF expression 
in the endothelium (endothelium (his 52, blue) VEGF (red)) C. Merged picture of A and B showing that 
VEGF is expressed by bone marrow derived (dashed arrow) and non bone marrow derived isolid arrow) 
endothelial cells. 
In addition, VEGF secretion in the myocardium was increased 4.5-fold by EPO, strongly 
correlating with neovascularization. VEGF was equally expressed by endothelial cells 
of myocardial and bone marrow origin, suggesting an additional auto-/paracrine 
mechanism distinct from bone-marrow-dependent neovascularization. 
Eryth rop o i e tin  preve n ts l eft-ventricular-dilatation a n d  left­
ventricular dysfu n ction a n d  regenerates the m yo cardial  
microvasc u lature, associated with e n doth el ial  proge n itor cell  
m o b ilizati o n  
In the present study, we confirm that EPO improves cardiac function when administered 
in the chronic stage after Ml. Similar to our previous study, 1 1  EPO treatment starting 3 
weeks after MI had no effect on myocardial infarct size or cardiomyocyte hypertrophy 
but restored capillary density to sham levels, suggesting that neovascularization is the 
predominant mechanism through which EPO improves the failing heart. Myocardial 
remodelling post-MI is associated with impaired perfusion of the noninfarcted LV 
wall due to disproportionate cardiomyocyte hypertrophy relative to (micro) vascular 
growth resulting in a progressive deterioration of cardiac function. 24 Our data clearly 
demonstrate that administration of EPO restores the microvascularization and halts 
the deterioration of cardiac function. EPO-induced improvement of cardiac function, 
cardiac neovascularization, and EPC mobilization in post-MI LY-dysfunction was 
recently confirmed by two independent studies.�· 11 Furthermore, in a distinct model of 
chronic myocardial dysfunction, EPO prevented doxorubicin induced cardiomyopathy, 
which was also linked to improved EPC mobilization and capillary density8 · 1 0  Thus, 
EPO consistently improves cardiac function in experimental models of CHF, strongly 
linked to increased EPC mobilization and improved microvascularization. 
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Endothelial progenitor cells mobilized by erythropoietin 
incorporate into newly formed capillaries 
Our data are the first to demonstrate that EPC importantly contribute to EPO­
mediated microvascular regeneration of the failing myocardium. The effects of EPO 
on EPC mobilization were first described by Heeschen et al. 1 8 , who also demonstrated 
an association with neovascularization of ischaemic tissues. Recently, Urao et al. 1 1 
were the first to demonstrate that EPO increased incorporation of EPC into the 
endothelium, in a model of acute aortic-wire injury. However, our data are the first 
to demonstrate that the EPC mobilized by EPO promote neovascularization of the 
hypertrophied myocardium in chronic post-MI LV dysfunction. The importance of 
EPC in EPO-induced cardiac repair has been indirectly signified by three other reports. 
First, Prunier et al. showed that administration of EPO in a dose that does not induce 
EPC mobilization, failed to improve cardiac function and induce neovascularization, 
suggesting that EPC-mobilization is required for EPO to improve post-MI myocardial 
dysfunction. 1 1 However, EPC were only characterized by expression of CD3 I ,  which is 
also expressed by a variety of leucocytes.16Therefore, the data by Prunier et al. should be 
interpreted with caution. Secondly, in a model of doxorubicin induced cardiotoxicity, 
infusion of isolated EPC prior to doxorubicin infusion, preserved cardiac function 
in a magnitude equal to EP0. 1 0  Third, in a model of hypoxia-induced pulmonary 
hypertension, mice with erythroid restricted expression of tl1e EPO-receptor 
demonstrated impaired EPC mobilization and augmented disease progression, which 
was restored by transplantation of wildtype bone marrow. 27 Hence, EPC-mediated 
neovascularization appears to be crucial for EPO-induced protection from chronic 
vascular disease. 
Erythropoietin increases vascular endothelial growth factor 
levels and induces expression of its own receptor 
Thirty percent of the new endothelium was bone marrow-derived indicating that the 
remaining new vessels originated from in situ proliferated endothelial cells. Both direct 
effects of EPO on in situ endothelial cell proliferation and paracrine functions of 
EPC may play a role in this process.28 In order to investigate whether EPO stimulated 
the paracrine effect of EPC, we evaluated the expression of the key angiogenic 
cytokine VEGF. We demonstrate that EPO treatment markedly increases expression of 
VEGF in the myocardium. Endothelial cells of myocardial and bone marrow origin 
demonstrated equal VEGF immunoreactivity, which indicates that EPO stimulates 
secretion of angiogenic factors by endothelial cells in an auto-/paracrine fashion 
irrespective of their origin. These findings suggest that in addition to EPC-mediated 
neovascularization, EPO increases in-situ proliferation of myocardial endothelial 
cells , providing a distinct parallel mechanisms of neovascularization. EPO-induced 
expression of VEGF has also been observed in cultured endothelial cells. Interestingly, 
neutralization of VEGF stopped the mitogenic effects of EPO in these cultures, 
suggesting that EPO-induced endothelial cell proliferation is dependent on VEGF. 19 · 3 0  
Moreover, in addition to auto-/paracrine effects on endotl1elial cells, myocardial 




expression would thereby stimulate homing of EPC into the myocardium, further 
augmenting EPC-mediated neovascularization. These data suggest an important role 
for VEGF in EPO-induced neovascularization. 
Further studies are needed to evaluate whether VEGF upregulation is a prerequisite 
for EPO-induced neovascularization. Although the exact role of VEGF remains to be 
established, our data are the first to demonstrate the broad range of pro-angiogenic 
effects exerted by EPO, namely EPC-mediated neovascularization, local upregulation 
of another key angiogenic factor (VEGF) ,  and stimulation of in-situ proliferation of 
endothelial cells. Furthermore, EPO increased the expression of its own receptor, possibly 
leading to increased sensitivity to EPO. This has previously been demonstrated in 
cultured endothelial cells where hypoxia and EPO synergistically induced EPO-receptor 
expression. 11 These data suggest that EPO regulates EPO-receptor expression through 
a positive feedback mechanism. Basal expression-levels of EPO-receptor are relatively 
low in the non-erythropoietic tissues, but a marked up-regulation of the EPO-receptor 
has been demonstrated by acute metabolic stress, including hypoxia. n Therefore, the 
elevated exogenous EPO levels during treatment might mimic a hypoxia related signal 
to increase EPO-receptor expression, further potentiating the effects of therapy. 
Clinical implications 
Our present and previous data clearly show that EPO treatment prevents LV dilatation 
and myocardial functional decline by regenerating the myocardial microvasculature. 
Treatment with EPO has been identified as a promising and safe therapy for 
acute MI. 33 35 Moreover, correction of anemia in CHF with EPO has proved both safe 
and feasible_lf• Our findings indicate, however, that EPO exerts beneficial hematocrit 
independent effects, which might also prove beneficial for non-anaemic CHF patients. 
Nevertheless, unrestricted dosing regimens of EPO could elevate hematocrit to 
unacceptable levels, which might lead to impaired rheology, thrombogenicity and 
hypertension. 3
1 Indeed, a significant increase in diastolic blood pressure was observed 
in our study, suggesting EPO-induced hypertension. However, increased arterial 
pressure might result from the improved myocardial contractility. Systolic and diastolic 
blood pressure were comparable between the MI-EPO and the sham group, supporting 
the hypothesis that the increased blood pressure is related to improved function. These 
limitations might be overcome by using dosing regimens that do not alter hematocrit 
levels. 38 Alternatively, EPO-derivatives have recently emerged that do not ligate the 
EPO receptor on erythropoietic cells, but still confer tissue protection.39 Finally, a very 
recent study by Schneider et al.40 revealed that endocardial EPO injections improves the 
contractile function of hibernating myocardium, without affecting hematocrit levels. 
Conc lusion 
EPO-induced myocardial neovascularization is  mediated tlrrough a combination of  EPC 
recruitment from tl1e bone marrow and increased VEGF expression in the myocardium. 
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Chapter 7 
Abst r a c t  
Purpose 
We aimed to evaluate whether ischemia is required for erythropoietin (EPO) induced 
stimulation of endothelial progenitor cells (EPCs) and their related effects on endothelial 
and cardiac function. 
Methods 
Bone marrow of rats was replaced by transgenic cells to allow tracking of EPCs. 
Ischemic heart failure was induced by left coronary artery ligation to induce myocardial 
infarction (MI) and control rats received a sham procedure. Three weeks after surgery, 
rats were randomized to receive EPO (darbepoetin alfa 40µg/kg/3weeks) or vehicle 
and were sacrificed 9 weeks after surgery. 
Results 
In all treated groups, EPO significantly increased circulating EPCs and their 
incorporation into the endothelium of the ischemic and non-ischemic hearts as 
well as in the control organs; kidney and liver. This was associated with significantly 
improved endothelial function, which was strongly correlated with circulating EPCs 
(R=0.7 ,  p<0.0 1 ) .  However, additional EPCs preferentially homed to the ischemic 
MI borderzone (p<0.0 I )  resulting in specific EPO-induced improvement of cardiac 
microvascularization and performance only in ischemic hearts (all p<0 .05) .  The 
differential stimulation of neovascularization by EPO was associated with increased 
EPO-receptor and VEGF expression in ischemic hearts only. 
Conclusions 
In general, EPO stimulates normal endothelial progenitor cell-mediated endothelial 
turnover, but improves cardiac microvascularization and function only in the presence 
of ischemia. 
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I ntro d u ction 
Erythropoietin (EPO) improves cardiac function and induces neovascularization in 
experimental models of chronic myocardial dysfunction and is currently evaluated 
in patients with chronic heart failure. 1 7 EPO-induced neovascularization is related 
to increased mobilization and incorporation of bone marrow derived endothelial 
progenitor cells (EPCs) and augmented expression of angiogenic factors in the 
myocardium. 8 These effects of EPO have also been demonstrated in the endothelium 
of other ischernic organs , such as the brain and ischernic limbs.9- 1 2  In addition to new 
vessel formation , EPCs replace injured endothelium and thereby maintain the integrity 
of the endothelial monolayer. 1 3 Since endothelial dysfunction has been recognized as 
one of the earliest events in atherosclerotic cardiovascular disease 14, stimulation of 
EPC-mediated endothelial repair by EPO might be of therapeutic interest. 
However, the beneficial effects of EPO on endothelial repair and new vessel 
formation have only been demonstrated in ischemic organs. It is therefore unknown 
whether these effects are attributable to the presence of ischemia or represent a 
general phenomenon. We therefore aimed to evaluate whether ischemia is required 
for erythropoietin (EPO) induced stimulation of endothelial progenitor cells (EPCs) 
and their related effects on endothelial and cardiac function. 
Meth o d s  
Animals and bone marrow labeling 
For bone marrow transplantation experiments we used male Fischer F 344 rats 
(n=7 5) weighing 200-230 grams (Charles Rivers, France) as recipients and R26-
hPAP donor rats ( n= 1 0 ,  F 3  44 background, ubiquitously expressing human placental 
alkaline phosphatase, hPAP) . ,s Details on transplantation have been described in detail 
previously.8 Briefly, whole R26-hPAP bone marrow cells were transfused to Fischer 
F344 recipients after total body irradiation and left to reconstitute for 5 weeks. 
Leucocyte chimerism was assessed by FACS and rats with chimerism >80% were 
included in the experimental protocol. Animals were fed and housed, according to 
institutional rules and regulations. The experimental protocol was approved by the 
Animal Ethical Committee of tl1e University of Groningen. Results of endothelial 
function were confirmed in Male Sprague Dawley rats weighing 270-3 20 grams. 
Experimental protocol 
MI was induced by ligating the left coronary artery. 6 Sham operated rats were used to 
control for surgery and post-operation inflammation. In sham operated rats , the same 
surgery was performed without closing the ligature. Three weeks after surgery, rats 
were randomly assigned to treatment with the long-acting EPO analogue darbepoetin 
alfa ( 40 µg/kg, Aranesp, Amgen Inc. , Thousand Oaks, CA, USA) or vehicle; once every 
three weeks, at week 3 and week 6. After 9 weeks, hemodynamic measurements were 
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performed with a microtip pressure transducer (Millar Instr. Inc. , Houston, Texas, 
USA) as described previously. Heart rate (HR) , left ventricular systolic pressure (LVSP) , 
and left ventricular end-diastolic pressure (LVEDP) were measured. The maximal rates 
of increase and decrease in LVP ( dP I dtrn,x and dP / dt""'.) were determined. Thereafter 
hearts were rapidly excised and weighed. Myocardial tissue was dissected transversally 
and processed for immunohistochemistry or snap frozen for Western blot analysis. 
Circu lating en doth e lial  progenitor  c ells 
Circulating EPCs were enumerated as previously described. 8 Mononuclear cells were 
isolated from whole blood by density centrifugation and seeded onto fibronectin­
precoated 24-well plates ( 1 x I o• cells per well) in EndoCult medium (StemCell 
Technologies, London, UK) as described previously. After 6 days of culture, adherent 
cells were incubated with I ,  I '  -dioctadecyl-3 ,  3 ,3 ' , 3  '-tetramethylindocarbocyanine 
labeled acetylated-LDL (DiL-AcLDL) for 1 2  hours, fixed with 1 % paraformaldehyde 
and counterstained with fluorescein- labeled isolectin B ... Cells double positive for 
DiI-AcLDL and lectin staining were considered EPCs and counted in S high-power 
fields, by blinded observers. 
Histology 
Infarct size and capillary density were determined as described in detail previously.6 
Briefly, infarct size was determined at the mid-papillary level in transverse slices on 
picrosirius red / fast green-stained sections. Endothelial cells were stained with GSL 
Lectin and image analysis was used to measure capillary density and calculated as 
the number of capillaries per tissue area (mm1) .  Cryosections were stained for hPAP 
(rabbit anti-hPAP, serotec, London, U.K. followed by FITC labeled goat anti-rabbit-IgG) 
and rat endothelial cell antigen (RECA; mouse anti rat HisS 2; a kind gift from dr. J.L. 
Hillebrands, followed byTRITC-labeled goat anti mouse-IgG isotype) . DAPI was used 
for nuclear counterstaining. hPAP positive cells were considered bone marrow derived 
cells (BMDC) and cells double positive for hPAP and His-5 2 were considered bone 
marrow derived endothelial like cells (BMDEC) . Cells in five random high power 
fields of the non-infarcted left ventricular free wall were counted independently by 
two blinded observers. 
EPO-receptor a n d  VEGF express ion  
The expression of  EPO-receptor, Vascular Endothelial Growth Factor (VEGF) and 
GAPDH was determined in tissue homogenates of the viable left ventricular free 
wall (non infarcted area) by standard Western blotting techniques.8 Antibodies were 
purchased from Santa Cruz biotechnology (EPO-receptor M-20 ,  1 : 5 00,  VEGF C l ,  
I : 250 ,  (recognizes all splice variants of VEGF) , and Fitzgerald Industries (GAPDH 
6c5 , I :  1 0000).  Horseradish peroxidase conjugated anti-mouse or anti-rabbit IgG 
were used as secondary antibodies. 
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Organ b ath studies with isola te d a o rtic rings 
Vascular measurements were performed as described previously. '6 In brief, thoracic 
aortic rings were connected to an isotonic displacement transducer and after 
stabilization rings were checked for viability by stimulation with phenylephrine 
( I mmol/L) . The endothelium-dependent vasodilatation was assessed by a cumulative 
dose of metacholine ( I O  9 to I o-s mmol/L). In parallel rings, endothelium-independent 
vasodilatation was assessed in the presence of NG-Methyl-L-arginine acetate salt 
(L-NMMA, I o-s mol/L) a nonspecific NOS blocker, or in the presence of indomethacine 
( I o·• mol/L) a nonspecific prostaglandin inhibitor, and finally in the presence of both 
L-NMMA and indomethacine. Drugs were purchased from Sigma-Aldrich. 
Statistical M e th ods 
Data are expressed as means ± SEM. Statistical analysis among groups was performed 
by ANOVA. Differences in vascular dose-response curves between groups were tested 
by ANCOVA for repeated measurements. Correlations were assessed with Spearman's 
correlation test. All P-values were two-tailed, and a P-value of <0.05 was considered 
statistically significant. All analyses were performed using SPSS version 1 2.0 software 
(SPSS, Chicago, IL, USA). 
Resu l ts 
Two sham rats were excluded due to accidental procedural damage to a coronary 
artery. Mortality after MI was 32%. Hematocrit levels increased from 4 1  ± 0. 5% to 
57  ± 0. 5 % in EPO treated rats. No differences in hematocrit were observed between 
sham and Ml. At sacrifice, body weight was similar among groups, but heart weight 
/ body weight ratio was significantly increased in the MI groups compared to shams 
(p<0.0 I ) . EPO treatment reduced the hypertrophic response after MI (heart weight / 
body weight ratio: 4. 1 ± I in MI vs 3 .6 ± 2 in MI-EPO p=0.04) . 
Effects of EPO on circulating EPCs n u mber  
In sham rats MI resulted in an almost 60% increase in the number of circulating EPCs 
(52 ± 6 vs 83 ± 1 2  per high-powered field in sham vs sham-EPO, p<0.0 1 ). MI was 
associated with significantly decreased numbers of circulating EPCs (3 I ± 7 in MI, p<0.0 I 
vs sham). Treatment with EPO resulted in a substantially more pronounced increase in 
number of circulating EPCs (3 1 ± 7 vs 1 1 5 ± 22 in MI vs MI-EPO, figure I A, p<0.0 1 ) .  
Circulating EPC-numbers did not differ significantly between EPO-treated groups. 
Effe ct of EPO on incorp ora tio n of EPCs into th e isc h e mic  a n d  
no n-is c h e m ic m yocardium 
We determined the number of BMDEC in the viable left ventricular free wall, distant 
from the infracted area, and in the viable borderzone directly adjacent to the infracted 
area if applicable. 
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Figure 1. Effect of EPO on circulating and cardiac Endothelial Progenitor Cells. 
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A. Graphic representation of the number of circulating EPCs. B. Bar graph representing the number of Bone 
Marrow derived Endothelial Cells (BMDEC, cells staining double positive for hPAP and His 52)  in the viable 
left ventricular free wall distant from the infarct (if applicable). C. Typical BM DEC , myocardial section stained 
with hPAP (green}. His 52 (endothelium, red) and DAPI (nucleus, blue). The three panels display respectively 
nuclei, endothelium, bane marrow derived cells and the overlay of the 3 channels, where BMDEC appear 
yellow. * p<0.05 vs sham, # p<0.05 vs Ml. 
Figure 2. Effect of ischemia on homing of Endothelial Progenitor Cells. 
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A. Typical myocardial section showing infarct scar (red), viable myocardium (blue) and panels showing the 
areas considered infarct borderzone (border) and viable left ventricular ( LV) free wall remote from the infarct 
(remote). B. Bar graph representing the difference between BMEDC in the barderzone and the remote LV-wall. 
C. Representative fluorescent overlay of the borderzane and the remote LV. * p<0.05 vs sham, # p<0.05 vs Ml. 
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Figure 3 .  Effect of EPO on incorporation of Endothelial Progenitor Cells i n  the liver and the kidney. 
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A. Bor graph representing the number of bone morrow derived endothelial cells (BM DEC) in the liver. 
B. Bar graph representing the number of BM DEC in the kidney. C. Representative fluorescent overlay of a liver 
section BMDEC incorporated into the endothelium which appear yellow (40x magnification). BMDEC ore 
indicated with a white arrow. D. Representative fluorescent overlay of a kidney section showing bone morrow 
derived cells incorporated in the interstitium (green) and the endothelium (yellow) surrounding the glomerulus 
(40x magnification) BMDEC ore indicated with a white arrow. * p<0.05 vs shorn, # p<0.05 vs Ml .  
In the left ventricular free wall, the number of BMDEC was comparable between sham and 
:tv1I rats (3.2 ± 0.6 vs 3.8 ± 0.3 BMDEC per high-powered field, p = 0.5, figure lB). EPO 
treatment almost doubled the number of BMDEC after MI in the left ventricular free 
wall, but to a similar extent after sham operation (5 .8 ± 0.9 in MI-EPO and 5.0 ± 0.9 
in sham-EPO both p<0.05,  figure I B) .The number of BMDEC in the borderzone was 
significantly higher compared to the left ventricular free wall in both MI groups (3 . 8  
± 0 .3  v s  10  ± 0 .6  in MI and 5.8 ± 0.9 vs  1 5  ± 1 . 7 in  MI  EPO, botl1 p<0.0 1 figure 
2) ,  indicating preferential homing of EPCs into the ischemic myocardium. Ischemia­
induced homing of EPCs to the MI-borderzone was also markedly augmented by 
EPO-induced EPC mobilization (p<0.05) .  
Effect of EPO on incorporation of EPCs in endothelium of other organs 
The number of BMDEC in kidneys and livers were comparable in sham and :tv1I rats 
( figure 3). EPO treatment resulted in a significantly increased incorporation of BMDC in 
the endothelium of kidneys and livers in both sham and :tv1I rats (figure 3). 
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A. Endothelium dependent vosodilototion to methocholine {ME) of each group of bone marrow transplanted 
Fischer F344 rats, expressed as the percentage of displacement induced by phenylephrine precantraction. 
B. Endothelium dependent vasodilatation to ME in Sprague Dawely sham operated rats. C. Endothelium 
dependent vasodilatation ta ME in Sprague Dawely rats with concomitant N O-blockade with L-NMMA. 
D. Correlation between maximal relaxation to ME and the number of circulating EPC in Sprague Dawely rats. 
To assess the relationship between circulating EPCs and incorporation of BMDEC, 
we analyzed all groups combined. A significant correlation between circulating EPC­
number and incorporated number of BMDEC were observed in the heart (R=0.S,  
p<0.0 1), kidney (R=0.6, p<0.0 1 ), and liver (R=0.5 6, p=0.02). 
Effe ct o f  EPO on endothelial function 
Endothelial-dependent vasodilatation in response to metacholine is depicted in figure 
4. Induction of MI resulted in a significant impairment of endothelial-dependent 
vasodilatation (p<0.0 I ,  figure 4A). EPO treatment significantly improved endothelial 
dependent relaxation in MI rats, almost restoring it to sham levels (p<0.05 vs MI) . 
Interestingly, EPO also tended to improve endothelial dependent vasodilatation in 
sham rats (p=0.09 vs sham). To assess the mechanisms involved and to exclude 
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potential effects of irradiation on endothelial function parameters, we also assessed 
vascular function in male Sprague Dawley rats. In these experiments we confirmed that 
EPO treatment resulted in an improvement of endothelial dependent vasodilatation 
(p= 0. 0 I 2, figure 4 B) . The effect of EPO on endothelial dependent -vasodilatation was 
completely abrogated by co-incubation with L-NMMA, suggesting involvement of 
eNOS (figure 4C) . Blockade of prostacyclins by indomethacin did not significantly 
change vasodilatation ( data not shown) . To assess the relationship between circulating 
EPCs and endothelial function we correlated the number of circulating EPCs and the 
maximal rate of metacholine induced relaxation. A strong correlation was observed 
(R=0 .7 ,  p<0.0 1 ,  Figure 4D) . 
Effect of EPO on myocardial  capillary density 
Induction of MI significantly reduced cardiac capillary density (p=0 . 0 1  versus sham, 
figure SA) . EPO significantly increased capillary density in MI rats, almost restoring 
it to sham levels(p<0 .0  I vs. MI; and p=NS vs sham, figure SA) . In parallel, EPO 
treatment resulted in a significant increase in the protein expression ofEPO-receptor 
and VEGF in MI rats (p<0.0 I ,  figure SC and SD) .  However, EPO treatment did not 
affect myocardial capillary density, EPO-receptor orVEGF expression in sham rats. 
Effect of EPO on cardiac function 
Cardiac function was significantly reduced in MI groups compared to sham (all p<0 .OS ,  
figure 6) . EPO treatment significantly increased myocardial contractility, relaxation and 
LVESP and a decrease in LVEDP in MI rats, but not in shams (figure 6) 
Disc ussion 
In the present study we demonstrate for the first time that the regenerative effects of 
EPO in chronic heart failure are dependent on the presence of ischernia. EPO stimulated 
mobilization of EPCs from the bone marrow which indiscriminately incorporated in 
the endothelium of ischernic and non-ischernic tissues and significantly improved 
endothelial function. However, EPO stimulated neovascularization and improved 
cardiac function only in ischemic hearts, which was possibly driven by augmented 
local VEGF and EPO-receptor expression. These results suggest that EPO regulates 
normal endothelial progenitor cell-mediated endothelial turnover, but improves 
microvascularization and cardiac function only in the presence of ischernia. The 
differential effects of EPO in the presence and absence of ischemia are summarized 
in table I .  
EPO a ug m e n ts EPC-m e diated en dothel ial  turn over 
The endothelium is recognized to play a crucial role in atherogenesis and considered 
to be involved early in the pathophysiology of cardiovascular disease. 1 4 In patients 
with essential hypertension and documented coronary artery disease, endothelial 
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Figure 5. Effects of EPO on neovascularization and expression of pro-angiogenic factors in 
ischemic and non-ischemic hearts. 
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A. Measurements of capillary density expresses as the number of capillaries /mm 1. B. typical examples of 
capillary density in the experimental groups. C. Protein expression of VEGF corrected for GAPDH in the left 
ventrlcular free wall. D. Protein expression of EPO-receptor corrected for GAPDH in the left ventricular free 
wall. * p<0.05 vs sham, # p<0.05 vs Ml .  
dysfunction appears a marker for future cardiovascular events. 1 7  Moreover, chronic heart 
failure is associated with endothelial dysfunction which promotes cardiac remodeling 
through increased peripheral resistance, eventually reducing prognosis. I K Maintaining 
a vital endothelial monolayer is therefore of pivotal importance in the prevention 
and treatment of cardiovascular disease. Endothelial turnover can be facilitated 
through migration and proliferation of neighboring endothelial cells, although the 
rate of endothelial-cell proliferation in arteries is relatively low. 1 • In contrast, EPCs 
rapidly repopulate denuded arteries, associated with an immediate improvement of 
endothelial function. 20 Thus in addition to their role in neovascularization, EPCs serve 
as gatekeepers for endothelial patency and function. 
Urao et al. were the first to demonstrate that EPO does not only induce EPC 
mobilization but also promotes incorporation ofEPCs into sites of endothelial injury. 1 2  
In addition, we recently revealed that EPO-induced neovascularization in chronic 
post-MI heart failure is at least partially mediated through increased incorporation of 
EPCs into the myocardial microvasculature. 8 The present study is however the first to 
1 06 


















l A O  




SHAM SHAM-EPO Ml 
J 

















Erythropoiet in and  ischemio 
I 
I * • 
SHAM SHAM-EPO Ml 
* 







A. Graphic representation of left ventricular controctility (dPdT max), B. Graphic representation of left 
ventricular reloxotion(dPdT min). C. Graphic representation of left ventricular systolic pressure (LVSP). 
D.Grophic representation of left ventricular systolic end diastolic pressure (LVEDP). * p<0.05 vs shorn, # 
p<0.05 VS Ml. 
demonstrate that increased EPC-mobilization by EPO augments incorporation ofEPCs 
into the endothelium, independent of the presence of ischemia. Therefore, our results 
substantiate the hypothesis that augmented EPC-mobilization by EPO accelerates 
endothelial turnover. 
The increased endothelial turnover was associated with restoration of heart 
failure-induced deterioration of endothelial function. Moreover, although we consider 
endothelial function relatively normal in sham-operated rats, EPO treatment further 
improved endothelial dependent relaxation, through augmented release of NO. 
Interestingly, in normal rats a strong correlation was observed between maximal 
rates of endothelial dependent relaxation and the number of circulating EPC ,  
substantiating a direct relationship between EPC-mediated endothelial turnover and 
vascular function outside the setting of an vascular injury. It is tempting to speculate 
that the improvement of endothelial function is caused by the replenishment of 
functionally impaired endothelial cells by EPCs. Alternatively, paracrine effects of 
incorporated EPCs might contribute to functional improvement of surrounding cells.20 
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Table 1. Effects of erythropoietin in the presence or absence of ischemia. 
Effacts of wythropoietin 
EPCs mobilization 


















EPO, erythropoietin; VEGF, Vascular Endothelial Growth Factor; +, increased by EPO, -, not increased by 
EPO, ++, markedly increased by EPO. 
Direct effects of EPO on resident endothelial cells should also be considered, since 
EPO has been shown to activate endothelial cells in vitro and in vivo, associated 
with eNOS up regulation and improved endothelial function.2 1 . 21 However, resident 
endothelial cells are relatively insensitive to EPO while EPCs respond to EPO-doses 
that are insufficient to activate erythropoietic cells.�· 23 Future studies are required to 
differentiate between direct and indirect effects of EPO on endothelial function. 
EPCs switch fro m  e n dothel ial  turnover to EPO-induced 
n e o vascularization in th e presen ce of i schemia 
After MI, perfusion of  the remaining vital myocardium will become insufficient 
due to disproportionate cardiomyocyte hypertrophy relative to (micro) vascular 
growth, resulting in ischemia and up regulation of hypoxia inducible factors. 14• 1 5  
Although non-specific incorporation of EPCs into the systemic endothelium was 
observed, EPCs preferentially homed to ischemic hearts and even more specifically 
to the regions with the most profound perfusion insufficiency. The specific homing 
of EPCs into ischemic myocardium was associated with differential induction of 
neovascularization, only in rats with ischemia due to post-MI heart failure. Hence, 
the presence of ischemia seems necessary to switch from vascular "maintenance" to 
EPO-induced neovascularization. 
VEGF levels were slightly increased in the untreated MI group, but EPO treatment 
augmented VEGF expression 4-fold. This effect of EPO could not be extended 
to sham operated rats withour cardiac ischemia. Upregulation of VEGF at sites of 
EPO-induced neovascularization in ischemic tissues has been substantiated in other 
reports. 1 1 ·16 Moreover, in mice that lack EPO-receptor expression in the vasculature, 
VEGF upregulation in the ischemic hind limb is markedly attenuated and associated 
with significantly reduced neovascularization and homing of EPCs.27 VEGF is a potent 
angiogenic factor that stimulates in situ proliferation of endothelial cells and has 
important chemotactic effects on EPCs.18 Therefore, EPO induced expression of 
1 08 
Erythropoietin end ischemio 
VEGF might mediate the preferential homing of EPCs into the ischemic tissue, thus 
facilitating EPC-mediated neovascularization. However, the increased VEGF expression 
might also stimulate resident endothelial cells and thereby induce neovascularization 
through EPC-independent mechanisms. 
EPO-induced VEGF upregulation is mediated through EPOR signaling 
pathways.26·27•29 In addition to VEGF upregulation, EPO was associated with 
augmented EPOR expression in the MI but not in the sham group, which confirms 
similar findings by others. 3° Extra-hematopoietic tissues are relatively insensitive to 
EPO, and binding affinities for EPO are I Q.fold lower in endothelial cells compared 
to erythropoietic progenitors. 23 The combined presence of hypoxia and ischernia 
however significantly augments sensitivity to EPO through an exponential increase 
in EPO-receptor expression. 3° Separately these factors exert minute effects. Therefore, 
the absence of EPO-induced VEGF expression and neovascularization might in part be 
explained through absence of ischernia-induced sensitization to EPO. 
Clinical  implications 
In the present study, we demonstrate that EPO treatment might reverse endothelial 
dysfunction in the early stages of cardiovascular disease and thereby prevent the 
progression into cardiovascular events. This important role for EPO in the regulation 
of endothelial cell turnover and endothelial function, might in part explain the 
high incidence of vascular events in patients with EPO deficiency due to chronic 
kidney disease. The beneficial effects of EPO treatment in these patients may not only 
result from the correction of anemia but from an improved endothelial function 
as well. Moreover, restoration of endothelial dysfunction in patients with heart 
failure will decrease peripheral resistance and thereby reduce cardiac afterload and 
possibly improve outcome as well. The improvement of endothelial function in our 
study was mediated through augmented endothelial NO-production. In addition 
to vasodilatation, augmented NO-production has been identified as an important 
compensatory mechanism against the pro-trombotic effects of EPO.2 1 A possible 
therapeutic role for EPO in its present form in non-anemic patients is however 
complicated by the unrestricted elevation of hematocrit. The safety of which is 
currently also questioned in patients with chronic kidney disease and cancer. 3 1 • 32 
Recently we have demonstrated that cardiac function in post-MI heart failure can be 
augmented with an EPO dose that does not increase hematocrit levels. This might 
suggest that even non-erytlrropoeitic doses of EPO will benefit patients.33 Ideally, a 
minimally effective dose should be established which exerts optimal benefit with 
little or no effects on hematocrit. In addition, non-erythropoietic EPO derivatives have 
emerged. 34 These strategies might provide us with tools to revitalize the endothelium 
of patients at risk of major cardiovascular events. Care should however be taken not to 
over stimulate the bone marrow as this may lead to functional exhaustion the bone­
marrow stem cell population. JS. 36 
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C o n c l usions 
In general, EPO stimulates normal endothelial progenitor cell-mediated endothelial 
turnover. However, EPO attributes to neovascularization and improves cardiac function 
only in the presence of local ischemia. 
1 1 0  
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Erythropoietin (EPO) may improve cardiac function and induce neovascularization in 
experimental models of chronic heart failure ( CHF) . However, the increased hematocrit 
associated with EPO treatment might exert concomitant deleterious effects. 
We aimed to investigate the hematocrit independent effects of EPO on cardiac 
function. 
Methods and results 
Rats were subjected to permanent coronary artery ligation to induce myocardial 
infarction (MI) or sham surgery. Three weeks after MI, rats were randomly allocated 
to treatment with vehicle (MI) or the long-acting EPO analogue darbepoetin alfa 
in a high ( 40 µg/kg/3 weeks, MI-EPO-high) or a low dose (0.4 µg/kg/3 weeks, 
MI-EPO low) . After 9 weeks, hemodynamic parameters, myocardial histology and 
Myocin Heavy Chain (MHC) isoforms were determined. High dose EPO resulted in 
a significant increase in hematocrit (p<0 .0 I )  while low dose EPO had no effect on 
hematocrit levels. EPO significantly improved cardiac function in both EPO groups , 
reflected by increased LY-developed pressure and improved contractility ( dP / dtm.) and 
relaxation (dP/dtmJ indices of the LV at 9-weeks (all p<0 .05 compared to MI) . The 
improved cardiac function was associated with an increased capillary growth (38% in 
MI-EPO-high (p<0.0 I )  and 27% in MI-EPO-low (p<0.05))  and an attenuated switch 
to slow (3-MHC isoforms in both EPO-treated groups. 
Conclusions 
EPO improves cardiac function and induces neovascularization in a dose that does 
not increase hematocrit, thereby circumventing the possible deleterious effects of 
increased erythropoiesis. 
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Intro du ction 
The classical role o f  erythropoietin (EPO) i s  related to  its hematopoietic effects. EPO 
is produced in kidneys and acts as a major regulator of erythropoiesis, by increasing 
survival and promoting proliferation of erythroid progenitor cells. 
However, EPO has recently been shown to render organ protection in various 
experimental models of acute ischemia , including stroke and myocardial infarction, 
mainly through a reduction of apoptotic cell death. H In addition , EPO improves 
cardiac function in experimental models of chronic myocardial dysfunction , which 
is consistently associated with improved microvascularization of the myocardium. 5 1 0  
The neovascularization by EPO is  associated with marked mobilisation and vascular 
incorporation of endothelial progenitor cells (EPC) . 1 1- 14 In addition , EPO stimulates 
neovascularization by inducing direct mitogenic effects on endothelial cells through 
local upregulation of VEGF. 1 4  1 6  Therefore, the ancillary properties of EPO seem 
independent of erythropoiesis. 
However, the effects of EPO in chronic myocardial dysfunction have been 
established with repetitive dosing regimens that significantly increased hematocrit 
levels. Therefore, they might at least to some extend, be related to the increased oxygen­
carrying capacity of blood. Moreover, EPO treatment in non-anemic patients could 
lead to unwanted elevation of hematocrit, associated with higher risk for thrombosis 
and hypertension. 1 7 Indeed, the recently published CREATE and the CHOIR study 
revealed tl1at overcorrection of anemia with recombinant human EPO in patients witl1 
chronic kidney disease (CKD) was associated with increased cardiovascular events. 1 8· 1 9  
In Chronic Heart Failure (CHF) patients , appropriately powered phase-3 studies are 
lacking, although safety and feasibility studies demonstrated promising beneficial 
effects without additional harm.20 Nevertheless , treatment aimed at improving 
cardiac function in non-anemic CHF patients at already elevated cardiovascular risk 
necessitates treatment strategies that exert the beneficial effects of EPO without 
increasing hematocrit levels. 
The erythropoietin receptor in the heart is structurally and functionally distinct 
from it's hematopoietic counterpart, and can be specifically targeted.2 1 Moreover, 
chronic EPO administration in a dose tliat was insufficient to increase hematocrit , 
improved tl1e survival, ameliorated endothelial damage and preserved renal function in 
a rat remnant kidney model, suggesting a different dose-response relationship for the 
erythropoietic and pleiotropic effects.22 Low-dose EPO might therefore exert similar 
beneficial effects on the myocardium, without tl1e deleterious effects on hematocrit. 
We hypothesized that the ancillary properties of EPO in CHF are independent 
of the effects on erythropoiesis , and can be induced with an EPO dose that does 
not increase hematocrit. We therefore studied the effects of high- and low-dose EPO 
treatment on cardiac function, neovascularization and myosin heavy chain (MHC) 
isoform expression in an experimental model of post-MI heart failure. 





Male Sprague Dawley rats weighing 270-330  g (Harlan, Zeist, The Netherlands) .  
Animals were fed ad libitum, and housed in groups of four to five rats, according 
to institutional rules with 1 2 :  1 2  hours light-dark cycles. The experimental protocol 
was approved by the Animal Ethical Committee of the University Medical Center 
Groningen. 
Design of the study 
Rats were either subjected to left coronary artery ligation (n=63) or sham surgery 
(n= 1 1 ) .  Rats with MI were randomly allocated to 3 groups: control (MI) and two EPO 
treatment groups with different dosages oflong-acting EPO analogue darbepoetin : 40 
µg/kg (MI-EPO-high) and 0.4 µg/kg (MI-EPO low). Darbepoetin-alpha (Aranesp, 
Amgen Inc., Thousands Oaks, CA, USA) was administered intraperitoneally, once 
every three weeks, starting three weeks after the coronary artery ligation, hence 
after the healing phase of MI. Control (MI) and SHAM rats received corresponding 
injections of saline. The high dose of darbepoetin was based on our previous study 1 0 ,  
demonstrating increased neovascularization in this model, together with significant 
elevation of hematocrit levels. To avoid the effect of EPO treatment on hematocrit we 
included a low-dose EPO group, with 1 DO-times lower darbepoetin dosage (0.4 µg/ 
kg/3 weeks) , which in a pilot experiment did not cause elevation ofhematocrit (data 
not shown) . Hematocrit was measured at baseline and at week 3, 4, 6 and 9 after 
surgery. 
Myocardial  infarction m odel 
This model has been described previously.23 Briefly, rats were anesthetized with 
2.5% isoflurane and placed on a heating pad (3 7°C). Animals were intubated and 
mechanically ventilated using room air enriched with 1 .0 I/min oxygen. After left­
side thoracotomy, MI was induced by ligating the proximal portion of the left coronary 
artery, beneath the left atrial appendage. In sham operated rats, the same surgery was 
performed, without ligating the suture. 
Hem odyna mic measurements 
After nine weeks, rats were anesthetized as described above. Microtip pressure 
transducer (Millar Instr. Inc., Houston, Texas, USA) was inserted into the left 
ventricular cavity via the right carotid artery. After a 3 -min period of stabilization, 
heart rate (HR) , left ventricular systolic pressure (LVSP), left ventricular end-diastolic 
pressure (LVEDP), and developed left ventricular pressure (dLVP=LVSP-LVEDP) were 
measured. As indices of contractility and relaxation, the maximal rates of increase and 
decrease in LVP ( dP / dtm., and dP / dtm,.) were determined. The catheter was retracted 
into the aortic arch and arterial systolic and diastolic blood pressures (SBP, DBP) were 
recorded. 
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Infa rct s ize and myocyte hypertrophy 
After hemodynamic measurements , hearts were rapidly excised and weighed. Mid­
papillary slices were fixed in 4% paraformaldehyde and paraffin-embedded. Infarct 
size was determined by planimeter in transverse slices on picrosirius red/fast green­
stained sections. Infarct size was expressed as the percentage of scar length to total 
left ventricular circumference, as previously describedY Deparaffinised 5-µm thick 
sections were stained with a Gomori's silver staining. Using image analysis (Zeiss 
KS 400, Germany) , concentric myocyte hypertrophy in the viable LV wall , remote 
from the infarcted area, was measured as the cross-sectional area of transversally cut 
myocytes showing a nucleus.23 Myocyte density was calculated as the average number 
of myocytes per tissue area (mm2) .  In each stained section, measurements were 
averaged from three different counting fields (± 7 5 myocytes per heart) 
Capillary density 
To visualize the capillaries in the myocardium of the LV free wall, endothelial cells were 
stained with biotin-labeled Lectin GSL ( I :  I 00; Sigma-Aldrich, St. Louis , Missouri, 
USA) , as previously described. Since lectins stain not only capillaries but other vessels 
as well, a size criterion of I O  µm was used to exclude small arterioles and venules. 
Image analysis (Image-Pro Plus for Windows, version 4.5 .0.29) was used to measure 
capillary density, calculated as the number of capillaries per tissue area (mm2) .  As 
a measure of neovascularization, capillary-to-myocyte ratio was calculated dividing 
capillary with myocyte density, as previously described. 23 
Myosin heavy ch ain (M H C) isoform a n a lysis 
As a molecular marker for changes in myocardial contractility, myosin heavy chain 
(MHC) isoform analysis was performed. Samples of the non-infarcted left ventricular 
free wall were snap frozen and stored at -80°C until analysis. Gel electrophoresis was 
performed on tissue lysates as described previously 25 . In brief, samples were run 
at constant current (24 mA) for 5 h .  Hereafter silver staining was performed and 
the percentage fast a-MHC vs. slow �-MHC was determined with laser scanning 
densitometry. Increased expression of slow �-MHC results in impaired contractility of 
cardiomyocytes and represents a molecular marker of impaired contractility. 
Apoptosis ana lysis 
To visualize apoptotic cells in the myocardium, deparaffinised sections were 
stained with a monoclonal anti-cleaved caspase-3 antibody (ASP ] 7 5 ,  cell signaling 
technologies, MA, USA) and visualized with the ENVISION kit (DAKO Cytomation , 
Glostrup, Denmark) according to the guidelines provided by the supplier. Cleaved 
caspase-3  positive cells were considered apoptotic and were expressed per I 0.000 
cells. 
Statistical ana lysis 
Data are presented as mean ± SEM, or as median ± IQR (25 th and 7 5 th percentile) 
depending on their distribution. Differences among groups were tested using one-
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way analysis of variance, followed by LSD post-hoc analysis if normally distributed, 
and by Kruskal-Wallis test if skewed distributed. Correlation analysis was performed 
with Spearman's correlation test. All reported probability values were 2-tailed, and 
a p-value <0.05 was considered statistically significant. All statistical analyses were 
performed with SPSS version 1 1 .0. 
Resul t s  
Genera/ characteristics 
Overall 24-hour mortality following MI was 4 1  %. Five additional MI rats died during 
follow-up (2 in MI group, 1 in MI-EPO-high and 2 in MI-EPO-low group). 
Two rats ( 1  in MI and 1 in MI-EPO-high group) had infarct size < 25%. These 
were excluded from further analysis. General characteristics after nine weeks are 
shown in table 1 .  LV-infarct size (% of LV) was comparable between all MI groups 
(table I ). Body weight (BW) was significantly higher only in the MI-EPO-low group 
( table 1 ) .  The heart weight to BW ratio was significantly increased in the rats with 
MI compared to the sham rats (all p<0.05 ;  table ! ) .  A lower heart weight to BW 
compared to MI group was observed in MI-EPO-high and MI-EPO-low groups (both 
p<0.05). 
Tobie 1 .  Chorocteristics of the experimental groups ot sacrifice {9 weeks). 
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General 
n 1 1  1 0  1 1  9 
Info rel size 45±3 47±2 50±3 
Hemodynomics 
Heart rote (bpm) 321±6 3 1 8±8 339±7 31 2±7 
LVSP (mmHg) 130±3 1 04±6' 1 1 9±3 *§ 1 1 5±4' 
LVEDP (mmHg) 10±1 24±41 16±21 19±2 * 
SBP {mmHg) 127±3 1 02±5 1 1 1 5±3 * 1 1 1 3±4 * 
DBP (mmHg) 81±2 73±3 * 83±3i 80±2 
Body/organ weight 
BW (g) 410±6 402±1 2  416±8 442±8* §  
Heart weight/BW(mg/g) 4.5±0.1 6.0±0.3 1 5.3±0.1 " 5.3±0.3 *1 
Doto ore presented as mean ± SEM; n indicates number of animals; bpm, beats per minute; LVSP, left 
ventricular systolic pressure; LVEDP, left ventricular end-diastolic pressure; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; BW, bodyweight. * p<0.05; lp<0.01 vs. Sham; *p<0.05, ip<0.01 vs. Mi. 
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Effects of EPO on hematocrit 
-+- Sham 
_,,,,_ Ml 
-Ir- MI-EPO high 
-+- MI-EPO low 
The changes of the hematocrit throughout the experiment are shown in figure I .  
Only the treatment with high-dose EPO led to significant increase in hematocrit 
levels, which persisted throughout the experiment. Importantly, hematocrit levels in 
MI-EPO-low group were similar to those of MI and sham groups. 
Effects of EPO on cardiac function 
Invasive pressure measurements were performed 9 weeks after the surgery 
immediately before the rats were sacrificed. Myocardial contractility ( dP / dt-) and 
myocardial relaxation ( dP / dtm,,) were both impaired in all MI groups compared to 
the sham group (all p<0.05) .  Both low- and high-dose EPO treatments resulted in 
improved contractility and relaxation compared to MI (both! p<0.05 ;  figure 2) .  
LVSP and developed LVP ( dLVP) were both decreased in all MI groups compared 
to sham operated rats (p<0.05  for all). MI-EPO-high showed a significantly higher 
LVSP and dLVP (table ! ) ,  compared to MI (both p<0.0 1 ) . Low-dose EPO resulted in 
a 1 7% higher dLVP (p<0.05) ,  and a trend towards elevation ofLVSP, compared to the 
control group (p=0.07; table ! ) .  LVEDP was elevated in the MI-group compared to 
the sham operated rats (p<0.0 I ;  table I ) .  Compared to the MI group, LVEDP was 34% 
(p<0.05) lower In the MI-EPO-high group and 20% lower in in the MI-EPO-low 
group (p=NS). SBP and DBP were higher only in the MI-EPO-high group, compared 
to control (both p<0.05) .  
Effects of EPO on neovascularization 
Figure 3C shows representative photomicrographs of the four different groups. Capillary 
density was significantly reduced in MI compared to sham-group (p<0.0 I ) . High­
dose EPO treatment prevented the decrease in capillary density after induction 
of MI and restored it to sham values, as shown in Figure 3A (p=NS vs. sham) . 
1 2 1  
E1 
Chapter 8 

















* *  * *  -10000 
T 
___ __,_ 0 
dP/dl max dP/dl min 
dP/dtmo, and dP/dtm,,' maximal rate of increase and decrease of ventricular pressure, respectively. 
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Figure 3. Effect of EPO treatment on neovascularization. 
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A. Actual measurements of capillary density in number of capillaries per mm2 . B. Bar graph representing the 
capillary-to-myocyte ratio in different groups. C. Tissue sections with lectin in the viable free wall of the lour 
different groups, showing individual capillaries. * p<0.05 vs. Ml, • • p<0.01 vs. Ml.  
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A. lmmunohistochemical staining af a cleaved caspase-3 positive cardiomyocyte under high power 
magnification showing a nucleus (blue) and cytoplasmatic presence of cleaved caspase 3 (brown, upper 
panel). Rabbit immunoglobulin lgG was used as a negative control (lower pannel). B. Graphic representation 
of the number of cleaved caspase-3 positive cells in the viable myocardium. • p<0.01 vs. sham. 
In this group (MI-EPO-high) we observed a 33% increase in capillary density 
compared to MI group (p<0. 0 1 ) .  Treatment with low-dose EPO resulted in a 20% 
higher capillary density (p<0.05) .  The cross-sectional area of cardiomyocytes 
increased in all MI groups compared to sham, although EPO treatment had no effect 
on cardiomyocyte hyperthrophy. Compared to MI group, the capillary-to-myocyte 
ratio increased by 39% in MI-EPO-high (p<0.0 1 )  and by 27% in MI-EPO-low 
(p<0 .05) (figure 3B). The differences between MI-EPO-high and MI-EPO-low group 
were not statistically significant. 
Effects of EPO o n  M H C  isoforms 
Induction of heart failure resulted in a 2 .  5 fold increase in the expression of �-MHC 
in the MI group (24 c 5 % vs. 5 8  ± 5 % in sham vs. MI, figure 4) . EPO significantly 
attenuated the shift from a-MHC to �-MHC (figure 5 ,  p<0.0 1 )  by 3 1  % in MI-EPO 
high (40 ± 3 %) and by 28 % in the MI-EPO low group (42 ± 4 %). 
Effects of EPO on myocardial  apoptosis 
The number of cleaved caspase-3 positive cells was significantly higher rats with heart 
failure, compared to shams (6.6 ± 2 ,  40 ± 3.4 , 29  ± 3 ,  32  ± 8 in sham, MI, MI­
EPO-high and MI-EPO-low respectively, p<0.0 1 ,  figure 4) . However, the numbers of 
cleaved caspase-3 positive cells did not differ significantly between the MI groups. 
Disc ussion 
In the present study we demonstrated that the beneficial effects of EPO on cardiac 
function in post-MI heart failure are at least in part independent of an increased 
hematocrit. EPO treatment in a dose that was insufficient to raise hematocrit levels, 
1 2 3  
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Graphic representation of the expression of �-MHC as a percentage of total MHC. * p<0.001 vs. sham 
t p<0.01 vs. Ml. 
markedly improved cardiac function. The functional improvement was associated with 
induction of neovascularization, and attenuated expression of slow �-MHC isoforms. 
Most of the beneficial effects were slightly less pronounced in the low dose group, 
which might indicate that part of the beneficial effects are related to an increased 
hematocrit. Alternatively, it might reflect the dose dependent nature of the pleiotropic 
effects of EPO on the heart, which are completely distinct from erythropoiesis. 
In the clinical setting, current therapy after MI is focused on prevention of 
ventricular remodelling and development of heart failure. Myocardial regeneration 
may offer possibilities that could improve cardiac function in these patients. 26 
Although cardiomyocytes proliferation after ischemic injury seems limited, the 
formation of new vessels in the non-infarcted part of the ventricle could lead to an 
improvement of function and attenuation of ventricular remodelling. 27 •2a Evidence is 
accumulating to suggest that EPO exerts potent pleiotropic effects on the myocardium 
in the setting of acute myocardial infarction and chronic heart failure as well.2 ·5 10·2 9  
Therefore, in addition to it's acute protective effects, EPO might evolve as a standard 
"cardioregenerative" therapy in the setting of chronic myocardial dysfunction. 
The dosing regimens used in previous studies, all resulted in a supraphysiological 
hematocrit levels. W hen applied to the clinical situation, this could lead to 
hypertension, seizures, vascular thrombosis and death, possibly related to abruptly 
increased hematocrit values. "· 1 9·30 This could be of potential concern in patients 
at already elevated cardiovascular risk. Therefore, we investigated the effects of a 
non-erythropoietic EPO dose to avoid elevation of hematocrit, and consequently 
the changes in rheology and oxygen-binding capacity of the blood. We compared 
these effects to a high EPO-dose, which effects on cardiac function in post-MI heart 
failure were already established. ' 0 Moreover, similar to the high-dose treatment, 
!ow-dose treatment resulted in noticeably improved cardiac function, reflected 
by a significantly enhanced developed LVP, together with improved contractility 
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and relaxation indices of the LV. Similar to high dose EPO, low-dose EPO induced 
neovascularization and attenuated the unfavourable switch to slow �-MHC isoforms. 
However, in contrast to high-dose EPO, LVEDP was not significantly attenuated in 
the low-dose group compared to the untreated MI. Thus, in spite of increased filling 
pressures, low-dose EPO improves contractile properties of the non-infarcted part of 
the myocardium. Although the (non significantly) larger infarct size in the low-dose 
EPO group could have partially averted the beneficial effects of EPO, neovascularization 
was also less pronounced in the MI-EPO-low group. This might indicate that part 
of the beneficial effects are related to an increased hematocrit and consequently 
increased oxygen delivery. However, the low dose EPO group was treated with a dose 
1 00 times lower than the high dose group. Therefore the slightly less pronounced 
effects in the MI-EPO-low group might also reflect a reduced magnitude of the non­
erythropoietic effects. The anti-apoptotic effects of EPO in the myocardium have been 
well described in the setting of acute ischemia, yet EPO did not reduce apoptotic cells 
in our study. Although these results might seem contradictory to previous reports, 
apoptosis was determined 3 weeks after the last EPO-dose, when EPO-levels are 
comparable between groups. 1 4 Since the anti apoptotic effects of EPO are dependent 
on EPO receptor signalling, possible effects of treatment will have elapsed. 
Application of lower doses of EPO was also shown to confer vascular and tissue 
protection in the kidney.22 Low-dose darbepoetin treatment in a rat remnant kidney 
model improved the survival , ameliorated endothelial damage and preserved renal 
function, without an increase in hematocrit levels. In contrast , Prunier et al. recently 
reported that a weekly dose of 0.7 5 µg/kg darbepoetin alfa, initiated 1 week after 
myocardial ischemia reperfusion injury, was insufficient to improve cardiac function 
and induce neovascularization. 9 The dose utilized by Prunier et al. was clearly higher 
than the present study and resulted in significant elevation of hematocrit.The reason for 
the discrepancy between the study by Prunier et al. and our study is unclear. Possibly, 
tl1e relatively limited infarct size associated with ischemia reperfusion injury, and 
tl1e consequently limited decline in cardiac function ,  might result in more equivocal 
results. Furthermore, since increased hematocrit levels might have deleterious effects, 
the balance between the negative effects of hematocrit elevation and the beneficial 
effects of EPO might become unfavourable. 
Another option to circumvent unwanted effects of EPO on hematocrit, could be 
the use of recently discovered non-erythropoietic derivates of EPO, retaining the tissue 
protective property, without undesired effect on erythropoiesis.2 1 The possibility to 
separate the erythropoietic and tissue-protective effects could be explained through 
interaction of EPO with different receptors in bone marrow and in "peripheral" 
tissues. Two independent studies have demonstrated that these non-erythropoietic 
EPO's retain their acute cardioprotective potential. 3 1 ·3 2  It is however uncertain whether 
these new EPO's will also improve cardiac function in CHF. F inally, a very recent study 
by Schneider et al. revealed that endocardial EPO injections improve the contractile 
function of hibernating myocardium, without affecting hematocrit levels.33 One of 
the mayor shortcomings of the present study is the lack proper evaluation of platelet 




effect low-dose EPO might include attenuated EPO-induced activation of platelets 
and coagulability. Although some reports have described enhanced coagulability 
in patients treated with EPO, a link between hematopoiesis-stimulating drugs and 
thrombosis has not been proven. Indeed, Lindenblatt et al. have recently demonstrated 
that high dose darbepoetin ( I O  µg/kg/week) did not affect coagulation and platelet 
aggregration in mice. Since we used an 8 times lower dose of EPO in the present 
study, similar results are expected, but should be proven in future studies. 
Conclusions 
In summary, EPO treatment improves cardiac function and induces neovasculari-sation 
in post-MI heart failure, even in a dose that doses not increase hematocrit. Although 
time-limited treatment with high-dose EPO may be beneficial and safe during acute 
ischemic injury, if prolonged tl1erapy is required (heart failure) ,  drug regimens using 
low-dose EPO may be more uitable to avoid the adverse effects of the treatment. 
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A bs tract  
Backgro und 
Erythropoietin (EPO) stimulates Vascular Endothelial Growth Factor (VEGF) expression 
in the heart. We aimed to delineate the cardiac cell types and signal transduction 
pathways responsible for EPO induced cardiac VEGF production and establish 
whether VEGF is responsible for EPO-induced improvement of cardiac function in 
heart failure. 
Methods and results 
EPO increased VEGF expression in cultured neonatal rat cardiomyocytes but not 
in cultured human umbilical vein endothelial cells. Augmented VEGF production 
was blocked by the STAT-3 inhibitor pPYLKTK-mts but not by the PBK inhibitor 
wortmannin or the ERK-inhibitor PD98059 .  This was confirmed in a rat aortic 
sprouting assay where the effects ofEPO on sprouting of endothelial cells were modest 
andVEGF independent. In rats with heart failure after myocardial infarction (MI) , EPO 
treatment ( darbepoetin alfa 40µg/kg/ 3weeks, starting 3 weeks after MI) resulted in 
as 3-fold increased expression of VEGF in cardiomyocytes and significantly improved 
cardiac capillary density (3 7 %, P<0.0 1 )  and left ventricular function (all P<0 .0 1 
vs untreated MI) . Neutralization ofVEGF with two distinct antibodies abrogated the 
salutary effects ofEPO on left ventricular microvascularization and function (P=NS vs 
MI, P<0.0 I vs MI-EPO) . VEGF neutralization attenuated EPO-induced proliferation of 
myocardial endothelial cells (P=0.0 1 ) .  In addition, neutralization of VEGF reduced 
myocardial homing of endothelial progenitor cells by 42% in rats with alkaline 
phosphatase labeled bone marrow cells. 
Conclus ions 
EPO stimulates STAT-3-mediated VEGF production by cardiomyocytes, which in  turn 
mediates EPO induced neovascularization and improvement of cardiac function in 
heart failure. 
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I ntro d u ction 
Although significant morbidity and mortality benefits have been made, chronic heart 
failure (CHF) remains a prevalent medical condition with a poor prognosis. The 
development of new therapeutic strategies is therefore of utter importance. 1 
A key pathophysiological feature that contributes to progressive cardiac dys­
function in heart failure is insufficient microvascular adaptation to cardiomyocyte 
hyperthrophy.1• 3 We and others have extensively shown that treatment withEPO restores 
microvascular insufficiency, and improves cardiac performance in experimental and 
clinical heart failure. 4 7 The mechanisms of EPO-induced neovascularization in heart 
failure are however incompletely understood. 
There are several reasons to believe that activation of Vascular Endothelial Growth 
Factor (VEGF) is involved the EPO-induced cardiac effects. First, EPO increases VEGF 
expression in various ischemic tissues and cardiac VEGF levels are strongly correlated 
with new vessel formation.8 1 1  Second, EPO only stimulates neovascularization in the 
heart at sites where VEGF expression is increased. 1 1 Third, mice that lack an EPO­
receptor (EPO-R) in the heart display defective VEGF-expression and dramatically 
accelerated development ofleft ventricular (LV) -dysfunction during pressure overload. 9 
Therefore, myocardial up regulation ofVEGF seems a pivotal process in EPO-induced 
stimulation of myocardial neovascularization. However, the direct effects of EPO on 
VEGF expression and its relation to new vessel formation and improvement of cardiac 
function have not been studied. 
We hypothesized that VEGF up regulation in the myocardium is crucial for 
EPO-derived restoration of cardiac microvascularization and performance. We 
aimed to identify cell types and signal transduction pathways responsible for EPO­
induced augmentation ofVEGF in the heart and establish whether augmented VEGF 
expression is crucial for EPO-induced improvement of cardiac microvascularization 
and function. 
Materials and metho d s  
Effect o f  EPO on VEGF-tran scription ,n  cardiomyocytes and 
endothelial  cells 
Neonatal rat cardiomyocytes (NRCMC, from Sprague Dawley rats, Zeist , The 
Netherlands) and Human Umbilical Vein Endothelial Cells (HUVECs) were isolated 
and maintained as described previously. 1 3• 14 NRCMC ( I 05 cells / well) were 
incubated without serum for 22 hours and HUVECs cultures at 90% confluence 
were incubated in RPMI I 640 medium with L-glutamin and 2 % fetal bovine serum 
for I 8 hours. Because we have previously described that ischemia is required for 
EPO-induced upregulation ofVEGF in the heart, cells were pre-incubated with or 
without the hypoxia mimetic deferoxamine ( I 00 µM, Sigma Aldrich) for 2 hours. 
The role of well described EPO-receptor signal transduction pathways was studied 
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by additional pre-incubation with the PB Kinase blocker wortmannin ( 1  µM, Sigma 
Aldrich) , the MEKK-kinase blocker PD98059 (25 µM, Sigma Aldrich) , or the cell 
permeable STAT3-inhibitor peptide (pPYLKTK-mts, I µM, Calbiochem) for 30  
minutes. After pre-incubation, EPO (Eprex, Janssen-Cilag, final concentration of  I 0 
IU/mL) , was added to the wells and cells were lysated after 30 ,  60 or 1 20 minutes 
with TRIZOL-reagent (Invitrogen) and RNA was isolated according to the suppliers 
guidelines. After reverse transcription with random primers (Promega) , quantitative 
reverse transcriptase polymerase chain reaction (qRT PCR) was performed with PCR­
master mix containing cyber green (AbGene) or with TAM-labeled primer / probe 
sets according to the suppliers guidelines (Applied Biosystems) . B2M was used as a 
housekeeping gene in all analysis and data are expressed as fold-difference compared 
to control. We analyzed at least 8 wells per group and experiments were divided over 
at least 3 separate experiments with cells from different donors· 
Aortic sprouting assay 
The aortic ring assay, which i s  a co-culture of  endothelial cells, fibroblasts and vascular 
smooth muscle cells, was performed using the method of Nicossia and Ottinetti with 
slight modifications. 1 5 Briefly, 0 .6  mm long aortic rings of the thoracic aorta were 
embedded in growth factor reduced Matrigel (Becton Dickinson) . The aortic rings 
were then cultured in endothelial cell culture medium (which contains endothelial 
cell growth factor (ECGF) and heparin) 14 with or without 1 0  IU/mL EPO or 1 µg/ 
mL goat anti-ratVEGF (AF 5 64, R&D systems) for 7 days. Maximal sprout length was 
measured with Image Pro (Version 4. 5 .  0. 2 9) and is expressed in arbitrary units. 
Animals and bone m arrow labeling 
Male Sprague Dawley rats (270-320 g) were purchased from Harlan (Zeist, the 
Netherlands) .  For bone marrow transplantation experiments we used male Fischer 
F344 rats (200-230 g) purchased from Charles Rivers (France) as recipients and 
R26-hPAP donor rats (F344 background, ubiquitously expressing human placental 
alkaline phosphatase, hPAP) !6 Details on transplantation have been described in 
detail previously.A Briefly, whole R26-hPAP bone marrow cells were transfused to 
Fischer F344 recipients after total body irradiation and left to reconstitute before 
commencing with the experimental protocol. Animals were fed and housed, according 
to institutional rules and regulations. The experimental protocol was approved by the 
Animal Ethical Committee of the University of Groningen. 
Experimental protocol in rats 
Because VEGF-signaling is crucial for the normal control of cardiac microvascularization 
in heart failure, 11 we inhibited VEGF signaling by neutralizing antibodies only in 
the first week after EPO treatment. Myocardial Infarction (MI) was induced by 
permanent ligation of the left coronary artery. 1 In sham operated rats, the same 
surgery was performed without closing the suture. Three weeks after MI, rats were 
randomly assigned to treatment with the long acting EPO analogue darbepoetin alfa 
(40 µg/kg/3 weeks, Aranesp, Amgen Inc., Thousand Oaks, CA, USA) or vehicle. Rats 
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were additionally randomized to treatment with goat anti rat-VEGF affinity purified 
antibody (5 µg/rat aVEGF l ;  R&D systems, AF564) or the irrelevant control antibody 
goat anti-mouse-IgG (5 µg/rat, R&D systems, AF007) three times per week during 
one week immediately following each EPO-administration. To control for potential 
non-specific effects of antibody cross reactivity, we additionally treated separate groups 
of rats with mouse anti-humanVEGF 1 65 (aVEGF2 ,  1 mg/rat) . This resulted in 7 
treatment groups, 3 treated with irrelevant control antibody (sham, untreated MI, MI­
EPO) and 2 with eachVEGF neutralizing antibody (MI-EPO + aVEGF l ,  MI + aVEGF l ,  
MI-EPO + aVEGF2,  MI + aVEGF2) . To evaluate the temporal characteristics ofVEGF­
neutralization, blood was drawn from the tail vein at week 3 ,  4, 6 and 7 .  After 9 weeks, 
at sacrifice, hemodynamic measurements were performed with a microtip pressure 
transducer (Millar Instr. Inc. ,  Houston, Texas, USA) as described previously. 18 Heart 
rate (HR) , left ventricular systolic pressure (LVSP) , and left ventricular end-diastolic 
pressure (LVEDP) were measured. The maximal rates of increase and decrease in LVP 
( dP / dtmax and dP / dtmJ and the developed LY-pressure ( dLVP) were determined. Next, 
whole blood was drawn and hearts were rapidly excised and weighed. Myocardial 
tissue was dissected transversally and processed for immunohistochemistry or snap 
frozen for molecular analysis. 
VEG F-n e u tra lizing capacity of plasma 
96-well plates were coated with donkey anti-goat-IgG in PBS overnight. Next, plates 
were washed 5 times and incubated with plasma samples of 4 rats that were treated 
with the irrelevant control antibody and 4 rats that received a VEGF I .  Recombinant 
human VEGF 1 6  5 (R&D systems) was added to the wells to reach a final concentration 
of 1 000 pg/ml and incubated for 60 minutes. Hereafter, VEGF concentration was 
determined by ELISA according to the suppliers' guidelines. (R&D systems) Percentage 
neutralization was determined as VEGF-measured pg/ml / 1 000) * 1 00%. The 
neutralizing characteristics of a VEGF2 have been described elsewhere. 1 9  
Myocardial  VEGF p rotein content  
The expression ofVEGF and GAPDH was determined in tissue homogenates of  the 
viable left ventricular free wall (non infarcted area) by standard Western blotting 
techniques as described previously.8 
Circu la ting e n doth e lial  progen itor cells 
Circulating EPCs were enumerated as previously described. 8 Briefly, mononuclear 
were seeded onto fibronectin-precoated wells in EndoCult medium (StemCell 
Technologies) . After 6 days, cells were incubated with l , l '-dioctadecyl-3 , 3 , 3 ' , 3 ' ­
tetramethylindocarbocyanine labelled acetylated-LDL (DiL-AcLDL) for 1 2  hours, fixed 
with 1 % paraformaldehyde and counterstained with fluorescein-labelled isolectin B
4
• 
Cells double positive for Di! AcLDL and lectin staining were considered EPCs and 
counted in 5 high-power fields, by blinded observers (BDW, WPTR) . 
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A. Graphic representation of temporal changes in VEGF mRNA expression alter EPO-treatment in neonatal 
rat cardiomyocytes (NRCMCI and endothelial cells (HUVECs) in the presence or absence of the hypoxia 
inducing agent deferoxamine. B. Graphic representation of VEGF mRNA expression in EPO-lreated NRCMC 
with or without specific blockers for EPO-receptor signal transduction pathways. E; EPO, D; deferoxamine, 
STAT-3inh; STAT-3 inhibiling peptide, PD98; PD98059. 
Left ve n tricular h isto logy 
Cardiomyocytes' cross sectional area and the number of cardiomyocytes / mm1 were 
determined after Gomoris' silver staining as described previously. 5 Deparaffinized 
sections were stained with the primary antibodies mouse anti Troponin T (JLT- 1 2, Sigma 
Aldrich), rabbit anti VEGF (A20, Santa Cruz biotechnology), mouse anti-Proliferating 
Cell Nuclear Antigen (PCNA, PC I O, Cell Signaling Technology) or biotin labeled GSL-
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Figure 2. Effects of VEGF inhibition on EPO induced in vitro angiogenesis. 




A. Graphic representation of the maximal aortic sprout length ofter 5 and 7 days in a motrigel aortic 
implantation assay. B. Typical examples of aortic sprouting in the different experimental groups. C: Control; 
E: EPO; oV: VEGF-neutrolising antibody. 
Lectin (Sigma Aldrich). For chromogenic detection, Streptavidin-HRP (Santa Cruz) 
or the Envision kit (Dako-Cytomation) were used and detection was performed with 
diamynobenzydine (DAB)-staining with mayers hematoxcillin (Sigma) for nuclear 
counterstaining. For fluorescent detection, streptavidin-FITC (Perkin Elmer), anti-mouse 
Alexa5 55 (Invitrogen) or goat anti-Rabbit-HRP followed by the biotynylrhodarnine­
TSA kit (Perkin Elmer) were used. Cyosections were stained for hPAP (rabbit anti-hPAP, 
serotec, London, U.K. followed by FITC labelled goat anti-rabbit-IgG) and rat endothelial 
cell antigen (RECA; mouse anti-rat His52; a kind gift from dr. J.L. Hillebrands, followed 
by TRITC-labeled goat anti-mouse-IgG) . Diamidino-2-phelylindole (DAPI) was used 
for all fluorescent nuclear staining. Infarct size was determined at the mid-papillary 
level and capillary density was determined as the number of capillaries per tissue area 
(mm2) after GSL-Lectin staining as described in detail previously.5 with the addition of I 
minute eosin-staining to enhance evaluation of tissue surface area.VEGF-positive area of 
the myocardium was determined with Image pro (version 4.5) after DAB staining and 
expressed as percentage of the total area. Cells double positive for lectin and PCNA were 
considered proliferating endothelial cells, and cells double positive for hPAP and His-
52 were considered bone marrow derived endothelial cells. Quantification of double 
positive cells was performed in 4-5 random high power fields of the non-infarcted left 
ventricular free wall and were counted independently by blinded observers (BDW, LY).  
Stati s tical methods 
Data are expressed a s  mean ± SEM. Statistical analysis among groups was performed by 
ANOVA with the bonferroni post hoc test if distributed normally or with the Kruskall­
Wallis test followed by Mann Whimey-U when skewed distributed. All P-values are 
two-tailed, and a P-value of <0.05 was considered statistically significant. All analyses 




Figure 3. Effect of EPO on VEGF expression in the myocordium. 
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A. Typical exomples al VEGF-immunohistachemistry of myocardia l  sections of treatment groups. 
B. lmmunolluarescent staining of rat myocardium. Co-localization of VEGF (redl and troponin-T (greenl 
confirms that VEGF is predominantly expressed in cardiomyocytes. C. Graphic representation of VEGF 
immunareoctive surface area. D. Graphic representation of the VEGF protein expression in the left ventricular 
free wall. 
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Resu l ts 
Effects of EPO on VEGF-transcription in cardiomyocytes a n d  
endothel ial  cells 
VEGF mRNA expression was significantly increased by EPO in NRCMC only in the 
presence of the hypoxia-mimicking agent deferoxamine (P=0.02, figure I A) .  In 
HUVECs, VEGF-expression was unaffected by EPO (P=non-significant (NS) , figure 
I A).  Extended incubation with deferoxarnine increased VEGF-expression in NRCMC 
and HUVECs compared to cultures without deferoxamine, but did not alter the effects 
of EPO on VEGF-expression ( data not shown). The effects of EPO on VEGF expression 
were blocked by STAT-3 inhibiting peptide, but not by wortmannin or PD98059 
(figure I B) ,  suggesting that the STAT-3 pathway is  the operative in this signal. 
Role of VEGF in EPO-induced aortic sprouting 
To corroborate the previous findings , we studied the effects of EPO in the aortic 
sprouting assay, which is a co-culture of vascular cells without parenchyma cells such 
as cardiomyocytes. EPO significantly increased maximal sprout length compared to 
control cultures, but the increase was less than I 0% (P<0.05 ,  figure 2).  Neutralization 
ofVEGF did not inhibit the effects of EPO on aortic sprouting. 
Effect of EPO on VEGF-production in rats with h e art fai lure 
In rats with post-MI heart failure, EPO treatment resulted in a 3-fold increased 
protein expression of VEGF in the viable left ventricular free wall (figure 3D) .  
In addition to increased protein levels, EPO-treatment also increased the VEGF­
immunoreactive area, suggesting that EPO additionally increased the number of 
cells that produced VEGF (figure 3 A+C). Immunofluorescent double staining 
showed that VEGF expression was especially apparent in cardiomyocytes (figure 
3B). VEGF neutralization did not significantly alter VEGF-expression (figure 2) .  
Effect of VEGF n e utralization on EPO-induced improve m e n t  of 
cardiac function 
A total of 1 50 Sprague Dawely rats were used. Peri-operative mortality in MI rats 
was 42% and 8% of rats were excluded because the infarct size was below 25%, 
leaving 7 5 rats for analysis. Characteristics of the study groups are presented in 
table I .  Immediately following antibody administration , plasma of a VEGF I 
treated rats neutralized 78% ofVEGF. In the subsequent weeks without antibody 
administration, values were normalized to the irrelevant control antibody, indicating 
transient neutralization of VEGF only during EPO treatment. EPO resulted in a 
significantly increased hematocrit and augmented numbers of circulating EPCs. 
VEGF neutralization did not affect hematocrit levels or circulating EPC-numbers 
(Table I ) .  MI resulted in a significant increase in heart weight and cardiomyocytes 
cross-sectional area , which was influenced neither by EPO treatment nor by VEGF 
inhibition (Table I ) .  Hemodynamic measurements are presented in table I and figure 
4. Induction of MI resulted in a decreased cardiac function in all MI groups (figure 4) . 
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Table 1. Characteristics of the experimental groups at sacrifice (week 9} 
Varlale 
SHAM + Ml + MI-IPO + Ml + IPO +  Ml + IPO +  Ml + Ml + 
lgG ltG lgO aYIGFl aVIOf2 aVIGFl aVIGP2 
N 9 9 1 1  1 3  1 0  1 1  12  
Infarct size 41 ± 2.3 42 ± 1.8 43 ± 1 .5 43 ± 2.0 43 ± 2.1 44 ± 1 .8 
Bodyweight 396 ± 7  409 ± 16  414 ± 7  406 ± 6  415 ± 9  416 ± 10 402 ± 13 
Hemotocrit 47 ± 1 .2  48 ± 1 .2 58 ± 1,511 56 ± 0.9!1 55 ± 2.6'' 49 ± 1 .4 47 ± 0.8 
Circ. EPCs 147 ± 15 9 1  ± 25'  280 ± 62'1 224 ± 34·1 135 ± 21 
Heart / body 3.4 ± 0.1 5 2 ± 0.41 4.9 ± 0.31 4.7 ± 0.3 1 4.4 ± 0.1 '  5.0 ± 0.3 1 5.4 ± 0.81 
Cordiom<ross. 405 ± 28 771 ± 46 1 806 ± 41 '  756 ± 241 806 ± 371 781 ± 471 804 ± 281 
lung / body 4.4 ±0.1 8.1 ± 1 .71 8.0 ± 1.3 1 8.1 ± 1 . 1 1 8.4 ± 1 .1 ' 1 0.6 ± I 2' 7.9 ± 1 .01 
Hemodynomics 
Heart rote (bpm) 298 ± 6.5 303 ± 19  3 17 ± 6  292 ± 8 300 ± 13  293  ± 8 291 ±5 
LV-syst (mmHg) 1 19 ±4 102 ± 21 1 1 2 ± 4!1 101 ± 21 1 05 ± 41 100 ± 31 98 ±21 
Aorto-syst (mmHg) 123  ± 3 101 ±31 1 1 2  ± 3• 100 ± 31 103 ± 31 96 ± 61 98 ±21 
Aorto-diost 80 ± 3  71  ± 3  82 ± 2 74 ± 4  73 ± 3  65 ± 6  71 ± 1 
(mmHg) 
Data are presented as mean ± SEM; N, number of animals; Circ. EPCs, circulating endothelial progenitor 
cells, Heart / Body; Heart weight / body weight ratio, Cardiom-cross.; cardiomyocytes crossectional area, 
Lung / Body; Lung weight / bady weight ratio, bpm, beats per minute, LV, left ventricle; mmHg, millimeters 
mercury; syst., systolic; diast, diastolic. • p<0.05; t p<0.0 1  vs sham, # p<0.05, + p<0.01 vs Ml .  
EPO-treatment significantly increased left ventricular (LV) contractility ( dPdT-max, 
dLVP) and LY-relaxation (dPdT-min) and decreased LY-filling pressures (LVEDP) 
compared to the untreated MI (all P < 0.0 1 , figure 3 ) .  Neutralization of VEGF with 
both antibodies blocked the salutary effects of EPO on cardiac function parameters 
(P=NS vs untreated MI , P < 0.02 vs MI-EPO, figure 4) , while intermittent neutralization 
itself did not further decrease cardiac function compared to the untreated MI. (P= NS, 
figure 4) . Systolic and diastolic blood pressure decreased after Ml and EPO-treatment 
resulted in a significant increase in systolic blood pressure compared to the MI group 
(P<0.05) although values did not exceed those of shams. The effect ofEPO on blood 
pressure was blocked by VEGF neutralization , while inhibition alone had no effect. 
Effect of VEG F  n e u tra lization on EPO-in duced left ve n tric ula r  
n e ovascularization 
Induction of heart failure significantly reduced cardiac capillary density, (3282 
± 182  vs .  1956 ± 1 5 1  capillaries / mm2 , in sham vs MI ,  P<0.00 1 ,  figure 5) .  
EPO-treatment increased capillary density by 37 % (2688 ± 1 83 capillaries / 
mm1 , P<0.01 vs MI, P< 0.0 1 vs sham, figure 5) and VEGF -inhibition completely 
blocked the effects of EPO on capillary density (p= NS vs untreated MI, P 
<0.0 I vs MI-EPO, figure 5 ) .  Intermittent neutralization of VEGF did not result 
in further reduction of capillary density (P=NS vs untreated MI , figure 5) .  
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• P < 0.05 VS Ml 
A. Graphic representation of left ventricular contractility {dP/dT max). B. Graphic representatianof left 
ventricular relaxation(dP/dT min). C. Graphic representation of left ventricular end diastolic pressure 
(lVEDP). D. Graphic representation of the developed left ventricular pressure (dtVP). E, EPO; oVEGF, VEGF 
neutralising antibodies. 
Capillary / cardiomyocyte ratio was slightly but non-significantly increased in all MI 
groups compared to sham. EPO treatment resulted in a 42% increase in capillary / 
cardiomyocyte ratio, which was completely abrogated byVEGF inhibition (figure 5) . 
Effect of  VEGF neutralization on EPO-induced prol iferation of 
en dothelial  cel ls  
The number of proliferating endothelial cells in the viable left ventricular free wall 
was comparable between sham and MI groups ( 5 .  I ± 0. 9 vs 7 .  6 ± I . I cells per 
field , P=NS, Figure 6 A +  B) . EPO treatment significantly increased the number of 
proliferating endothelial cells in the left ventricular free wall ( I  5 . 7  ± 1 . 6 ,  P<0.00 I 
vs sham and MI) . VEGF inhibition significantly attenuated the stimulatory effect of 
EPO on endothelial cell proliferation ( 1 0 .7  ± 0 .9  cells / field in MI-EPO + aVEGF, 
P=0.0 I vs MI-EPO) although the number of proliferating cells was still significantly 
higher than in the sham and MI-group (P<0.05 vs sham and untreated MI) . 
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Figure 5. Effeds of VEGF-neutralization on EPO-induced neovascularization. 
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A. typical examples cf capillary density in the experimental groups. B. Graphic representation of capillary 
density expresses as lhe number of capillaries / mm2• C. Graphic representation of the capillary / 
cardiomyocytes ratio. E; EPO. 
Effe ct of VEGF n e u tra lization myoca rdial  h o m ing of EPCs 
EPO significantly increased circulating EPCs in MI-EPO and MI-EPO + aVEGF groups 
(P<0.05 vs MI) . To evaluate the effect of myocardial VEGF upregulation on homing 
of EPCs we replaced the bone marrow by hPAP-labelled cells, VEGF inhibition 
reduced the number of bone marrow derived endothelial cells in the left ventricular 
free wall by 44% ( 9 ± 0.4 vs 6 ± 0.4 cells /field, P<0.0 l , figure 6 B + C). 
Disc ussion 
I n  the present study we reveal for the first time a crucial role forVEGF in EPO-induced 
neovascularization and restoration of left ventricular function. In cardiomyocytes, 
EPO promoted VEGF-transcription through the JAK / STAT-3 signal transduction 
pathway. In contrast, EPO did not stimulate VEGF-transcription in endothelial cells 
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Figure 6. Effects of VEGF inhibition on EPO induced myocardial endothelial cell proliferation 
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A. Typical example of immunofluorecent double staining showing PCNA-positive nuclei {red) in capillary 
endothelial cells {green) highlighted with on arrow. B. Graphic representation of the number of proliferating 
endothelial cells in the left ventricular free wall of the experimental groups. C. Representative fluorescent 
overlay of a myocardial section from on EPO treated animal stained with hPAP [green), His 52 [endothelium, 
red) and DAPI (nucleus, blue), showing hPAP-positive lie. bone morrow derived) endothelium, which 
oppeorsyellow and is highlighted with arrows. D. Graphic representation of the number of bone marrow 
derived endothelial cells in the left ventricular free wall. 
and the direct angiogenic effects ofEPO on sprouting of endothelial cells was modest 
and VEGF independent. In rats with heart failure, EPO stimulated VEGF-production 
predominantly in cardiomyocytes and neutralization ofVEGF completely abrogated 
the salutary effects of EPO on cardiac function and microvascularization. VEGF was 
responsible for proliferation of myocardial endothelial cells and homing EPCs to the 
myocardium. Our study therefore underscores the crucial role for paracrine control 
of myocardial angiogenesis by cardiomyocytes and proves that the beneficial effects 
of EPO on cardiac function are truly hematocrit-independent. 
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EPO restores cardiac function ,n h ea r t  fa ilure by targ eting th e 
myocardium 
In patients with chronic heart failure, correction of anemia with EPO has been 
associated with restoration of cardiac function for more than 3 decades. 20• 1 1 Moreover, in 
experimental heart failure without anemia, EPO consistently improves cardiac function 
and microvascularization even in a dose that does not increase hematocrit levels. 21 These 
observations suggest that EPO mediates these salutary effects by targeting cardiac cells. 
Our study importantly substantiates this hypothesis. First, we show that EPO-receptor 
mediated transcription ofVEGF by cardiomyocytes conveyed tl1e beneficial effects ofEPO 
on the heart. Second; EPO failed to exert beneficial effect on the heart when VEGF was 
antagonized, despite a markedly increased hematocrit. Third; although the effect ofEPO 
on the number of circulating EPCs was not affected by VEGF-neutralization, myocardial 
homing ofEPCs and myocardial neovascularization were attenuated, which indicates that 
EPC-mobilization alone is not sufficient to improve cardiac function in heart failure. 
EPO-in duced n e ovas c ularization i s  reg ulated by a ug m e n te d  
p a ra crine secretion of VEG F  by c a rdiomyo cytes 
Cardiac hypertrophy disproportional to (micro) vascular growth, causes an impaired 
vascular supply to cardiomyocytes in heart failure. 3 Since VEGF-expression was 
induced in cardiomyocytes strictly under ischemic conditions ,  EPO seems to primarily 
stimulate the normal paracrine angiogenic response of cardiomyocytes to cellular 
ischemia. 23 F urthermore, EPO-inducedVEGF gene transcription was mediated through 
the JAK / STAT-3 signal transduction pathway. STAT-3 is a crucial transcription factor 
for growth factor receptor and hypoxia mediated VEGF production_H F urthermore, 
STAT-3 in cardiomyocytes has been identified as an indispensable transcription 
factor for adaptive angiogenesis to cardiomyocyte hypertrophy. 2 5 The important role 
for STAT-3 in EPO-mediated VEGF gene transcription therefore provides additional 
support for the suggestion that EPO stimulates neovascularization through paracrine 
mechanisms in cardiomyocytes. The ischemia specific kinetics ofEPO-inducedVEGF ­
production in cardiomyocytes might be explained by ischemia-dependent EPO­
receptor upregulation. 26 Alternatively, this might indicate that other hypoxia sensing 
pathways are also operative in this signal. Further studies are required to delineate the 
mechanisms of the hypoxia-specific nature of EPO. 
The finding that the angiogenic effects ofEPO are mediated in a paracrine fashion 
seems to contradict previous studies which showed that EPO markedly stimulates 
endothelial cell proliferation and vascular tubule formation in numerous in vitro-models 
of angiogenesis.17 However, although we did observe stimulatory effects ofEPO in the 
aortic sprouting assay, the effects were modest compared to other growth factors. These 
results confirm recent observations by Asuami et al. whom also demonstrated that the 
angiogenic effects ofEPO on top ofVEGF were limited.9 The angiogenic effects ofEPO 
in vivo were however profound and amenable by VEGF neutralization, as evidenced 
by marked attenuation of PCNA-positive endothelial cells after VEGF-inhibition. 
Therefore, the effects of EPO on cardiomyocytes seem more important for myocardial 
angiogenesis that direct stimulation of endothelial cells. 
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VEGF regu lates EPO-in duced homing of EPCs to the 
myocardium 
EPO mobilizes EPCs from the bone marrow and we and others have therefore postulated 
an important role for EPCs in EPO-induced neovascularization. We recently showed that 
EPO stimulates incorporation of EPCs into the myocardial microvasculature.8 However, 
the present study indicates that EPC-mobilization alone does not necessarily augment 
neovascularization. We previously demonstrated that EPCs incorporated into healthy and 
diseased tissues, whereas consecutive neovascularization was specifically induced in the 
presence ofVEGF upregulation and ischernia. 1 2  Moreover, transplantation of normal bone 
marrow to EPO-receptor null mice does not rescue VEGF-expression and accelerated 
development of heart failure.9 One might therefore suggest that EPCs are dispensable for 
EPO-induced neovascularization. However, attenuated expression ofVEGF in these mice 
was also associated with impaired homing ofEPCs. zs Furthermore, although not affecting 
circulating EPC-numbers, homing ofEPCs in our study was significantly reduced byVEGF 
neutralization.Thus, in addition to the stimulation oflocal endothelial proliferation,VEGF 
seems to serve as an important chemotactic factor for EPO-mobilized EPCs. 
Clinical implication s  
Our study demonstrates that EPO-induced restoration of cardiac function in heart 
failure is mediated by EPO-receptor signaling in cardiomyocytes. After several 
promising phase 2 studies,29 i i  a phase 3 clinical trial is currently evaluating the effect 
of EPO on outcome in CHF patients with anemia. From our data, we propose that 
trials aimed at restoration of cardiac function in CHF-patients without anemia should 
circumvent unwanted elevation of hematocrit levels. Ideally, EPO-derivatives that 
specifically target the EPO-receptor on cardiomyocytes might restore cardiac function 
without hematopoietic or thrombotic side-effects.32 Possibly, (post)transcriptional 
cardiomyocyte-specific modification of the EPO-receptor occurs that might enable us 
to design cardiac-specific EPO-derivatives. However, we can not completely exclude that 
the beneficial effects of EPO are in part dependent on direct effects on endothelial cells 
or EPCs. Hence, efficacy of novel compounds should be compared in an experimental 
setting before embarking onto clinical trials. 
C o n c l usion 
EPO stimulates STAT-3-mediated VEGF production by cardiomyocytes, which in turn 
mediates EPO induced neovascularization and improvement of cardiac function in heart 
failure. These findings underscore the non-hematopoietic, pro-angiogenic and salutary 
effects of EPO in heart failure patients. 
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Sum ma r y  
Anemia is common in chronic heart failure (CHF) patients and related to impaired 
survival. The etiology of anemia in CHF patients is often unknown. 1 • 2 We hypothesized 
that dysregulation of erythropoietin (EPO) synthesis by the kidney or an altered 
sensitivity of the bone marrow to EPO might represent causes specific for CHF. In 
addition, recombinant human EPO (rhEPO) has been shown to improve cardiac 
function in heart failure. 3•4 We hypothesized that EPO-induced improvement of 
cardiac function is mediated through mechanisms that are unrelated to increases in 
hematocrit levels. 5 In the present thesis we explored EPO as a pathophysiological 
factor in anemia and the mechanisms of its ancillary beneficial cardiac effects in heart 
failure. 
In the FIRST PART of the thesis we explored the role of EPO in anemia of CHF. 
In Chapter I and 2, we introduced the clinical significance of anemia in CHF-patients 
and reviewed the present knowledge of the etiology. In addition, we introduced the 
extra-hematopoietic EPO-receptor system and discussed the present evidence for a 
therapeutic potential for rhEPO in cardiovascular disease. In Chapter 3 ,  we evaluated 
whether anemia in CHF patients is caused by renal failure. We hypothesized that 
impaired renal perfusion in heart failure will compromise EPO-synthesis in the 
kidney. Alternatively, renal hypoperfusion might cause fluid retention and consequently 
hemodilution, which can cause anemia as well. Using a novel radionucleotide technique 
which allows simultaneous evaluation of renal perfusion and extracellular volume, 
we demonstrated that anemic CHF patients displayed significantly impaired renal 
function and perfusion compared to non-anemic subjects. Moreover, although EPO 
levels were slightly higher in anemic CHF patients, the levels were insufficient when 
corrected for the prevailing hemoglobin (Hb) levels. In addition to blunted EPO­
production, anemic CHF patients displayed significantly higher extracellular volumes. 
Lower renal perfusion, blunted EPO production and higher extracellular volume were 
all independent predictors of anemia, thereby showing that renal compromise in CHF 
contributes to the occurrence of anemia through multiple pathways. It additionally 
signifies the multifactorial etiology of anemia in CHF. 
Despite the fact that the EPO-response is blunted in anemic CHF patients, CHF 
patients generally display relatively elevated EPO levels. This could indicate that the 
bone marrow of CHF patients is relatively resistant to EPO and would therefore require 
higher levels to maintain adequate erythropoiesis. In Chapter 4, we evaluated the EPO 
response of hematopoietic progenitor cells of CHF patients. In a well established in 
vitro erythropoiesis assay, CD34 + hematopoietic progenitors isolated from the bone 
marrow of CHF patients displayed a 3-fold lower number of Burst Forming Units­
Erythroid (BFU-E) colonies compared to matched controls with normal cardiac 
function. Impaired erythropoiesis in vitro was accompanied by a relative depletion of 
the erythroid lineage and markedly increased apoptosis in the bone marrow. Elevated 
levels of NT-proBNP independently predicted impaired BFU-E formation, indicating 
that the extent of erythropoiesis-impairment is related to the severity of heart failure. 
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In contrast to our expectations, EPO-receptor expression was comparable in CHF­
patients and controls, suggesting that the sensitivity of erythroid cells to EPO is 
equivalent. Moreover, BFU-E formation was equally impaired in anemic and non­
anemic CHF patients. Therefore, it seems that CHF causes general bone marrow 
dysfunction which translates into impaired erythropoiesis and might in part explain 
the high incidence of anemia in CHF. In Chapter S ,  we postulated a model that 
explains how heart failure results in changes in the kidney and the bone marrow 
that eventually culminate into anemia. The model explains why anemia is an intrinsic 
component of the CHF-syndrome. We also reviewed treatment options, including 
meticulous control of fluid retention and recombinant human EPO. In addition we 
reviewed current experimental evidence that EPO has important ancillary effects in 
heart failure through the induction of myocardial neovascularisation. 
In the SECOND PART of the thesis we aimed to evaluate the mechanisms 
through which EPO improves cardiac function in CHF. For this purpose we employed 
a rat model of chronic post-myocardial infarction (MI) heart failure.6 In order to 
study the effects of EPO in a chronically remodelled heart, we initiated treatment 
3 weeks after MI, when infarct healing had completed and remodelling of the 
remaining viable myocardium had occurred. In Chapter 6, we evaluated whether 
bone marrow derived endothelial progenitor cells (EPC) 7 contribute to EPO-induced 
neovascularization and restoration of cardiac function. By replacing the bone marrow 
of rats with labelled cells, we showed that EPO-induced restoration of cardiac function 
and neovascularization is associated with increased mobilization, myocardial homing 
and vascular incorporation of EPCs. Approximately 30% of the new endothelium 
comprised of bone marrow derived cells. In addition, Vascular Endothelial Growth 
Factor (VEGF) protein expression in the myocardium was more than 4-fold increased 
by EPO and correlated with new vessel formation. VEGF was not primarily expressed 
by EPCs, suggesting an additional EPC-independent mechanism. The effects of EPO 
on microvascularization have only been described in the presence of ischemia and 
might in part be dependent on its presence. In Chapter 7, we therefore evaluated 
whether the effects ofEPO on cardiac microvascularization and function only occur in 
ischemic tissues or represent a general phenomenon. We compared the effects of EPO 
in rats with ischemic heart failure or with a normal cardiac function. EPO generally 
stimulated mobilization of EPCs from the bone marrow, which indiscriminately 
incorporated in the endothelium of ischemic and non-ischemic tissues. Incorporation 
of EPCs was associated with a significant improvement of endothelial function, 
independent of ischemia. However, additional EPCs specifically homed to the ischemic 
MI-borderzone and EPO stimulated neovascularization and improved cardiac function 
only in ischemic hearts. This was possibly driven by augmented VEGF and EPO­
receptor expression. These results suggest that EPO regulates normal EPC- mediated 
endothelial turnover, but improves cardiac microvascularization and function only in 
the presence of ischemia. 
The experiments described above were all performed with a high dose of EPO, 
which increases hematocrit to supra-physiological levels.The elevated hematocrit levels 
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might i n  part explain the salutary effects, but might also significantly hinder its clinical 
application.8• 9 We aimed to evaluate whether EPO can also improve cardiac function in 
CHF with a dose that does not increase hematocrit levels. In Chapter 8 ,  we therefore 
compared the effects of a regular EPO-dose with a I 00-fold lower dose. Low dose 
EPO did not raise hematocrit levels, but still significantly improved cardiac function. 
The functional improvement was associated with induction of neovascularization and 
attenuated expression of slow 13-MHC-isoforms. Most of the effects were however 
slightly less pronounced in the low-dose group. This might indicate that the beneficial 
effects of EPO in heart failure are partially dependent on an increased hematocrit. 
Alternatively, they reflect the dose dependent nature of the non-hematocrit related 
effects of EPO on the heart, which are completely distinct from erythropoiesis. 
In the previous chapters we showed that the effect of EPO on EPCs is a relatively 
generalized phenomenon, while EPO-induces VEGF-expression strictly under 
ischernic conditions and specifically at tl1e site of neovascularization. Therefore, 
cardiac VEGF-expression might be crucial for EPO-induced neovascularization. In 
Chapter 9 we evaluated the cellular mechanisms of EPO-induced VEGF-upregulation 
and its necessity for the restoration of cardiac function and neovascularization. In 
vitro, EPO promoted VEGF-transcription through the JAK / STAT-3 signal transduction 
pathway in cardiomyocytes, but not in endothelial cells. Moreover, in rats witli 
heart failure, EPO-treatment resulted in a 4-fold increase in VEGF expression, which 
was also predominantly observed in cardiomyocytes. Antagonization ofVEGF with 
neutralizing antibodies abrogated the salutary effects of EPO on cardiac performance 
and microvascularization. VEGF-neutralization blocked EPO-induced proliferation of 
endothelial cells and myocardial homing of EPCs. Thus, EPO mediates its effects in 
heart failure at least partly through stimulation ofVEGF-production in cardiomyocytes, 
which in turn stimulates angiogenesis in a paracrine fashion. It further proves that tlie 
beneficial effects ofEPO on tlie failing heart are dependent on EPO-receptor signaling 
in cardiomyocytes and are truly independent of an increased hematocrit. 
F u tu re perspectives 
Etiology of anemia in CHF 
In  the FIRST PART of the thesis we demonstrate that anemia in CHF patients is 
directly related to the extent of cardiac dysfunction. 10 Therefore, (partial) restoration 
of cardiac dysfunction should restore anemia. Moreover, increased levels of EPO are 
required in CHF due to bone marrow dysfunction, while EPO production in the 
kidney is impaired. Production of EPO is thus attenuated in the setting of increased 
demands, suggesting that correction of anemia with rhEPO is feasible. 10• 1 1  Moreover, 
since the second part of the thesis shows that EPO also improves cardiac function 
through direct stimulation of the heart, rhEPO might not only restore hemoglobin 
levels but might also prevent the recurrence of anemia. A phase 3 clinical trial is 
currently evaluating the effect of EPO on outcome in CHF patients with anemia and 
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will hopefully provide more insight. 1 2 Nevertheless , bone marrow dysfunction in 
CHF patients has been demonstrated in multiple hematopoietic lineages and might 
therefore originate in early stem or progenitor cells. 1 3 1 5 Consequently, stimulation 
of erythropoiesis with rhEPO might correct anemia, but could also accelerate the 
progression of bone marrow dysfunction by inducing replicative exhaustion in 
undifferentiated stem or progenitor cells. 1 6• 17 In addition to anemia , bone marrow 
dysfunction might have consequences for the cellular immune response and stem 
cell mediated cardiovascular repair. Future studies are required to delineate the type, 
extent and the mechanisms of bone marrow dysfunction in CHF both at a cellular and 
molecular level. Moreover, research on the interplay between cardiac performance, 
renal perfusion and bone marrow function might reveal a common pathway with 
therapeutic opportunities. 
The present thesis also demonstrates that hemodilution contributes to anemia 
in CHF, suggesting that meticulous control of fluid retention might be a feasible 
treatment as well. 1 8• 1 9 Although interventional studies are lacking, high dose diuretics or 
intensive sodium and fluid restrictions might provide a simple but effective treatment 
for anemia in certain patients. F inally, the multitude of factors that have so far been 
associated with anemia in CHF indicates that we should not neglect other treatable 
causes of anemia. For instance, recent studies have shown that intravenous iron might 
be an effective treatment for anemia caused by iron deficiency in CHF patients. 20· 1 1  
Moreover, the fact that most cardiologists dont perform a proper evaluation of anemia 
in CHF patients suggests that referring each anemic CHF patients for a proper workup 
will improve morbidity as well. 22 Finally, it is uncertain whether correction of anemia 
will improve survival in CHF patients, since anemia might merely be a marker for the 
severity of cardiac dysfunction. 
EPO induced improve m e n t  of cardiac fun ction in h ea r t  fai lure 
In the SECOND PART of this thesis we demonstrated that EPO-induced improvement 
of cardiac function in CHF is mediated through neovascularization and is truly 
independent of an increased hematocrit. Moreover, this thesis demonstrated that 
although EPO stimulates mobilization and myocardial incorporation ofEPCs, it is the 
presence of myocardial ischemia and the stimulation of myocardial VEGF production 
which determines neovascularization and subsequent restoration of cardiac function. 
Therefore, trials with EPO aimed at restoration of cardiac function in CHF-patients 
should circumvent unwanted elevation ofhematocrit. 3• 23 Several approaches might be 
feasible for this purpose. F irst, a non-erythropoietic EPO dose as described in chapter 
8 might be effective, although the low dose of EPO that is required to circumvent 
erythropoiesis might have limited cardiac effects as well. H Second, since EPO induces 
neovascularization through direct effects on the heart, myocardial application of EPO 
might be beneficial without inducing erythropoiesis. Indeed, several studies have 
shown that intra-myocardial injections of EPO or myocardial implantation of EPO­
releasing hydrogels improves cardiac function without increasing hematocrit. 21· 21 
Third, several EPO analogues have been designed that specifically ligate the EPO­
receptor in peripheral tissues but not in the bone marrow, thereby allowing systemic 
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application of high doses of EPO without increasing hematocrit .1•-10 Since VEGF­
secretion by cardiomyocytes is pivotal for the salutary effects of EPO in heart failure, 
design of cardiomyocyte specific EPO-derivatives might be feasible as well. Possibly, 
(post)transcriptional cardiomyocyte-specific modification of the EPO-receptor occurs 
that will enable us to design such cardiac-specific EPO-derivatives. However, we can 
not completely exclude that the beneficial effects of EPO are in part dependent on 
endothelial cells or EPCs, since we and others also found direct effects ofEPO on these 
cells. 1 ' Future studies with cardiomyocyte-specific knock-out of the EPO-receptor 
might confirm the pivotal role of cardiomyocytes. However, despite accumulating 
experimental evidence, it remains uncertain whether EPO also improves cardiac 
function in humans. First proof for such ancillary beneficial effects of EPO might 
emerge from current trials in anemic heart failure patients or patients with an acute 
myocardial infarction (NCT00449488 and NCT003 7 83 5 2) .  In the future, EPO might 
evolve into a designated heart failure drug with erythropoietic side effects. 
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Sa menvatting 
Hartfalen is het gemeenschappelijke eindstadium van vrijwel alle hartziekten en vormt 
de belangrijkste doodsoorzaak in de westerse wereld. De behandeling van hartfalen 
is voornamelijk gericht op het hart. Echter, wanneer het hart faalt, heeft dit ook 
gevolgen voor het functioneren van andere organen zoals de nieren, longen, lever en 
de hersenen. Dit multipele orgaanfalen bepaald in belangrijke mate de prognose van 
hartfalenpatienten en vormt daarom mogelijk een aangrijpingspunt voor behandeling. 
Anemie komt vaak voor bij patienten met hartfalen en is een onafhankelijke voorspeller 
van morbiditeit en mortaliteit. Anemie kan daarom ook worden beschouwd als een 
uiting van multipel orgaanfalen. Hoewel de nadelige gevolgen van anemie voor 
hartfalenpatienten al in 1 9  3 7 zijn beschreven, is de etiologie nog niet opgehelderd 
waardoor gerichte behandeling ontbreekt. 
Erythropoietine (EPO) wordt gemaakt in de nier en stimuleert vervolgens de 
aanrnaak van rode bloedcellen in het beenmerg. Omdat de doorbloeding van de 
nier verstoord raakt bij hartfalen, zou dit de productie van EPO kunnen verstoren. 
Daarnaast veroorzaakt verminderde nierdoorbloeding vochtretentie, wat kan leiden 
tot hemodilutie anemie. Daarnaast bestaan er aanwijzingen dat het beenmerg van 
patienten met hartfalen minder gevoelig is voor EPO. In Deel I van dit proefschrift 
onderzochten we de rol van erythropoietine (EPO) in de pathofysiologie van anemie 
bij patienten met hartfalen. In Hoofdstuk 1 en 2 wordt de rol van EPO in de aanmaak 
van rode bloedcellen en de mogelijke rol die EPO speelt bij de pathofysiologie van 
anemie bij patienten met hartfalen beschreven. In Hoofdstuk 3 onderzochten we wat 
het effect van verminderde nierdoorbloeding is op het ontstaan van anemie. In een 
groep van 97 hartfalenpatienten hebben we gelijktijdig de nierdoorbloeding, de EPO­
productie en het extracellulaire volume (ECV) gemeten. Hieruit bleek dat patienten 
met anemie aanmerkelijk slechtere nierdoorbloeding hadden. Dit leidde vervolgens tot 
een verminderde EPO-productie door de nier en een verhoging van het extracellulaire 
volume. Multivariate analyse toonde verder aan dat verminderde nierdoorbloeding, 
verstoorde EPO productie en een verhoogd extracellulair volume alien onafhankelijke 
voorspellers waren voor anemie.Verminderde nierdoorbloeding veroorzaakt dus anemie 
door de productie van EPO te verminderen en het bloed te verdunnen. In Hoofdstuk 
4 onderzochten we of een verminderde beenmergfunctie bijdraagt aan het ontstaan 
van anemie. Om dit te onderzoeken vergeleken we het vermogen van het beenmerg 
om rode bloedcellen te vormen tussen patienten met hartfalen en vergelijkbare 
proefpersonen met een goede hartfunctie. Het beenmerg van hartfalenpatienten 
maakte 3 keer minder rode bloedcellen dan het beenmerg van controle patienten. 
In tegenstelling tot wat we aanvankelijk verwacht hadden, was er geen verschil in 
beenmergfunctie tussen anemische en niet anemische hartfalenpatienten. Hoewel 
de verstoorde beenmergfunctie het ontstaan van anemie niet volledig kan verklaren, 
maakt het hartfalenpatienten waarschijnlijk we! gevoeliger voor anemie. Hoofdstuk 5 
beschrijft een hypothetisch model waarin de relatie tussen verminderde hartfunctie en 
het ontstaan van anemie wordt verklaard uit de bovenstaande bevindingen. 
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Naast bekende effecten op de erythropoiese, is recent ontdekt dat EPO de 
hartfunctie verbetert bij proefdieren en patienten met hartfalen. Het is echter nog 
onduidelijk of de hartfunctieverbetering kan worden toegeschreven aan directe 
stimulatie van de EPO-receptor in het hart, aan stimulatie van stamcellen uit het 
beenmerg of toch het gevolg is van een verhoging van het hematocriet. In Deel 2 
onderzochten we het mechanisme van deze cardiale effecten van EPO in ratten met 
hartfalen. In Hoofdstuk 6 werd de rol van de zogenoemde endotheel progenitor 
cellen (EPCs) onderzocht. Deze uit beenmergafkomstige stamcellen migreren naar 
ischemische weefsels om vervolgens bij te dragen aan de vaamieuwvorming. Door 
het beenmerg van ratten te vervangen door gelabelde cellen konden we de bijdrage 
van de uit beenmerg afkomstige cellen onderzoeken. Hierbij zagen we dat EPO zowel 
het vrijkomen van EPCs uit het beenmerg als oak de inbouw van deze EPCs in nieuwe 
bloedvaten stimuleerde. Deze EPCs waren echter verantwoordelijk voor slechts 3 0 % 
van de nieuwe vaten. Dit suggereert dat aanvullende mechanismen oak een rol spelen. 
Zo ontdekten we tevens dat EPO de productie van de vasculaire groeifactor VEGF 
stimuleerde. In Hoofdstuk 7 werd onderzocht of de stimulerende effecten van EPO 
op de vaatnieuwvorming uitsluitend optreden in een ischemisch hart of dat ze oak 
optreden in gezonde situaties. Daarom vergeleken we de effecten van EPO tussen ratten 
met ischemisch hartfalen en gezonde ratten. Hieruit bleek dat EPO het vrijkomen van 
EPCs uit het beenmerg en de inbouw van EPCs in de vaten stimuleerde in zieke en 
gezonde organen, geassocieerd met een verbetering van de endotheelfunctie. VEGF 
productie, vaamieuwvorming en hartfunctieverbetering traden echter uitsluitend 
op in het falende hart. Het lijkt er dus op dat EPO de inbouw van EPCs algemeen 
stimuleert terwijl de eigenlijke vaatnieuwvorming alleen optreed in het beschadigde 
hart waar VEGF vrijkomt. 
De onderzoeken die hierboven worden beschreven, werden steeds uitgevoerd met 
een hoge dosering EPO. Deze hoge dosis stimuleerde niet alleen de hartfunctie maar 
ook de aanmaak van rode bloedcellen. De verhoging van het hematocriet dat hierdoor 
ontstaat, zou enerzijds de hartfunctieverbetering op zichzelf kunnen verklaren, maar 
tevens voor bijwerkingen kunnen zorgen in patienten met een normaal hematocriet. 
In Hoofdstuk 8 onderzochten we daarom of EPO de hartfunctie ook kan verbeteren 
met een dosering die te laag is om het hematocriet te laten stijgen. In ratten met 
hartfalen vergeleken we de reguliere dosis EPO met een I 00 x lagere dosis die geen 
effect had op het hematocriet. Zowel de hoge als de !age dosering EPO veroorzaakte 
vaatnieuwvorming en verbeterden de hartfunctie. De effecten van de !age dosering 
waren echter wel minder uitgesproken. Met dit hoofdstuk werd dus aangetoond dat 
de gunstige effecten van EPO op het hart onafhankelijk zijn van hematocrietstijging en 
mogelijk zouden kunnen warden toegepast bij niet-anemische hartfalenpatienten. 
In de hoofdstukken die hierboven zijn beschreven zagen we dat het effect van 
EPO op EPCs gegeneraliseerd is, terwijl vaatnieuwvorming uitsluitend optreedt op 
plaatsen waar EPO de VEGF-productie stimuleert. VEGF-stimulatie zou daarom de 
gunstige effecten van EPO op het hart kunnen verklaren. In Hoofdstuk 9 werd daarom 
onderzocht of de toegenomen VEGF-productie in het hart cruciaal is voor de gunstige 
effecten van EPO bij hartfalen. Zowel in celkweek als in het falende hart stimuleerde 
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EPO de productie van VEGF in cardiomyocyten, maar niet in endotheelcellen. Wanneer 
we in ratten met hartfalen tijdens EPO behandeling gelijktijdig VEGF neutraliseerden, 
was het effect van EPO op zowel de vaatnieuwvorming als de hartfunctie verdwenen. 
Neutralisatie van VEGF verminderde het aantal delende endotheelcellen en de inbouw 
van EPCs in het hart. De gunstige effecten van EPO op de hartfunctie kunnen dus 
zeker ten dele kunnen worden toegeschreven aan de verhoogde VEGF-productie door 
cardiomyocyten. Naast de cruciale rol voor VEGF tonen we hiermee ook aan dat de 
directe stimulatie van de EPO-receptor in het hart belangrijker is clan de mobilisatie 
van EPCs. 
Toeko m s tperspectieven 
Uit het eerste dee! van het proefschrift blijkt dat anemie bij hartfalenpatienten 
gerelateerd is aan de ernst van de hartfunctievermindering. Verbetering van de 
hartfunctie zou daarom de beste behandeling zijn voor anemie bij hartfalen. Helaas 
is dit bij veel patienten niet mogelijk. Verder laten we zien dat de productie van 
EPO in de nier verstoord raakt terwijl het beenmerg juist meer EPO nodig heeft. 
Toediening van EPO lijkt daarom een logische behandeling. Uit het tweede dee! van dit 
proefschrift blijkt tevens dat EPO de hartfunctie kan verbeteren bij hartfalen. Hierdoor 
wordt mogelijk niet alleen de anemie behandeld, maar wordt ook de oorzaak van de 
anemie ( deels) weggenomen. Of EPO ook daadwerkelijk effectief is moet blijken uit 
aanvullend onderzoek. In dit proefschrift wordt tevens aangetoond dat hemodilutie 
een rol speelt bij anemie. Dit zou kunnen worden behandeld met stringente vocht en 
zoutbeperking of diuretica. Verder moeten we er voor waken dat iedere patient een 
goede evaluatie  krijgt van de oorzaak van anemie, aangezien er voor veel bekende 
oorzaken al een behandeling bestaat. 
Het tweede deel van dit proefschrift toont aan dat EPO naast effecten op de 
bloedcelaanmaak ook de hartfunctie bij hartfalen kan verbeteren via directe stimulatie 
van het hart. Wanneer we de effectiviteit van EPO zouden willen onderzoeken bij 
mensen zullen we idealiter een methode moeten gebruiken waarmee we optimale EPO 
concentraties in het hart bereiken zonder dat het hematocriet hierbij stijgt. Hiervoor 
zijn verschillende mogelijkheden. Ten eerste kunnen er !age doseringen EPO worden 
toegediend zoals in hoofdstuk 8. Het gevaar bestaat echter dat !age doseringen ook 
minder werkzaam zijn. Een andere mogelijkheid betreft EPO via injecties direct in 
het hart te brengen. Als laatste kan gedacht worden aan aanpassingen van het EPO 
molecuul waardoor het alleen op de EPO-receptor in het hart aangrijpt en zo het 
beenmerg niet meer stimuleert. Desalniettemin is tot op heden nog niet onomstotelijk 
bewezen dat de hartfunctie van hartfalenpatienten ook daadwerkelijk kan worden 
verbeterd met EPO. Aanwijzingen hiervoor volgen mogelijk uit de onderzoeken met 
EPO in anemische hartfalenpatienten en patienten met een acuut hartinfarct. In de 
toekomst zou EPO kunnen evolueren tot een specifiek hartfalen medicijn met als 
hinderlijke bijwerking het stimuleren van de rode bloedcel productie. 
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Aan het tot stand komen van cl.it proefschrift hebben velen bijgedragen, mijn dank 
daarvoor. Een aantal van hen wil ik graag met naam noemen. 
Mijn promotores prof. dr. D.]. van Veldhuisen en prof. dr. W.H. van Gilst. 
Beste Dirk Jan, met jouw aanstekelijke enthousiasme voor onderzoek in het 
algemeen en de EPO-lijn in het bijzonder werd de EPO-trein gestookt. Jouw zakelijke 
benadering van complexe problemen en de onnavolgbare manier waarop je meteen 
tot de kern van de zaak komt, waren belangrijk voor dit proefschrift. Door jouw 
internationale reputatie in EPO-land kwam ik mijn resultaten overal tegen. Daarnaast 
zorgden de vele telefoontjes over het onderzoek en onze gezamenlijke hobby "ci taties 
scoren" voor een leuke promotie- en hopelijk ook opleidingstijd. Ik hoop je in de 
toekomst nog vaak over nieuwe projecten en H-scores te spreken. 
Beste Wiek, al tijdens onze eerste gesprekken kreeg ik bij jou het gevoel dat 
de wetenschappelijke mogelijkheden eindeloos waren en dat promoveren vooral 
leuk moest zijn. Jouw groot optimisme, scherpe analyses en originele ideeen 
waren essentieel voor het bedenken, uitvoeren en analyseren van de verschillende 
projecten. De vrijheid die ik kreeg bij het opzetten van nieuwe experimenten was 
onovertroffen. Ook de laagdrempelige manier waarop ik altijd binnen kon lopen 
met nieuwe ontdekkingen of voor het relativeren van de zoveelste tegenslag heb ik 
erg gewaardeerd. Buiten de werkvloer zorgden jouw humor en voorliefde voor de 
grootste vleesgerechten voor memorabele avonden. Ik hoop clan oak dat we in de 
toekomst nog vaak gezamenlijke projecten zullen bespreken onder het genot van een 
stevige Porterhouse. 
Mijn copomotores dr.A.A.Voors en dr. R.G. Schoemaker. 
Beste Adriaan, jouw enorme drive en ambitie, die je combineert met een passie 
voor de goede dingen in het ]even zijn aanstekelijk. Ondanks je vele ondernemingen 
stand de deur altijd open voor een bespreking van de lopende projecten of de jongste 
manuscripten. Terwijl je naar eigen zeggen maar beperkt inhoudelijk kon bijdragen 
aan het pre-klinische gedeelte van cl.it proefschrift, was het vaak juist jouw kwaliteit 
als bruggenbouwer die er voor zorgde dat deze projecten doorgang konden vinden. 
Beste Regien, met engelengeduld toonde jij me de snuit, de staart maar 
belangrijker de weg naar het hart (infarct) van de Sprague Dawely rat. Jouw specifieke 
kennis van "de hartfaalrat" en de intensieve begeleiding tijdens de eerste wankele 
stappen in proefdierland waren essentieel voor cl.it proefschrift. Hoewel het enige tijd 
heeft geduurd voordat je me kon overtuigen, schaar ik me nu toch openlijk onder de 
capillary-density believers. 
Dr. R. A. de Boer, beste Rudolf, bedankt voor de "ontdekking van EPO" en de 
hulp tijdens de laatste fase van mijn promotietraject. Door jouw moleculaire expertise 
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werd hoofdstuk 9 steeds mooier (maar niet significanter). Ik hoop nog meer proefjes 
met je te doen nu je officieel experimenteel cardioloog bent. 
I would like to express great gratitude to the members of the reading committee. 
Prof dr. M. Bohm, I deeply respect your great scientific reputation and your readiness 
to accept membership in the reading committee. Pro( dr. E. Hack wil ik niet alleen 
bedanken voor het beoordelen van mijn manuscript maar ook voor de interessante 
discussies tijdens de vergaderingen over EPO. Prof. Dr. G. Navis, beste Gerjan, naast je 
rol in de beoordelingscommissie, wil ik je bedanken voor je bijdrage aan hoofdstuk 3. 
Ook onze spontane "wetenschappelijke" fietstochtjes waren inspirerend. Prof dr. JH. 
Kingma, beste Herre, hoewel je geen officiele rol hebt gespeeld bij de beoordeling 
van dit proefschrift, was je historische helicopter-view vaak zeer bijdragend voor 
de interpretatie van de jongste resultaten. Verder wil ik je bedanken dat je me hebt 
binnengeloodst in jouw "eigen" lab en voor de hand van je dochter, bedankt voor 
dit vertrouwen. 
Dr. M.P. van den Berg, beste Maarten, bedankt voor je vertrouwen en de 
mogelijkheid om mij te kunnen specialiseren tot cardioloog. Pro( dr. P.A. de Graeff en 
pro( dr. D. de Zeeuw, Beste Pieter en Dick , bedankt voor de mogelijkheid om rnij te 
certificeren als klinisch farmacoloog. 
Onderzoek doe je niet alleen , zeker niet als je samenwerkt met een heus EPO­
team. De EPO-tweeling Erik en Peter wil ik bedanken voor het op stoom brengen van 
de EPO-trein en de hulp bij het vervolgen van de reis. Anne en Willem Peter wil ik 
bedanken voor de vele gezellige uren die we gezamenlijk in het CDL of op het lab 
hebben doorgebracht. Ik laat de trein en rnijn muizen in goede handen achter. Hisko, 
hoewel je geen officieel lid bent van het EPO team, waren de samenwerking en de 
discussies over de gezamenlijke projecten erg gezellig. Helaas liepen deze discussies 
vaak zo uit de hand dat we soms tot 3 uur 's ochtends moesten doorwerken. Pim, 
ik wil jou bedanken voor je vriendschap en de bijdrage die je hebt geleverd aan 
dit proefschrift. Ik hoop dat we in de toekomst nog vaak over manuscripten zullen 
filosoferen. Lennaert ,  jouw inspanningen als "mijn student" waren waardevol. Ik 
wens je veel succes met het vervolg van de opleiding tot onderzoeker en hopelijk ook 
tot cardioloog. Bianca jouw hulp en geduld tijdens de dierexperimenten en de vele 
histologische analyses vormen de ruggengraat van dit proefschrift, bedankt daarvoor. 
Annet , jij bent vrijwel volledig verantwoordelijk voor het welslagen van de "Annet'' 
studies, bedankt voor je inzet en expertise. Lili , your precision and hard work were 
absolutely above and beyond the call of duty. I would like to express my gratitude for 
your efforts and the "good results" .  Silke, I would like to thank you for providing 
your help and expertise with the "use" of newborn babies. Daarnaast was hulp op het 
laboratorium van Maaike, Alex, Jan, Asuwerus, Jacko, Marry, Germaine, Inge en Linda 
onontbeerlijk voor het tot stand komen van dit proefschrift. 
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de huidige en vroegere bewoners van " the Greenhouse". De koffie en cola rondjes, 
maar ook de vele avonden aan de bar in het Feithuis zorgden voor een geweldige 
werksfeer. Pieter, Sheba , Jasper, Sandra, Rik, Bas, Martin, Michie! , Marcelle, Jessica, 
Christiane, Tone ,  Tom,  Wim, Patrick, Lisa, Jardi, Suzanne, Lieuwe, Ali, Meint, Johan, 
Lucas, Youlan, Marieke, Pieter-Jan en Mathijs ,  bedankt. Ook de collega promovendi 
en anderen op de verschillende laboratoria van de klinische farmacologie en later 
de experimentele cardiologie, nefrologie en farmacologie wil ik bedanken voor de 
leuke sfeer; Mirjam, Bernadet, Bart, Ying, Els, Annemarieke ,  Maria, Peter, Willemijn ,  
Jurjen, Irma , Hiddo, Nadir, Bo  Lu , Mei Mei en nog vele anderen. Anton, Rob, Hendrik, 
Leo, Floor en Richard bedankt voor jullie analyses en discussies bij de verschillende 
experirnenten. Alma, Ardy, Audrey, Alexandra, Ellen en Marjan wil ik bedanken voor 
alle hulp en betrokkenheid. De medewerkers van Cardioresearch,  Peter, Anja,  Trynke, 
Margriet, Zazza, maar vooral Greetje wil ik bedanken voor de prettige samenwerking 
en begrip voor mijn wisselende werkplek. V02-max dames, bedankt voor jullie 
hulp. 
Ook buiten de eigen onderzoeksgroep hebben velen in belangrijke mate 
bijgedragen aan de verschillende projecten. Allereerst wil ik prof. dr. E. Vellenga en dr. 
J]. Schuringa bedanken voor het verlenen van hun expertise bij de beenmergstudie. 
Ik hoop dat we met hoofdstuk 4 een basis hebben gelegd voor een verdere exploratie 
van beenmergdisfunctie bij hartfalen. Prof. dr. P.A. Boonstra, dr. A.H. Epema en drs. 
H. Mungroop wil ik bedanken voor hun enthousiasme bij de "DREAM pilot" studie. 
Hoewel het nog niet tot een publicatie heeft geleid was de samenwerking erg plezierig. 
Jessica Volders wil ik bedanken voor het coordineren van de logistiek rondom de 
EPO en de beenmerg studie. Daarnaast wil ik alle thorax chirurgen uit het UMCG 
bedanken voor het verzamelen van het beenmerg. De afdeling medische biologie en 
in het bijzonder prof. dr. G. Molema , Marco Harmsen , Martine Broekema, Eliane Popa 
en Machteld van Amerongen wil ik bedanken voor de waardevolle adviezen en de 
vele immunohistochemische protocollen. Henk van der Molen wil ik bedanken voor 
het miracu)eus tot !even wekken van de EPO-receptor knock out embryo's. De FACS­
mannen, Geert en Henk wil ik bedanken voor het geduld bij de flow cytometrie. Mijn 
Jaarclub "JC RIOT" wil ik bedanken voor de mooie jaren die aan <lit promotie traject 
vooraf gingen en hun begrip voor mijn wederkerige afwezigheid. Prof. dr. T.S. van der 
Werf, beste Tjip, bedankt voor de avontuurlijke introductie in de wetenschap en de 
Ghanese cultuur. 
Mijn paranimfen Kevin Damman en Christiaan van Marren. 
Beste Kevin, al voor je mijn collega werd in the greenhouse probeerde ik je als 
student te betrekken bij het EPO onderzoek. Helaas bleek jij minder gecharmeerd 
van de "cellulaire" aspecten van het !even. Desalniettemin was jouw rol als vriend 
en sparringpartner in de "hartfalen kamer" ,  op de golfbaan en aan de bar een 
aangename vanzelfsprekendheid. Ik hoop je in de komende jaren nog vaak op jezelf 
te l10ren schelden en kijk uit naar de dagen <lat we samen op de I c rij zitten. Beste 
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Dankwoord 
CJ, de afgelopen 9 jaar was jij mijn medische maatje, al hebben we nog maar 1 
patient samen behandeld. Deze samenwerking verliep niet zo voorspoedig, want het 
was niet ons ingrijpen maar de Caribische zee die onze patient van zijn dreigende 
necrotiserende fasciitis redde. Toch zie ik voor jou een glorieuze toekomst weggelegd 
als chirurg. Image is everything . . .  
Ik prijs me gelukkig dat jullie mijn paranimfen willen zijn. 
Mijn Ouders wil ik bedanken voor de steun, liefde, stimulans en diepgewortelde 
interesse in wat mij bezig houdt. Hierdoor heb ik mij kunnen ontplooien tot wie ik 
nu ben. 
Mijn broers, zus en schoonfamilie; weer een feestje! Dit keer kunnen jullie 
achteroverleunen. 
Lieve Lotje, jouw steun, geduld en de overweldigende liefde waren onontbeerlijk 
tijdens dit promotie traject en maken mijn !even compleet. Ik kijk uit naar een 
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